Dimitrios P. Kontoyiannis, MD, MS, ScD, PhD, FACP, FIDSA, FECMM, FAAM, FAAAS

Peer-Reviewed Articles

1. García, JP, Wurster, ST, Albert, ND, Bharadwaj, U, Bhoda, K, Kulkarni, VK, Ntita, M, Carstens, PR, Burch-Eapen, M, López, DC, Lizaola, JF, Larsen, KE, Matula, LM, Moghaddam, SM, Wang, Y, Kontoyiannis, DP, Evans, S. Immunotherapy with nebulized pattern recognition receptor agonists restores severe immune paralysis and improves outcomes in mice with influenza-associated pulmonary aspergillosis. mBio 16(5), 2025. e-Pub 2025. PMID: 40197039.
2. Sasaki, K, Garcia-Manero, G, Nigo, M, Jabbour, EJ, Ravandi-Kashani, F, Wierda, WG, Jain, N, Takahashi, K, Montalban Bravo, G, Daver, N, Thompson, PA, Pemmaraju, N, Kontoyiannis, DP, Sato, J, Karimaghaei, S, Soltysiak, KA, Raad, II, Kantarjian, HM, Carter, B. Artificial Intelligence Assessment of Chest Radiographs for COVID-19. Clinical Lymphoma, Myeloma and Leukemia 25(5):319-327, 2025. e-Pub 2025. PMID: 39710565.
3. Douglas, AP, Lamoth, F, John, TM, Groll, A, Shigle, TL, Papanicolaou, GA, Chemaly, RF, Carpenter, P, Dadwal, SS, Walsh, TJ, Kontoyiannis, DP. American Society of Transplantation and Cellular Therapy Series. Transplantation and Cellular Therapy 31(4):194-223, 2025. e-Pub 2025. PMID: 39923936.
4. Kontoyiannis, DP, Casadevall, A. Would global warming bring an increase of invertebrate-associated cutaneous invasive fungal infections?. mBio 16(3), 2025. e-Pub 2025. PMID: 39907444.
5. Chiu, CY, Hicklen, RS, Kontoyiannis, DP. Fungal-Induced Hemophagocytic Lymphohistiocytosis. Journal of Fungi 11(2), 2025. e-Pub 2025. PMID: 39997452.
6. Aslan, AT, Akova, M, Kontoyiannis, DP. The Heterogeneous Syndrome of Noninfectious Causes of Persistent Fever in Neutropenic Patients With Hematologic Malignancy. Clinical Infectious Diseases 79(6):1333-1337, 2024. e-Pub 2024. PMID: 39397538.
7. Matsuo, T, Wurster, ST, Ivan, D, Hicklen, RS, Mcconn, KK, Bagwell, KA, Khawaja, F, Chemaly, RF, Kontoyiannis, DP. Lethal Disseminated Mucorales Infection With Positive Blood Cultures With Purpura Fulminans Complicating Hemophagocytic Lymphohistiocytosis After Chimeric Antigen Receptor T-Cell Therapy. Open Forum Infectious Diseases 11(11), 2024. e-Pub 2024. PMID: 39507882.
8. Bertagnolio, S, Dobreva, Z, Centner, CM, Olaru, ID, Donà, D, Burzo, S, Huttner, BD, Chaillon, A, Gebreselassie, N, Wi, T, Hasso-Agopsowicz, M, Allegranzi, B, Sati, H, Ivanovska, V, Kothari, KU, Balkhy, H, Cassini, A, Hamers, RL, Weezenbeek, KV, Aanensen, D, Alanio, A, Alastruey-Izquierdo, A, Alemayehu, T, Al-Hasan, M, Allegaert, K, Al-Maani, AS, Al-Salman, J, Alshukairi, AN, Amir, A, Applegate, T, Araj, GF, Villalobos, MA, Årdal, C, Ashiru-Oredope, D, Ashley, EA, Babin, FX, Bachmann, L, Bachmann, T, Baker, KS, Balasegaram, M, Bamford, C, Baquero, F, Barcelona, LI, Bassat, Q, Bassetti, M, Basu, S, Beardsley, J, Vásquez, GB, Berkley, JA, Kontoyiannis, DP. WHO global research priorities for antimicrobial resistance in human health. The Lancet Microbe 5(11), 2024. e-Pub 2024.
9. Wurster, ST, Cho, SY, Allos, H, Franklin, A, Axell-House, DB, Jiang, Y, Kontoyiannis, DP. Concordance of Chest Radiography and Chest Computed Tomography Findings in Patients with Hematologic Malignancy and Invasive Mucormycosis. Journal of Fungi 10(10), 2024. e-Pub 2024. PMID: 39452655.
10. Matsuo, T, Wurster, ST, Jiang, Y, Tarrand, JJ, Evans, S, Kontoyiannis, DP. Determinant of 30-Day Mortality of Pulmonary Legionellosis. Open Forum Infectious Diseases 11(9), 2024. e-Pub 2024. PMID: 39319087.
11. Matsuo T, Singh BS, Wurster S, Jiang Y, Bhutani MS, Chatterjee D, Kontoyiannis DP. The modern face of esophageal candidiasis in an oncology center: Correlating clinical manifestations, endoscopic grade, and pathological data in 323 contemporary cancer patients. J Infect 89(1):106172, 2024. e-Pub 2024. PMID: 38735485.
12. Seidel, D, Wurster, ST, Jenks, JD, Sati, H, Gangneux, JP, Egger, M, Alastruey-Izquierdo, A, Ford, NP, Chowdhary, A, Sprute, R, Cornely, OA, Thompson, GR, Hoenigl, M, Kontoyiannis, DP. Impact of climate change and natural disasters on fungal infections. The Lancet Microbe 5(6):e594-e605, 2024. e-Pub 2024. PMID: 38518791.
13. Kumaresan PR, Wurster S, Bavisi K, da Silva TA, Hauser P, Kinnitt J, Albert ND, Bharadwaj U, Neelapu S, Kontoyiannis DP. A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Aspergillus fumigatus. mBio 15(4):e0341323, 2024. e-Pub 2024. PMID: 38415653.
14. Babakhanlou R, Ravandi-Kashani F, Hita AG, Kontoyiannis DP. Anorectal Infections in Neutropenic Leukemia Patients: A Common Clinical Challenge. J Hematol 13(1-2):1-11, 2024. e-Pub 2024. PMID: 38644983.
15. Lamoth F, Kontoyiannis DP. PCR diagnostic platforms for non-Aspergillus mold infections: ready for routine implementation in the clinic?. Expert Rev Mol Diagn 24(4):273-282, 2024. e-Pub 2024. PMID: 38501431.
16. Chiu CY, John TM, Matsuo T, Wurster S, Hicklen RS, Khattak RR, Ariza-Heredia EJ, Bose P, Kontoyiannis DP. Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections. J Fungi (Basel) 10(4), 2024. e-Pub 2024. PMID: 38667935.
17. Matsuo T, Wurster S, Jiang Y, Tarrand J, Kontoyiannis DP. Adjunct Terbinafine in Patients With Leukemia and Invasive Fusariosis With Skin Lesions: Discordance Between Responses of Skin Lesions and Systemic Outcomes. Open Forum Infect Dis 11(2):ofae068, 2024. e-Pub 2024. PMID: 38379571.
18. Marvin-Peek, J, Sasaki, K, Kontoyiannis, DP, Adachi, JA, Ohanian, M, Takahashi, K, Issa, GC, Kornblau, SM, Abbas, HA. Nontuberculosis mycobacteria (NTM) infections in patients with leukemia. Frontiers in Medicine 11, 2024. e-Pub 2024. PMID: 39149601.
19. Matsuo, T, Wurster, ST, Hoenigl, M, Kontoyiannis, DP. Current and emerging technologies to develop Point-of-Care Diagnostics in medical mycology. Expert Review of Molecular Diagnostics 24(9):841-858, 2024. e-Pub 2024. PMID: 39294931.
20. Egge SL, Wurster S, Cho SY, Jiang Y, Axell-House DB, Miller WR, Kontoyiannis DP. Co-Occurrence of Gram-Negative Rods in Patients with Hematologic Malignancy and Sinopulmonary Mucormycosis. J Fungi (Basel) 10(1), 2024. e-Pub 2024. PMID: 38248950.
21. Matsuo T, Wurster S, Jiang Y, Sasaki K, Tarrand J, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes. J Antimicrob Chemother. e-Pub 2023. PMID: 38073151.
22. Dailey Garnes NJM, Kontoyiannis DP. Mucormycosis: update on clinical presentation, diagnosis, and treatment. Curr Opin Infect Dis 36(6):427-435, 2023. e-Pub 2023. PMID: 37732771.
23. Chiu CY, Matsuo T, Wurster S, Gerstein Y, Hammond DE, Chien KS, DiNardo C, Kontoyiannis DP. Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML: A case report and literature review of invasive fungal infections in GATA2 deficiency. Mycoses 66(12):1029-1034, 2023. e-Pub 2023. PMID: 37550272.
24. Jenks JD, Prattes J, Wurster S, Sprute R, Seidel D, Oliverio M, Egger M, Del Rio C, Sati H, Cornely OA, Thompson GR, Kontoyiannis DP, Hoenigl M. Social determinants of health as drivers of fungal disease. EClinicalMedicine 66:102325, 2023. e-Pub 2023. PMID: 38053535.
25. Chowdhary A, Gupta N, Wurster S, Kumar R, Mohabir JT, Tatavarthy S, Mittal V, Rani P, Barman P, Sachdeva N, Singh A, Sharma B, Jiang Y, Cuomo CA, Kontoyiannis DP. Multimodal analysis of the COVID-19-associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical and environmental risk factors. Mycoses 66(6):515-526, 2023. e-Pub 2023. PMID: 36790120.
26. Wurster S, Pantaleón García J, Albert ND, Jiang Y, Bhoda K, Kulkarni VV, Wang Y, Walsh TJ, Evans S, Kontoyiannis DP. Development of a corticosteroid-immunosuppressed mouse model to study the pathogenesis and therapy of influenza-associated pulmonary aspergillosis. J Infect Dis 227(7):901-906, 2023. e-Pub 2023. PMID: 36611269.
27. Babakhanlou R, Ravandi-Kashani F, Kontoyiannis DP. Neutropenic Enterocolitis: An Uncommon, but Fearsome Complication of Leukemia. J Hematol 12(2):59-65, 2023. e-Pub 2023. PMID: 37187499.
28. Toda M, Williams S, Jackson BR, Wurster S, Serpa JA, Nigo M, Grimes CZ, Atmar RL, Chiller TM, Ostrosky-Zeichner L, Kontoyiannis DP. Invasive Mold Infections Following Hurricane Harvey-Houston, Texas. Open Forum Infect Dis 10(3):ofad093, 2023. e-Pub 2023. PMID: 36910694.
29. Szvalb AD, Yepez Guevara E, Euscher E, Nahmod KA, Kontoyiannis DP. Acute Peritoneal Histoplasmosis Mimicking Ovarian Cancer and Review of the Literature on Histoplasma Peritonitis. Open Forum Infect Dis 10(1):ofac705, 2023. e-Pub 2023. PMID: 36686636.
30. Raad II, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Fernández Cruz A, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S, Dragovich T, Vong Kiat YE, Fakhreddine S, Pierre AH, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Yepez EY, Torres HA, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, García AG, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA, Effort Team DDFCOD, Kontoyiannis DP, Malek AE, Chaftari AM. International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship. Elife 12, 2023. e-Pub 2023. PMID: 36715684.
31. Aminu M, Daver N, Godoy MCB, Shroff G, Wu C, Torre-Sada LF, Goizueta A, Shannon VR, Faiz SA, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim ST, Kontoyiannis DP, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Front Immunol 14:1249511, 2023. e-Pub 2023. PMID: 37841255.
32. Franklin A, Wurster S, Axell-House DB, Jiang Y, Kontoyiannis DP. Impact of Hyperglycemia and Diabetes Mellitus on Breakthrough Mucormycosis Outcomes in Patients with Hematologic Malignancies-Complex and Intriguing Associations. J Fungi (Basel) 9(1), 2022. e-Pub 2022. PMID: 36675866.
33. Gamaletsou MN, Rammaert B, Brause B, Bueno MA, Dadwal SS, Henry MW, Katragkou A, Kontoyiannis DP, McCarthy MW, Miller AO, Moriyama B, Pana ZD, Petraitiene R, Petraitis V, Roilides E, Sarkis JP, Simitsopoulou M, Sipsas NV, Taj-Aldeen SJ, Zeller V, Lortholary O, Walsh TJ, Osteoarticular Mycoses ICF. Osteoarticular Mycoses. Clin Microbiol Rev 35(4):e0008619, 2022. e-Pub 2022. PMID: 36448782.
34. Gudiol C, Hicklen RS, Okhyusen PC, Malek AE, Kontoyiannis DP. Infections Simulating Immune Checkpoint Inhibitor Toxicities: Uncommon and Deceptive. Open Forum Infect Dis 9(11):ofac570, 2022. e-Pub 2022. PMID: 36420059.
35. Rausch CR, DiPippo AJ, Jiang Y, DiNardo CD, Kadia T, Maiti A, Montalban-Bravo G, Ravandi F, Kontoyiannis DP. Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. Clin Infect Dis 75(9):1503-1510, 2022. e-Pub 2022. PMID: 35325094.
36. Stafylaki D, Maraki S, Vaporidi K, Georgopoulos D, Kontoyiannis DP, Kofteridis DP, Chamilos G. Impact of Molecular Syndromic Diagnosis of Severe Pneumonia in the Management of Critically Ill Patients. Microbiol Spectr 10(5):e0161622, 2022. e-Pub 2022. PMID: 36154180.
37. Colombo AL, De Almeida JN, Lewis RE, Kontoyiannis DP. Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis. J Antimicrob Chemother 77(11):2897-2900, 2022. e-Pub 2022. PMID: 36059133.
38. Harish E, Sarkar A, Handelman M, Abo Kandil A, Shadkchan Y, Wurster S, Kontoyiannis DP, Osherov N. Triazole Priming as an Adaptive Response and Gateway to Resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 66(8):e0045822, 2022. e-Pub 2022. PMID: 35856665.
39. Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer 128(14):2736-2745, 2022. e-Pub 2022. PMID: 35452134.
40. Thompson GR, Boulware DR, Bahr NC, Clancy CJ, Harrison TS, Kauffman CA, Le T, Miceli MH, Mylonakis E, Nguyen MH, Ostrosky-Zeichner L, Patterson TF, Perfect JR, Spec A, Kontoyiannis DP, Pappas PG. Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. Open Forum Infect Dis 9(6):ofac112, 2022. e-Pub 2022. PMID: 35611348.
41. Spallone A, Alotaibi AS, Jiang Y, Daver N, Kontoyiannis DP. Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors. Clin Lymphoma Myeloma Leuk 22(5):305-310, 2022. e-Pub 2022. PMID: 34810120.
42. Wurster S, Paraskevopoulos T, Toda M, Jiang Y, Tarrand JJ, Williams S, Chiller TM, Jackson BR, Kontoyiannis DP. Invasive mould infections in patients from floodwater-damaged areas after hurricane Harvey - a closer look at an immunocompromised cancer patient population. J Infect 84(5):701-709, 2022. e-Pub 2022. PMID: 35288118.
43. Spallone A, Moran CA, Wurster S, Axell-House DB, Kontoyiannis DP. Taking a closer look: Clinical and histopathological characteristics of culture-positive versus culture-negative pulmonary mucormycosis. J Fungi (Basel) 8(4), 2022. e-Pub 2022. PMID: 35448611.
44. Wurster S, Albert ND, Kontoyiannis DP. Candida auris bloodstream infection induces upregulation of the PD-1/PD-L1 immune checkpoint pathway in an immunocompetent mouse model. mSphere 7(2):e0081721, 2022. e-Pub 2022. PMID: 35224979.
45. Hu C, Fong G, Wurster S, Kontoyiannis DP, Beyda ND. Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata. Microbiol Spectr 10(1):e0183721, 2022. e-Pub 2022. PMID: 35107318.
46. Thompson GR, Garcia-Diaz J, Miceli MH, Nguyen MH, Ostrosky-Zeichner L, Young JH, Fisher CE, Clark NM, Greenberg RN, Spec A, Kovanda L, Croos-Dabrera R, Kontoyiannis DP. Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study. Mycoses 65(2):186-198, 2022. e-Pub 2022. PMID: 34888961.
47. Franklin S, Aitken SL, Shi Y, Sahasrabhojane PV, Robinson S, Peterson CB, Daver N, Ajami NA, Kontoyiannis DP, Shelburne SA, Galloway-Peña J. Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients. Front Cell Infect Microbiol 12:848580, 2022. e-Pub 2022. PMID: 35433514.
48. Wurster S, Albert ND, Bharadwaj U, Kasembeli MM, Tarrand JJ, Daver N, Kontoyiannis DP. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis. Front Immunol 13:838344, 2022. e-Pub 2022. PMID: 35251033.
49. Wurster S, Watowich SS, Kontoyiannis DP. Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions. Front Immunol 13:1018202, 2022. e-Pub 2022. PMID: 36389687.
50. Rossato L, Carlesse F, Nobrega de Almeida J, Kontoyiannis DP, Colombo AL. How different is invasive fusariosis in pediatric patients than in adults? A systematic review. Curr Opin Infect Dis 34(6):619-626, 2021. e-Pub 2021. PMID: 34751181.
51. DiPippo AJ, McDaneld PM, Tverdek FP, Kontoyiannis DP. Effect of High-Dose Posaconazole on Serum Levels in Adult Patients with Hematologic Malignancy. Antimicrob Agents Chemother 65(12):e0123021, 2021. e-Pub 2021. PMID: 34570643.
52. Malek AE, Khalil M, Hachem R, Chaftari AM, Fares J, Jiang Y, Kontoyiannis DP, Fossella F, Chaftari P, Mulanovich VE, Viola GM, Raad II. Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study. Clin Infect Dis 73(9):e2697-e2704, 2021. e-Pub 2021. PMID: 32564081.
53. Dhal U, Hicklen RS, Tarrand J, Kontoyiannis DP. Cat Scratch Disease as a mimicker of malignancy. Open Forum Infect Dis 8(11):ofab500, 2021. e-Pub 2021. PMID: 34926712.
54. Fekkar A, Neofytos D, Nguyen MH, Clancy CJ, Kontoyiannis DP, Lamoth F. COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it?. Clin Microbiol Infect 27(9):1376-1378, 2021. e-Pub 2021. PMID: 34192575.
55. Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, Stamatelopoulos K, Terpos E, Kotanidou A, Hagberg CA, Dimopoulos MA, Kontoyiannis DP. Epidemiology and organ specific sequelae of post-acute COVID19: A Narrative Review. J Infect 83(1):1-16, 2021. e-Pub 2021. PMID: 33992686.
56. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
57. Viola GM, Malek AE, Rosen LB, DiNardo AR, Nishiguchi T, Okhuysen PC, Holland SM, Kontoyiannis DP. Disseminated cryptococcosis and anti-granulocyte-macrophage colony-stimulating factor autoantibodies: An underappreciated association. Mycoses 64(6):576-582, 2021. e-Pub 2021. PMID: 33476401.
58. Lass-Flörl C, Dietl AM, Kontoyiannis DP, Brock M. Aspergillus terreus Species Complex. Clin Microbiol Rev:e0031120. e-Pub 2021. PMID: 34190571.
59. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2021. PMID: 32236406.
60. Aitken SL, Sahasrabhojane PV, Kontoyiannis DP, Savidge TC, Arias CA, Ajami NJ, Shelburne SA, Galloway-Peña JR. Alterations of the oral microbiome and cumulative carbapenem exposure are associated with Stenotrophomonas maltophilia infection in patients with acute myeloid leukemia receiving chemotherapy. Clin Infect Dis 72(9):1507-1513, 2021. e-Pub 2021. PMID: 32544947.
61. John TM, Jacob CN, Kontoyiannis DP. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi (Basel) 7(4), 2021. e-Pub 2021. PMID: 33920755.
62. Gudiol C, Lewis RE, Strati P, Kontoyiannis DP. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?. Lancet Haematol 8(3):e216-e228, 2021. e-Pub 2021. PMID: 33460558.
63. Axell-House DB, Wurster S, Jiang Y, Kyvernitakis A, Lewis RE, Tarrand JJ, Raad II, Kontoyiannis DP. Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer. J Fungi (Basel) 7(3), 2021. e-Pub 2021. PMID: 33802827.
64. Wurster S, Ruiz OE, Samms KM, Tatara AM, Albert ND, Kahan PH, Nguyen AT, Mikos AG, Kontoyiannis DP, Eisenhoffer GT. EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion. Cell Rep 34(12):108896, 2021. e-Pub 2021. PMID: 33761358.
65. Pérez-Jacoiste Asín MA, López-Medrano F, Fernández-Ruiz M, Silva JT, San Juan R, Kontoyiannis DP, Aguado JM. Risk factors for the development of invasive aspergillosis after kidney transplantation: Systematic review and meta-analysis. Am J Transplant 21(2):703-716, 2021. e-Pub 2021. PMID: 32780498.
66. Chamilos G, Lionakis MS, Kontoyiannis DP. Are All Patients with Cancer at Heightened Risk for Severe Coronavirus Disease 2019 (COVID-19)?. Clin Infect Dis 72(2):351-356, 2021. e-Pub 2021. PMID: 33501958.
67. Wurster S, Lyos S, Albert ND, Kontoyiannis DP. Pharmacological serum concentrations of epinephrine and norepinephrine do not affect growth rate, morphogenesis, stress tolerance, and virulence of Candida albicans. Med Mycol 59(1):102-105, 2021. e-Pub 2021. PMID: 32678869.
68. Wurster S, Sass G, Albert ND, Nazik H, Déziel E, Stevens DA, Kontoyiannis DP. Live imaging and quantitative analysis of Aspergillus fumigatus growth and morphology during inter-microbial interaction with Pseudomonas aeruginosa. Virulence 11(1):1329-1336, 2020. e-Pub 2020. PMID: 33017225.
69. Szvalb AD, Malek AE, Jiang Y, Bhatti MM, Wurster S, Kontoyiannis DP. Serum (1,3)-Beta-d-Glucan has suboptimal performance for the diagnosis of Pneumocystis jirovecii pneumonia in cancer patients and correlates poorly with respiratory burden as measured by quantitative PCR. J Infect 81(3):443-451, 2020. e-Pub 2020. PMID: 32650108.
70. Johnson MD, Lewis RE, Dodds Ashley ES, Ostrosky-Zeichner L, Zaoutis T, Thompson GR, Andes DR, Walsh TJ, Pappas PG, Cornely OA, Perfect JR, Kontoyiannis DP. Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. J Infect Dis 222(Supplement_3):S175-S198, 2020. e-Pub 2020. PMID: 32756879.
71. Spallone A, Hicklen RS, Kontoyiannis DP. Invasive fungal infections at presentation of untreated hematologic malignancies: rare and elusive. Open Forum Infect Dis 7(7):ofaa247, 2020. e-Pub 2020. PMID: 32704512.
72. Frei M, Aitken SL, Jain N, Thompson P, Wierda W, Kontoyiannis DP, DiPippo AJ. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma:1-4. e-Pub 2020. PMID: 32530347.
73. Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, DP K, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis:e13395. e-Pub 2020. PMID: 32602954.
74. Wurster S, Tatara AM, Albert ND, Ibrahim AS, Heitman J, Lee SC, Shetty AC, McCracken C, Graf KT, Mikos AG, Bruno VM, DP K. Tornadic shear stress induces a transient, calcineurin-dependent hyper-virulent phenotype in Mucorales molds. mBio 11(3), 2020. e-Pub 2020. PMID: 32605990.
75. Wurster S, Robinson P, Albert ND, Tarrand JJ, Goff M, Swamydas M, Lim JK, Lionakis MS, Kontoyiannis DP. PD-1 blockade improves survival and fungal clearance, induces pro-inflammatory lung cytokines and synergizes with caspofungin in a pulmonary aspergillosis model. J Infect Dis. e-Pub 2020. PMID: 32432714.
76. Robinson S, Peterson CB, Sahasrabhojane P, Ajami NJ, Shelburne SA, Kontoyiannis DP, Galloway-Peña JR. Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia. mSphere 5(2), 2020. e-Pub 2020. PMID: 32295867.
77. Galloway-Peña JR, Kontoyiannis DP. The gut mycobiome: The overlooked constituent of clinical outcomes and treatment complications in patients with cancer and other immunosuppressive conditions. PLoS Pathog 16(4):e1008353, 2020. e-Pub 2020. PMID: 32240277.
78. Fernández-Cruz A, Lewis RE, Kontoyiannis DP. How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions. Clin Infect Dis. e-Pub 2020. PMID: 32170948.
79. Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol 11:590494, 2020. e-Pub 2020. PMID: 33552049.
80. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrisey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. e-Pub 2019. PMID: 31802125.
81. Lewis RE, Wurster S, Beyda ND, Albert ND, Kontoyiannis DP. Comparative In Vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis. Diagn Microbiol Infect Dis 95(3):114861, 2019. e-Pub 2019. PMID: 31427139.
82. Kontoyiannis DP, Koons GL, Hicklen RS, Mikos AG, Kontoyiannis DP. Insect Bite-Associated Invasive Fungal Infections. Open Forum Infect Dis 6(10):ofz385, 2019. e-Pub 2019. PMID: 31660349.
83. Cornely OA, Hoenigl M, Lass-Flörl C, Chen SC, Kontoyiannis DP, Morrissey CO, Thompson GR, Group Education MS, Consortium R, Medical Mycology TECO. Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses 62(9):716-729, 2019. e-Pub 2019. PMID: 31254420.
84. Wang Q, Kontoyiannis DP, Li R, Chen W, Bu D, Liu W. A Novel Broad Allele-Specific TaqMan Real-Time PCR Method To Detect Triazole-Resistant Strains of Aspergillus fumigatus, Even with a Very Low Percentage of Triazole-Resistant Cells Mixed with Triazole-Susceptible Cells. J Clin Microbiol 57(9), 2019. e-Pub 2019. PMID: 31315952.
85. Abers MS, Lionakis MS, Kontoyiannis DP. Checkpoint Inhibition and Infectious Diseases: A Good Thing?. Trends Mol Med, 2019. e-Pub 2019. PMID: 31494023.
86. Tatara AM, Watson E, Albert ND, Kontoyiannis PD, Kontoyiannis DP, Mikos AG. A Murine Model of Cutaneous Aspergillosis for Evaluation of Biomaterials-based Local Delivery Therapies. J Biomed Mater Res A 107(9):1867-1874, 2019. e-Pub 2019. PMID: 30882993.
87. Lewis RE, Kontoyiannis DP, Viale P, Sarpong EM. Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension. Antimicrob Agents Chemother. e-Pub 2019. PMID: 31527039.
88. Szvalb AD, Kontoyiannis DP. Acute acalculous cholecystitis due to Fusarium species and review of the literature on fungal cholecystitis. Mycoses 62(9):847-853, 2019. e-Pub 2019. PMID: 31166627.
89. Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan MAW, Wargo JA, Do KA, Jenq RR, Kontoyiannis DP, Shelburne SA. Gut Microbiome Signatures are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clin Infect Dis, 2019. e-Pub 2019. PMID: 31436833.
90. Magira EE, Chemaly RF, Jiang Y, Tarrand J, Kontoyiannis DP. Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients With Hematologic Malignancies: A Case-Control Study. Open Forum Infect Dis 6(7):ofz247, 2019. e-Pub 2019. PMID: 31338382.
91. Wurster S, Bandi A, Beyda ND, Albert ND, Raman NM, Raad II, Kontoyiannis DP. Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris. J Antimicrob Chemother 74(7):1904-1910, 2019. e-Pub 2019. PMID: 31225606.
92. Vargas-Cruz N, Reitzel RA, Rosenblatt J, Chaftari AM, Wilson Dib R, Hachem R, Kontoyiannis DP, Raad II. Nitroglycerin-Citrate-Ethanol (NiCE) Catheter Lock Solution is Highly Effective for in vitro Eradication of Candida auris Biofilm. Antimicrob Agents Chemother 63(7), 2019. e-Pub 2019. PMID: 31036689.
93. Stanzani M, Vianelli N, Cavo M, Kontoyiannis DP, Lewis RE. Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. J Infect 78(6):484-490, 2019. e-Pub 2019. PMID: 30974130.
94. Chow NA, Toda M, Pennington AF, Anassi E, Atmar RL, Cox-Ganser JM, Da Silva J, Garcia B, Kontoyiannis DP, Ostrosky-Zeichner L, Leining LM, McCarty J, Al Mohajer M, Murthy BP, Park JH, Schulte J, Shuford JA, Skrobarcek KA, Solomon S, Strysko J, Chiller TM, Jackson BR, Chew GL, Beer KD. Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey - Houston, Texas, 2017. MMWR Morb Mortal Wkly Rep 68(21):469-473, 2019. e-Pub 2019. PMID: 31145717.
95. Zhang H, Tan J, Kontoyiannis DP, Zhou Y, Liu W, Zhu P, Shi X, Wan Z, Li R, Liu W. Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China. Diagn Microbiol Infect Dis. e-Pub 2019. PMID: 31174994.
96. Wurster S, Kumaresan PR, Albert ND, Hauser PJ, Lewis RE, Kontoyiannis DP. Live monitoring and analysis of fungal growth, viability, and mycelial morphology using the IncuCyte NeuroTrack processing module. MBio 10(3), 2019. e-Pub 2019. PMID: 31138745.
97. Galloway-Peña JR, Peterson CB, Malik F, Sahasrabhojane PV, Shah DP, Brumlow CE, Carlin LG, Chemaly RF, Im JS, Rondon G, Felix E, Veillon L, Lorenzi PL, Alousi AM, Jenq RR, Kontoyiannis DP, Shpall EJ, Shelburne SA, Okhuysen PC. Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. Open Forum Infect Dis 6(5):ofz173, 2019. e-Pub 2019. PMID: 31065565.
98. Kontoyiannis DP, Shah EC, Wurster S, Aitken SL, Graviss L, Raad II, Chemaly RF. Culture-Documented Invasive Mold Infections at MD Anderson Cancer Center in Houston, Texas, Pre- and Post-Hurricane Harvey. Open Forum Infect Dis 6(4):ofz138, 2019. e-Pub 2019. PMID: 31024975.
99. DiPippo AJ, Kontoyiannis DP. Lack of toxicity with long term isavuconazole use in patients with hematologic malignancy. Clin Infect Dis. e-Pub 2019. PMID: 30861066.
100. Potenza L, Chitasombat MN, Klimko N, Bettelli F, Dragonetti G, Del Principe MI, Nucci M, Busca A, Fracchiolla N, Sciumè M, Spolzino A, Delia M, Mancini V, Nadali GP, Dargenio M, Shadrivova O, Bacchelli F, Aversa F, Sanguinetti M, Luppi M, Kontoyiannis DP, Pagano L. Rhodotorula infection in haematological patient: risk factors and outcome. Mycoses 62(3):223-229, 2019. e-Pub 2019. PMID: 30525252.
101. Wurster S, Lewis RE, Albert ND, Kontoyiannis DP. Pre-Exposure to Isavuconazole Increases the Virulence of Mucorales but not Aspergillus fumigatus in a Drosophila melanogaster Infection Model. Antimicrob Agents Chemother 63(2), 2019. e-Pub 2019. PMID: 30455245.
102. Alfayez M, Wang SA, Bannon SA, Kontoyiannis DP, Kornblau SM, Orange JS, Mace EM, DiNardo CD. Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype. Leuk Lymphoma:1-9. e-Pub 2019. PMID: 30648453.
103. DiPippo AJ, Rausch CR, Kontoyiannis DP. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. Mycoses 62(1):81-86, 2019. e-Pub 2019. PMID: 30230043.
104. Magira EE, Jiang Y, Economides M, Tarrand J, Kontoyiannis DP. Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre. Mycoses 61(11):861-867, 2018. e-Pub 2018. PMID: 30015364.
105. Tatara AM, Wurster S, Lockworth CR, Albert ND, Walsh TJ, Mikos AG, Eisenhoffer GT, Kontoyiannis DP. Immunosuppressed Adult Zebrafish Model of Mucormycosis. Antimicrob Agents Chemother 62(11), 2018. e-Pub 2018. PMID: 30150461.
106. Magira EE, Jiang Y, Kontoyiannis DP. Baseline serum Aspergillus galactomannan index in patients with hematologic malignancy and culture-documented invasive pulmonary aspergillosis: is there a difference among Aspergillus species?. Med Mycol, 2018. e-Pub 2018. PMID: 30339235.
107. Fernández-Cruz A, Magira E, Heo ST, Evans S, Tarrand J, Kontoyiannis DP. Bronchoalveolar lavage fluid cytology in culture-documented invasive pulmonary aspergillosis in patients with hematologic diseases: analysis of 67 episodes. J Clin Microbiol 56(10), 2018. e-Pub 2018. PMID: 30021823.
108. Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Soliman SSM, Shetty AC, McCracken C, Akoumianaki T, Stylianou K, Ioannou P, Pontikoglou C, Papadaki HA, Tzardi M, Belle V, Ettiene E, Beauvais A, Samonis G, Kontoyiannis DP, Andreakos E, Bruno VM, Ibrahim AS, Chamilos G. Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species. Nat Commun 9(1):3333, 2018. e-Pub 2018. PMID: 30127354.
109. Kyrmizi I, Ferreira H, Carvalho A, Figueroa JAL, Zarmpas P, Cunha C, Akoumianaki T, Stylianou K, Deepe GS, Samonis G, Lacerda JF, Campos A, Kontoyiannis DP, Mihalopoulos N, Kwon-Chung KJ, El-Benna J, Valsecchi I, Beauvais A, Brakhage AA, Neves NM, Latge JP, Chamilos G. Calcium sequestration by fungal melanin inhibits calcium-calmodulin signalling to prevent LC3-associated phagocytosis. Nat Microbiol 3(7):791-803, 2018. e-Pub 2018. PMID: 29849062.
110. Lacourt TE, Kavelaars A, Ohanian M, Shah ND, Shelburne SA, Futreal A, Kontoyiannis DP, Heijnen CJ. Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia. Oncotarget 9(58):31244-31252, 2018. e-Pub 2018. PMID: 30131851.
111. Strati P, Gabutti C, Thompson PA, Kontoyiannis DP, Ferrajoli A. Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. Leuk Lymphoma:1-3, 2018. e-Pub 2018. PMID: 29911929.
112. Castillo P, Wright KE, Kontoyiannis DP, Walsh T, Patel S, Chorvinsky E, Bose S, Hazrat Y, Omer B, Albert N, Leen AM, Rooney CM, Bollard CM, Cruz CRY. A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae. Mol Ther Methods Clin Dev 9:305-312, 2018. e-Pub 2018. PMID: 30038934.
113. Clancy CJ, Pappas PG, Vazquez J, Judson MA, Kontoyiannis DP, Thompson GR, Garey KW, Reboli A, Greenberg RN, Apewokin S, Lyon GM, Ostrosky-Zeichner L, Wu AHB, Tobin E, Nguyen MH, Caliendo AM. Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. Clin Infect Dis, 2018. e-Pub 2018. PMID: 29438475.
114. Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough fungal infections in leukemia patients receiving isavuconazole. Clin Infect Dis, 2018. e-Pub 2018. PMID: 29771293.
115. Schwartz S, Kontoyiannis DP, Harrison T, Ruhnke M. Advances in the diagnosis and treatment of fungal infections of the CNS. Lancet Neurol 17(4):362-372, 2018. e-Pub 2018. PMID: 29477506.
116. Liu J, Mouhayar E, Tarrand JJ, Kontoyiannis DP. Fulminant Cryptococcus neoformans infection with fatal pericardial tamponade in a patient with chronic myelomonocytic leukemia who was treated with ruxolitinib: Case report and review of fungal pericarditis. Mycoses 61(4):245-255, 2018. e-Pub 2018. PMID: 29280197.
117. Lacourt TE, Kavelaars A, Galloway-Peña JR, Sahasrabhojane PV, Shah ND, Futreal A, Kontoyiannis DP, Shelburne SA, Heijnen CJ. Associations of inflammation with symptom burden in patients with acute myeloid leukemia. Psychoneuroendocrinology 89:203-208, 2018. e-Pub 2018. PMID: 29414033.
118. Zoran T, Sartori B, Sappl L, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, Kontoyiannis DP, Alastruey-Izquierdo A, Lagrou K, Cascio GL, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, Tortorano AM, Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadis J, Prammer W, Tullio V, Vehreschild JJ, Trovato L, Lewis RE, Segal E, Rath PM, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikan-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Uzun O, Roudbary M, de la Fuente S, Houbraken J, Risslegger B, Lass-Flörl C, Lackner M. Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Front Microbiol 9:516, 2018. e-Pub 2018. PMID: 29643840.
119. Sagiv O, Thakar SD, Kandl TJ, Kontoyiannis DP, Debnam JM, Esmaeli B. Clinical Course of Preseptal and Orbital Cellulitis in 50 Immunocompromised Patients with Cancer. Ophthalmology. e-Pub 2017. PMID: 29128228.
120. Kontoyiannis DP, Selleslag D, Mullane K, Cornely OA, Hope W, Lortholary O, Croos-Dabrera R, Lademacher C, Engelhardt M, Patterson TF. Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. e-Pub 2017. PMID: 29194488.
121. Taj-Aldeen SJ, Gamaletsou MN, Rammaert B, Sipsas NV, Zeller V, Roilides E, Kontoyiannis DP, Henry M, Petraitis V, Moriyama B, Denning DW, Lortholary O, Walsh TJ, Mycoses Consortium IO. Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century. Med Mycol 55(7):691-704, 2017. e-Pub 2017. PMID: 28053147.
122. Risslegger B, Zoran T, Lackner M, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, Kontoyiannis DP, Alastruey-Izquierdo A, Lagrou K, Lo Cascio G, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, Tortorano AM, Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadis J, Prammer W, Tullio V, Vehreschild JJ, Trovato L, Lewis RE, Segal E, Rath PM, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikan-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Houbraken J, Uzun O, Edlinger M, Fuente S, Lass-Flörl C. A Prospective International Aspergillus terreus Survey: An EFISG, ISHAM and ECMM Joint Study. Clin Microbiol Infect 23(10):776.e1-776.e5, 2017. e-Pub 2017. PMID: 28412383.
123. Kontoyiannis DP, Bassetti M, Nucci M, Capparella MR, Yan JL, Aram J, Hogan PA. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses 60(10):663-667, 2017. e-Pub 2017. PMID: 28597967.
124. Chamilos G, Lionakis MS, Kontoyiannis DP. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clin Infect Dis. e-Pub 2017. PMID: 29029010.
125. Economides MP, Ballester LY, Kumar VA, Jiang Y, Tarrand J, Prieto V, Torres HA, Kontoyiannis DP. Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000-2016): Uncommon, with improved survival but still deadly often. J Infect. e-Pub 2017. PMID: 28919347.
126. Le A, Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Initial treatment of cancer patients with fluconazole susceptible dose-dependent Candida glabrata fungemia: Better outcome with an echinocandin or polyene compared to an azole?. Antimicrob Agents Chemother 61(8), 2017. e-Pub 2017. PMID: 28584138.
127. Tverdek FP, Heo ST, Aitken SL, Granwehr B, Kontoyiannis DP. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections: Analysis of 343 courses. Antimicrob Agents Chemother 61(8), 2017. e-Pub 2017. PMID: 28507111.
128. Ben Yaakov D, Shadkchan Y, Albert N, Kontoyiannis DP, Osherov N. The quinoline bromoquinol exhibits broad-spectrum antifungal activity and induces oxidative stress and apoptosis in Aspergillus fumigatus. J Antimicrob Chemother. e-Pub 2017. PMID: 28475687.
129. Tatara AM, Watson E, Satish T, Scott DW, Kontoyiannis DP, Engel PS, Mikos AG. Synthesis and Characterization of Diol-based Unsaturated Polyesters: Poly(Diol Fumarate) and Poly(Diol Fumarate-co-Succinate). Biomacromolecules. e-Pub 2017. PMID: 28486802.
130. Heo ST, Tatara AM, Jiménez-Ortigosa C, Jiang Y, Lewis RE, Tarrand J, Tverdek F, Albert ND, Verweij PE, Meis JF, Mikos AG, Perlin DS, Kontoyiannis DP. Changes in in vitro susceptibility patterns of Aspergillus to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center (1999-2015). Clin Infect Dis, 2017. e-Pub 2017. PMID: 28379304.
131. El Boghdadly Z, Oran B, Jiang Y, Rondon G, Champlin R, Kontoyiannis DP. Pretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome. Bone Marrow Transplant 52(3):476-479, 2017. e-Pub 2017. PMID: 27941772.
132. Lionakis MS, Albert ND, Swamydas M, Lee CR, Loetscher P, Kontoyiannis DP. Pharmacological blockade of the chemokine receptor CCR1 protects mice from systemic candidiasis of hematogenous origin. Antimicrob Agents Chemother 61(3), 2017. e-Pub 2017. PMID: 27993850.
133. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, Shpall EJ, Daver N, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Med 9(1):21, 2017. e-Pub 2017. PMID: 28245856.
134. Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. Open Forum Infect Dis 4(1):ofw261, 2017. e-Pub 2017. PMID: 28480254.
135. Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis 19(1), 2017. e-Pub 2017. PMID: 27862740.
136. Heo ST, Aitken SL, Tverdek FP, Kontoyiannis DP. How Common is Subsequent Central Nervous System Toxicity in Asymptomatic Patients with Haematologic Malignancy and Supratherapeutic Voriconazole Serum Levels?. Clin Microbiol Infect, 2017. e-Pub 2017. PMID: 28082193.
137. Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis 16(1):730, 2016. e-Pub 2016. PMID: 27905900.
138. Gamaletsou MN, Rammaert B, Bueno MA, Sipsas NV, Moriyama B, Kontoyiannis DP, Roilides E, Zeller V, Taj-Aldeen SJ, Henry M, Petraitis V, Denning DW, Lortholary O, Walsh TJ, Mycoses Consortium IO. Aspergillus arthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases. Med Mycol. e-Pub 2016. PMID: 27609563.
139. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 63(4):433-42, 2016. e-Pub 2016. PMID: 27481947.
140. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer 122(14):2186-96, 2016. e-Pub 2016. PMID: 27142181.
141. Stempel JM, Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Time-to-reporting of blood culture positivity and central venous catheter-associated Candida glabrata fungemia in cancer patients. Diagn Microbiol Infect Dis 85(3):391-3, 2016. e-Pub 2016. PMID: 27133559.
142. Bellanger AP, Tatara AM, Shirazi F, Gebremariam T, Albert ND, Lewis RE, Ibrahim AS, Kontoyiannis DP. Sub-minimum inhibitory concentrations of statins attenuate the virulence of Rhizopus oryzae. J Infect Dis 214(1):114-21, 2016. e-Pub 2016. PMID: 26984141.
143. Tatara AM, Mikos AG, Kontoyiannis DP. Factors affecting patient outcome in primary cutaneous aspergillosis. Medicine (Baltimore) 95(26):e3747, 2016. e-Pub 2016. PMID: 27367980.
144. Gebremariam T, Lin L, Liu M, Kontoyiannis DP, French S, Edwards JE, Filler SG, Ibrahim AS. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J Clin Invest 126(6):2280-94, 2016. e-Pub 2016. PMID: 27159390.
145. Nigo M, Vial MR, Munita JM, Jiang Y, Tarrand J, Jimenez CA, Kontoyiannis DP. Fungal empyema thoracis in cancer patients. J Infect 72(5):615-21, 2016. e-Pub 2016. PMID: 26945845.
146. Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K. Symptomatic BK Virus Infection Is Associated with Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant 16(5):1492-502, 2016. e-Pub 2016. PMID: 26608093.
147. Ben Yaakov D, Rivkin A, Mircus G, Albert N, Dietl AM, Kovalerchick D, Carmeli S, Haas H, Kontoyiannis DP, Osherov N. Identification and characterization of haemofungin, a novel antifungal compound that inhibits the final step of haem biosynthesis. J Antimicrob Chemother 71(4):946-52, 2016. e-Pub 2016. PMID: 26747101.
148. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. e-Pub 2016. PMID: 27085727.
149. Ioannou P, Andrianaki A, Akoumianaki T, Kyrmizi I, Albert N, Perlin D, Samonis G, Kontoyiannis DP, Chamilos G. Albumin enhances caspofungin activity against Aspergillus species by facilitating drug delivery to germinating hyphae. Antimicrob Agents Chemother 60(3):1226-33, 2016. e-Pub 2016. PMID: 26643329.
150. Aitken SL, Zhou J, Ghantoji SS, Kontoyiannis DP, Jones RB, Tam VH, Chemaly RF. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother 71(3):727-30, 2016. e-Pub 2016. PMID: 26612873.
151. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non inferiority trial. Lancet 387(10020):760-9, 2016. e-Pub 2016. PMID: 26684607.
152. Throckmorton K, Lim FY, Kontoyiannis DP, Zheng W, Keller NP. Redundant synthesis of a conidial polyketide by two distinct secondary metabolite clusters in Aspergillus fumigatus. Environ Microbiol 18(10.1111/1462-2920.13007):246-59, 2016. e-Pub 2016. PMID: 26242966.
153. Akoumianaki T, Kyrmizi I, Valsecchi I, Gresnigt MS, Samonis G, Drakos E, Boumpas D, Muszkieta L, Prevost MC, Kontoyiannis DP, Chavakis T, Netea MG, van de Veerdonk FL, Brakhage AA, El-Benna J, Beauvais A, Latge JP, Chamilos G. Aspergillus Cell Wall Melanin Blocks LC3-Associated Phagocytosis to Promote Pathogenicity. Cell Host Microbe 19(1):79-90, 2016. e-Pub 2016. PMID: 26749442.
154. Gamaletsou MN, Rammaert B, Bueno MA, Sipsas NV, Moriyama B, Kontoyiannis DP, Roilides E, Zeller V, Taj-Aldeen SJ, Miller AO, Petraitiene R, Lortholary O, Walsh TJ. Candida Arthritis: Analysis of 112 Pediatric and Adult Cases. Open Forum Infect Dis 3(1):ofv207, 2016. e-Pub 2016. PMID: 26858961.
155. Shirazi F, Ferreira JA, Stevens DA, Clemons KV, Kontoyiannis DP. Biofilm Filtrates of Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients Inhibit Preformed Aspergillus fumigatus Biofilms via Apoptosis. PLoS One 11(3):e0150155, 2016. e-Pub 2016. PMID: 26930399.
156. Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD, Farmakiotis D, Kontoyiannis DP, Sanglard D, Taj-Aldeen SJ, Alexander BD, Jimenez-Ortigosa C, Shor E, Perlin DS. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun 7:11128, 2016. e-Pub 2016. PMID: 27020939.
157. Bellanger AP, Albert ND, Lewis RE, Walsh TJ, Kontoyiannis DP. Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae. Antimicrob Agents Chemother 59(12):7830-2, 2015. e-Pub 2015. PMID: 26392499.
158. Taj-Aldeen SJ, Rammaert B, Gamaletsou M, Sipsas NV, Zeller V, Roilides E, Kontoyiannis DP, Miller AO, Petraitis V, Walsh TJ, Lortholary O, Mycoses Consortium IO. Osteoarticular Infections Caused by Non-Aspergillus Filamentous Fungi in Adult and Pediatric Patients: A Systematic Review. Medicine (Baltimore) 94(50):e2078, 2015. e-Pub 2015. PMID: 26683917.
159. Jung DS, Tverdek FP, Jiang Y, Kontoyiannis DP. Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests. J Antimicrob Chemother 70(11):3100-6, 2015. e-Pub 2015. PMID: 26311837.
160. Jung DS, Farmakiotis D, Jiang Y, Tarrand JJ, Kontoyiannis DP. Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA. Emerg Infect Dis 21(11):1942-50, 2015. e-Pub 2015. PMID: 26488845.
161. Davoudi S, Kumar VA, Jiang Y, Kupferman M, Kontoyiannis DP. Invasive mould sinusitis in patients with haematological malignancies: a 10 year single-centre study. J Antimicrob Chemother 70(10):2899-905, 2015. e-Pub 2015. PMID: 26188039.
162. Shirazi F, Lewis RE, Kontoyiannis DP. Micafungin induced apoptosis in Candida parapsilosis independent of its susceptibility to micafungin. Microb Cell 2(11):445-450, 2015. e-Pub 2015. PMID: 28357269.
163. Mircus G, Albert N, Ben-Yaakov D, Chikvashvili D, Shadkchan Y, Kontoyiannis DP, Osherov N. Identification and characterization of a novel family of selective antifungal compounds (CANBEFs) that interfere with fungal protein synthesis. Antimicrob Agents Chemother 59(9):5631-40, 2015. e-Pub 2015. PMID: 26149982.
164. Meller S, Di Domizio J, Voo KS, Friedrich HC, Chamilos G, Ganguly D, Conrad C, Gregorio J, Le Roy D, Roger T, Ladbury JE, Homey B, Watowich S, Modlin RL, Kontoyiannis DP, Liu YJ, Arold ST, Gilliet M. TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. Nat Immunol 16(10.1038/ni.3211):970-9, 2015. e-Pub 2015. PMID: 26168081.
165. Wang E, Farmakiotis D, Yang D, McCue DA, Kantarjian HM, Kontoyiannis DP, Mathisen MS. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother 70(8):2362-8, 2015. e-Pub 2015. PMID: 25855759.
166. Bellanger AP, Minetos YD, Albert N, Shirazi F, Walsh TJ, Kontoyiannis DP. Glucocorticosteroids do not impact directly growth rate and biomass of Rhizopus arrhizus (syn. R. oryzae) in vitro. Virulence 6(5):441-3, 2015. e-Pub 2015. PMID: 25942104.
167. McCarty TP, Baddley JW, Walsh TJ, Alexander BD, Kontoyiannis DP, Perl TM, Walker R, Patterson TF, Schuster MG, Lyon GM, Wingard JR, Andes DR, Park BJ, Brandt ME, Pappas PG, Investigators T. Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). Med Mycol 53(5):440-6, 2015. e-Pub 2015. PMID: 25908651.
168. Shirazi F, Kontoyiannis DP, Ibrahim AS. Iron starvation induces Apoptosis in Rhizopus oryzae in vitro. Virulence 6(2):121-6, 2015. e-Pub 2015. PMID: 25830548.
169. Miller AO, Gamaletsou MN, Henry MW, Al-Hafez L, Hussain K, Sipsas NV, Kontoyiannis DP, Roilides E, Brause BD, Walsh TJ. Successful treatment of Candida osteoarticular infections with limited duration of antifungal therapy and orthopedic surgical intervention. Infect Dis (Lond) 47(3):1-6, 2015. e-Pub 2015. PMID: 25539148.
170. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 60(6):892-9, 2015. e-Pub 2015. PMID: 25586686.
171. Raad II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents 45(3):283-8, 2015. e-Pub 2015. PMID: 25455847.
172. Simitsopoulou M, Walsh TJ, Kyrpitzi D, Petraitis V, Kontoyiannis DP, Perlin DS, Roilides E. Methylprednisolone impairs conidial phagocytosis but does not attenuate hyphal damage by neutrophils against Exserohilum rostratum. Med Mycol 53(2):189-93, 2015. e-Pub 2015. PMID: 25056961.
173. Torres HA, Mahale P, Blechacz B, Miller E, Kaseb A, Herlong HF, Fowler N, Jiang Y, Raad II, Kontoyiannis DP. Effect of Hepatitis C Virus Infection in Patients with Cancer: Addressing a Neglected Population. J Natl Compr Canc Netw 13(1):41-50, 2015. e-Pub 2015. PMID: 25583768.
174. Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, Heinz WJ, Jagannatha S, Koh LP, Kontoyiannis DP, Lee DG, Nucci M, Pappas PG, Slavin MA, Queiroz-Telles F, Selleslag D, Walsh TJ, Wingard JR, Maertens JA. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 162(2):81-9, 2015. e-Pub 2015. PMID: 25599346.
175. Farmakiotis D, Kyvernitakis A, Tarrand JJ, Kontoyiannis DP. Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation. Clin Microbiol Infect 21(1):79-86, 2015. e-Pub 2015. PMID: 25636931.
176. Neofytos D, Railkar R, Mullane KM, Fredricks DN, Granwehr B, Marr KA, Almyroudis NG, Kontoyiannis DP, Maertens J, Fox R, Douglas C, Iannone R, Kauh E, Shire N. Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. PLoS One 10(6):e0129022, 2015. e-Pub 2015. PMID: 26107507.
177. Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Galloway-Peña J, Albert N, Chemaly RF, Ghantoji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS One 10(11):e0139851, 2015. e-Pub 2015. PMID: 26556047.
178. Shirazi F, Kontoyiannis DP. Micafungin triggers caspase-dependent apoptosis in Candida albicans and Candida parapsilosis biofilms, including caspofungin non-susceptible isolates. Virulence 6(4):385-94, 2015. e-Pub 2015. PMID: 26065323.
179. Zanette RA, Bitencourt PE, Kontoyiannis DP, Fighera RA, Flores MM, Kommers GD, Silva PS, Ludwig A, Moretto MB, Alves SH, Santurio JM. Complex interaction of deferasirox and Pythium insidiosum: iron-dependent attenuation of growth in vitro and immunotherapy-like enhancement of immune responses in vivo. PLoS One 10(3):e0118932, 2015. e-Pub 2015. PMID: 25738758.
180. Rammaert B, Gamaletsou MN, Zeller V, Elie C, Prinapori R, Taj-Aldeen SJ, Roilides E, Kontoyiannis DP, Brause B, Sipsas NV, Walsh TJ, Lortholary O. Dimorphic fungal osteoarticular infections. Eur J Clin Microbiol Infect Dis 33(12):2131-40, 2014. e-Pub 2014. PMID: 24939620.
181. Davoudi S, Anderlini P, Fuller GN, Kontoyiannis DP. A Long-Term Survivor of Disseminated Aspergillus and Mucorales Infection: An Instructive Case. Mycopathologia 178(5-6):465-70, 2014. e-Pub 2014. PMID: 25086667.
182. Lewis RE, Albert ND, Kontoyiannis DP. Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis. Antimicrob Agents Chemother 58(11):6767-72, 2014. e-Pub 2014. PMID: 25182639.
183. Farmakiotis D, Shirazi F, Zhao Y, Saad PJ, Albert ND, Roilides E, Walsh TJ, Perlin DS, Kontoyiannis DP. Methylprednisolone Enhances the Growth of Exserohilum rostratum In-Vitro, Attenuates Spontaneous Apoptosis, and Increases Mortality Rates in Immunocompetent Drosophila Flies. J Infect Dis 210(9):1471-5, 2014. e-Pub 2014. PMID: 24837401.
184. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-Resistant Candida glabrata Infection in Cancer Patients. Emerg Infect Dis 20(11):1833-40, 2014. e-Pub 2014. PMID: 25340258.
185. Jung DS, Tverdek FP, Kontoyiannis DP. Switching from Posaconazole Suspension to Tablets Increased Serum Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity. Antimicrob Agents Chemother 58(11):6993-5, 2014. e-Pub 2014. PMID: 25199774.
186. Shirazi F, Farmakiotis D, Yan Y, Albert N, Kim-Anh D, Kontoyiannis DP. Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. PLoS One 9(9):e108635, 2014. e-Pub 2014. PMID: 25268492.
187. Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP, Cooper LJ. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A 111(29):10660-5, 2014. e-Pub 2014. PMID: 25002471.
188. Thompson GR, Albert N, Hodge G, Wilson MD, Sykes JE, Bays DJ, Firacative C, Meyer W, Kontoyiannis DP. Phenotypic Differences of Cryptococcus Molecular Types: implications for virulence in a Drosophila model of infection. Infect Immun 82(7):3058-3065, 2014. e-Pub 2014. PMID: 24799631.
189. Shirazi F, Kontoyiannis DP. Heat shock protein 90 and calcineurin pathway inhibitors enhance the efficacy of triazoles against Scedosporium prolificans via induction of apoptosis. Microb Cell 1(6):179-188, 2014. e-Pub 2014. PMID: 28357242.
190. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. The efficacy and tolerability of monotherapy with micafungin for candidemia and deep-seated candidiasis in adults with cancer. Antimicrob Agents Chemother 58(6):3526-9, 2014. e-Pub 2014. PMID: 24637687.
191. Zhao Y, Armeanu E, DiVerniero R, Lewis TA, Dobson RC, Kontoyiannis DP, Roilides E, Walsh TJ, Perlin DS. Fungal DNA Detected from Blood of Patients Who Received Contaminated Methylprednisolone Injections reveals more complexity of causative agents. J Clin Microbiol 52(6):2212-5, 2014. e-Pub 2014. PMID: 24719442.
192. Gomes MZ, Jiang Y, Mulanovich VE, Lewis RE, Kontoyiannis DP. Effectiveness of Primary anti-Aspergillus Prophylaxis During Remission Induction Chemotherapy of Acute Myeloid Leukemia. Antimicrob Agents Chemother 58(5):2775-80, 2014. e-Pub 2014. PMID: 24590477.
193. Katragkou A, Pana ZD, Perlin DS, Kontoyiannis DP, Walsh TJ, Roilides E. Exserohilum infections: Review of 48 cases before the 2012 United States outbreak. Med Mycol 52(4):376-86, 2014. e-Pub 2014. PMID: 24682112.
194. Gamaletsou MN, Rammaert B, Bueno MA, Moriyama B, Sipsas NV, Kontoyiannis DP, Roilides E, Zeller V, Prinapori R, Taj-Aldeen SJ, Brause B, Lortholary O, Walsh TJ. Aspergillus osteomyelitis: Epidemiology, clinical manifestations, management, and outcome. J Infect 68(5):478-93, 2014. e-Pub 2014. PMID: 24378282.
195. Kontoyiannis DP, Azie N, Franks B, Horn DL. Prospective antifungal therapy (PATH) alliance(®) : focus on mucormycosis. Mycoses 57(4):240-6, 2014. e-Pub 2014. PMID: 24147728.
196. Gomes MZ, Mulanovich VE, Jiang Y, Lewis RE, Kontoyiannis DP. Incidence Density of Invasive Fungal Infections during Primary Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia in a Tertiary Cancer Center, 2009 - 2011. Antimicrob Agents Chemother 58(2):865-73, 2014. e-Pub 2014. PMID: 24277033.
197. Dimopoulou D, Hamilos G, Tzardi M, Lewis RE, Samonis G, Kontoyiannis DP. Anidulafungin vs Caspofungin in a Mouse Model of Candidiasis Caused by Anidulafungin-Susceptible C. parapsilosis Isolates with Different Degrees of Caspofungin Susceptibility. Antimicrob Agents Chemother 58(1):229-36, 2014. e-Pub 2014. PMID: 24145540.
198. Lewis RE, Georgiadou SP, Sampsonas F, Chamilos G, Kontoyiannis DP. Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. Mycoses 57(1):49-55, 2014. e-Pub 2014. PMID: 23905713.
199. Lewis RE, Liao G, Young K, Douglas C, Kontoyiannis DP. Macrophage Reporter Cell Assay for Screening Immunopharmacological Activity of Cell-Wall Active Antifungals. Antimicrob Agents Chemother 58(3):1738-43, 2014. e-Pub 2014. PMID: 24395226.
200. Lewis RE, Cahyame-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli P, Tarrand J, Bodey GP, Luna M, Kontoyiannis DP. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 56(6):638-45, 2013. e-Pub 2013. PMID: 23551865.
201. Zanette RA, Santurio JM, ÉS L, Alves SH, Kontoyiannis DP. Toll-deficient Drosophila is susceptible to Pythium insidiosum infection. Microbiol Immunol 57(10):732-5, 2013. e-Pub 2013. PMID: 23865688.
202. Farmakiotis D, Ciurea AM, Cahuayme-Zuniga L, Kontoyiannis DP. The diagnostic yield of skin biopsy in patients with leukemia and suspected infection. J Infect 67(4):265-72, 2013. e-Pub 2013. PMID: 23769840.
203. Shirazi F, Kontoyiannis DP. The Calcineurin Pathway Inhibitor Tacrolimus Enhances The In Vitro Activity Of Azoles Against Mucorales Via Apoptosis. Eukaryot Cell 12(9):1225-34, 2013. e-Pub 2013. PMID: 23851337.
204. Shirazi F, Pontikos MA, Walsh TJ, Albert N, Lewis RE, Kontoyiannis DP. Hyperthermia Sensitizes Rhizopus oryzae To Posaconazole And Itraconazole Action Through Apoptosis. Antimicrob Agents Chemother 57(9):4360-8, 2013. e-Pub 2013. PMID: 23817366.
205. Kaluarachchi WD, Cisneros BT, Corr SJ, Albert ND, Curley SA, Kontoyiannis DP. Aspergillus fumigatus hyphal damage caused by noninvasive radiofrequency field hyperthermia. Antimicrob Agents Chemother 57(9):4444-8, 2013. e-Pub 2013. PMID: 23836166.
206. Kyrmizi I, Gresnigt MS, Akoumianaki T, Samonis G, Sidiropoulos P, Boumpas D, Netea MG, van de Veerdonk FL, Kontoyiannis DP, Chamilos G. Corticosteroids Block Autophagy Protein Recruitment in Aspergillus fumigatus Phagosomes via Targeting Dectin-1/Syk Kinase Signaling. J Immunol 191(3):1287-99, 2013. e-Pub 2013. PMID: 23817424.
207. Ben-Ami R, Rahav G, Elinav H, Kassis I, Shalit I, Gottesman T, Megged O, Weinberger M, Ciobotaro P, Shitrit P, Weber G, Paz A, Miron D, Oren I, Bishara J, Block C, Keller N, Kontoyiannis DP, Giladi M, Study Group IC. Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel. Clin Microbiol Infect 19(8):752-756, 2013. e-Pub 2013. PMID: 23005038.
208. Kontoyiannis DP, Georgiadou SP, Wierda WG, Wright S, Albert ND, Ferrajoli A, Keating M, Lewis RE. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma 54(8):1730-3, 2013. e-Pub 2013. PMID: 23163595.
209. Zanette RA, Kontoyiannis DP. Paradoxical effect to caspofungin in Candida species does not confer survival advantage in a Drosophila model of candidiasis. Virulence 4(6):497-8, 2013. e-Pub 2013. PMID: 23863608.
210. Diaz L, Kontoyiannis DP, Panesso D, Albert ND, Singh KV, Tran TT, Munita JM, Murray BE, Arias CA. Dissecting the Mechanisms of Linezolid Resistance in a Drosophila melanogaster Infection Model of Staphylococcus aureus. J Infect Dis 208(1):83-91, 2013. e-Pub 2013. PMID: 23547139.
211. Lewis RE, Albert NP, Liao G, Wang W, Prince RA, Kontoyiannis DP. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia. J Antimicrob Chemother 68(5):1148-51, 2013. e-Pub 2013. PMID: 23349440.
212. Zanette RA, Kontoyiannis DP. Pre-exposure of Candida species to cytarabine and daunorubicin does not affect their in vitro antifungal susceptibility and virulence in flies. Virulence 4(4):344-6, 2013. e-Pub 2013. PMID: 23611830.
213. Georgiadou SP, Tarrand J, Sipsas NV, Kontoyiannis DP. Candiduria in haematologic malignancy patients without a urinary catheter: nothing more than a frailty marker?. Mycoses 56(3):311-4, 2013. e-Pub 2013. PMID: 23170870.
214. Ben-Ami R, Albert ND, Lewis RE, Kontoyiannis DP. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis 207(7):1066-74, 2013. e-Pub 2013. PMID: 23303813.
215. Berthier E, Lim FY, Deng Q, Guo CJ, Kontoyiannis DP, Wang CC, Rindy J, Beebe DJ, Huttenlocher A, Keller NP. Low-Volume Toolbox for the Discovery of Immunosuppressive Fungal Secondary Metabolites. PLoS Pathog 9(4):e1003289, 2013. e-Pub 2013. PMID: 23592999.
216. Farmakiotis D, Tverdek FP, Kontoyiannis DP. The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B. Clin Infect Dis 56(5):701-3, 2013. e-Pub 2013. PMID: 23166189.
217. Lewis RE, Ben-Ami R, Best L, Albert N, Walsh TJ, Kontoyiannis DP. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis. J Infect Dis 207(5):834-41, 2013. e-Pub 2013. PMID: 23242544.
218. Ben-Ami R, Watson CC, Lewis RE, Albert ND, Arias CA, Raad II, Kontoyiannis DP. Drosophila melanogaster as a model to explore the effects of methicillin-resistant Staphylococcus aureus strain type on virulence and response to linezolid treatment. Microb Pathog 55:16-20, 2013. e-Pub 2013. PMID: 23232438.
219. McGrath DM, Barbu EM, Driessen WH, Lasco TM, Tarrand JJ, Okhuysen PC, Kontoyiannis DP, Sidman RL, Pasqualini R, Arap W. Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic. Proc Natl Acad Sci U S A 110(9):3477-82, 2013. e-Pub 2013. PMID: 23345420.
220. Baddley JW, Andes DR, Marr KA, Kauffman CA, Kontoyiannis DP, Ito JI, Schuster MG, Brizendine KD, Patterson TF, Lyon GM, Boeckh M, Oster RA, Chiller T, Pappas PG. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol 51(2):128-35, 2013. e-Pub 2013. PMID: 22680976.
221. Georgiadou SP, Sampsonas FL, Rice D, Granger JM, Swisher S, Kontoyiannis DP. Open-lung biopsy in patients with undiagnosed lung lesions referred at a tertiary cancer center is safe and reveals noncancerous, noninfectious entities as the most common diagnoses. Eur J Clin Microbiol Infect Dis 32(1):101-5, 2013. e-Pub 2013. PMID: 22895891.
222. Petraitis V, Petraitiene R, Antachopoulos C, Hughes JE, Cotton MP, Kasai M, Harrington S, Gamaletsou MN, Bacher JD, Kontoyiannis DP, Roilides E, Walsh TJ. Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism. Med Mycol 51(1):72-82, 2013. e-Pub 2013. PMID: 22686246.
223. Georgiadou SP, Lewis RE, Best L, Torres HA, Champlin RE, Kontoyiannis DP. The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis. Bone Marrow Transplant 48(1):141-3, 2013. e-Pub 2013. PMID: 22635244.
224. Palmer JM, Bok JW, Lee S, Dagenais TR, Andes DR, Kontoyiannis DP, Keller NP. Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in Aspergillus fumigatus. PeerJ 1:e4, 2013. e-Pub 2013. PMID: 23638376.
225. Barbu EM, Shirazi F, McGrath DM, Albert N, Sidman RL, Pasqualini R, Arap W, Kontoyiannis DP. An Antimicrobial Peptidomimetic Induces Mucorales Cell Death through Mitochondria-Mediated Apoptosis. PLoS One 8(10):e76981, 2013. e-Pub 2013. PMID: 24098573.
226. Shirazi F, Kontoyiannis DP. Mitochondrial Respiratory Pathways Inhibition in Rhizopus oryzae Potentiates Activity of Posaconazole and Itraconazole via Apoptosis. PLoS One 8(5):e63393, 2013. e-Pub 2013. PMID: 23696824.
227. Gamaletsou MN, Sipsas NV, Kontoyiannis DP, Tsiakalos A, Kontos AN, Stefanou I, Kordossis T. Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-γ. Diagn Microbiol Infect Dis 74(4):409-11, 2012. e-Pub 2012. PMID: 22975207.
228. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 57(6):1177-85, 2012. e-Pub 2012. PMID: 22871500.
229. Gamaletsou MN, Kontoyiannis DP, Sipsas NV, Moriyama B, Alexander E, Roilides E, Brause B, Walsh TJ. Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). Clin Infect Dis 55(10):1338-51, 2012. e-Pub 2012. PMID: 22911646.
230. Chamilos G, Gregorio J, Meller S, Lande R, Kontoyiannis DP, Modlin RL, Gilliet M. Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. Blood 120(18):3699-707, 2012. e-Pub 2012. PMID: 22927244.
231. Georgiadou SP, Kontoyiannis DP. Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis?. J Infect 65(3):262-8, 2012. e-Pub 2012. PMID: 22580034.
232. Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, Ibrahim AS, Brass EP. Risk factors for mortality in patients with mucormycosis. Med Mycol 50(6):611-8, 2012. e-Pub 2012. PMID: 22435877.
233. Torres HA, Nevah MI, Barnett BJ, Mahale P, Kontoyiannis DP, Hassan MM, Raad II. Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: a retrospective multicenter study. J Clin Virol 54(3):218-22, 2012. e-Pub 2012. PMID: 22459004.
234. Cahuayme-Zuniga L, Lewis RE, Mulanovich VE, Kontoyiannis DP. Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies. Med Mycol 50(5):543-8, 2012. e-Pub 2012. PMID: 22103347.
235. Georgiadou SP, Pongas G, Fitzgerald NE, Lewis RE, Rytting M, Marom EM, Kontoyiannis DP. Invasive mold infections in pediatric cancer patients reflect heterogeneity in etiology, presentation, and outcome: a 10-year, single-institution, retrospective study. J Pediatric Infect Dis Soc 1(2):125-35, 2012. e-Pub 2012. PMID: 26619165.
236. Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 54(11):1629-36, 2012. e-Pub 2012. PMID: 22431807.
237. Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, Wiener-Well Y, Weinberger M, Zimhony O, Chowers M, Weber G, Potasman I, Chazan B, Kassis I, Shalit I, Block C, Keller N, Kontoyiannis DP, Giladi M, Study Group IC. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother 56(5):2518-23, 2012. e-Pub 2012. PMID: 22314534.
238. Tarrand JJ, LaSala PR, Han XY, Rolston KV, Kontoyiannis DP. Dimethyl sulfoxide enhances effectiveness of skin antiseptics and reduces contamination rates of blood cultures. J Clin Microbiol 50(5):1552-7, 2012. e-Pub 2012. PMID: 22378911.
239. Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, Fredricks D, Brass EP. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 67(3):715-22, 2012. e-Pub 2012. PMID: 21937481.
240. Pongas G, Hamilos G, Rolston KV, Kontoyiannis DP. Formal adult infectious disease specialist consultations in the outpatient setting at a comprehensive cancer center (1998-2008): Diverse and impactful. Support Care Cancer 20(2):261-5, 2012. e-Pub 2012. PMID: 21191800.
241. Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, Kontoyiannis DP. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect 64(1):68-75, 2012. e-Pub 2012. PMID: 22101079.
242. Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt L, Ito JI, Kauffman CA, Lyon GM, Marr KA, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wingard JR, Walsh TJ, Kontoyiannis DP. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 17(10):1855-64, 2011. e-Pub 2011. PMID: 22000355.
243. Perfect JR, Pfaller MA, Ostrosky-Zeichner L, Kontoyiannis DP. Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity). Am J Med 124(10):S2-3, 2011. e-Pub 2011. PMID: 21962326.
244. Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, Kontoyiannis DP, Champlin RE, Ciurea SO. Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. Biol Blood Marrow Transplant 17(10):1551-5, 2011. e-Pub 2011. PMID: 21396475.
245. Al Akhrass F, Hachem R, Mohamed JA, Tarrand J, Kontoyiannis DP, Chandra J, Ghannoum M, Haydoura S, Chaftari AM, Raad I. Central venous catheter-associated Nocardia bacteremia in cancer patients. Emerg Infect Dis 17(9):1651-8, 2011. e-Pub 2011. PMID: 21888790.
246. Lockhart SR, Zimbeck AJ, Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Pappas PG, Chiller T. In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the transplant-associated infection surveillance network. Antimicrob Agents Chemother 55(8):3944-6, 2011. e-Pub 2011. PMID: 21670187.
247. Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, Kontoyiannis DP. Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance. J Infect Dis 204(4):626-35, 2011. e-Pub 2011. PMID: 21791665.
248. Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: A Prospective 2-Year Study. Cancer 117(15):3424-33, 2011. e-Pub 2011. PMID: 21246537.
249. Rizos EC, Salanti G, Kontoyiannis DP, Ioannidis JP. Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents. J Clin Epidemiol 64(8):830-42, 2011. e-Pub 2011. PMID: 21411286.
250. Lewis RE, Leventakos K, Liao G, Kontoyiannis DP. Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrob Agents Chemother 55(7):3584-7, 2011. e-Pub 2011. PMID: 21537029.
251. Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence 2(4):348-55, 2011. e-Pub 2011. PMID: 21788730.
252. Lewis RE, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. J Antimicrob Chemother 66(6):1324-31, 2011. e-Pub 2011. PMID: 21486855.
253. Al Akhrass F, Debiane L, Abdallah L, Best L, Mulanovich V, Rolston K, Kontoyiannis DP. Palatal mucormycosis in patients with hematologic malignancy and stem cell transplantation. Med Mycol 49(4):400-5, 2011. e-Pub 2011. PMID: 21077735.
254. Ben-Ami R, Lewis RE, Kontoyiannis DP. In vitro interactions among echinocandins against Aspergillus fumigatus: lack of concordance among methods. Med Mycol 49(3):285-8, 2011. e-Pub 2011. PMID: 21028945.
255. Mulanovich VE, Ahmed SI, Öztürk T, Khokhar FA, Kontoyiannis DP, de Lima M. Toxoplasmosis in allo-SCT patients: risk factors and outcomes at a transplantation center with a low incidence. Bone Marrow Transplant 46(2):273-7, 2011. e-Pub 2011. PMID: 20436521.
256. Lewis RE, Pongas GN, Albert N, Ben-Ami R, Walsh TJ, Kontoyiannis DP. Activity of deferasirox in Mucorales: Influences of species and exogenous iron. Antimicrob Agents Chemother 55(1):411-3, 2011. e-Pub 2011. PMID: 20956598.
257. Ramos ER, Jiang Y, Hachem R, Kassis C, Kontoyiannis DP, Raad I. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. Oncologist 16(7):1049-60, 2011. e-Pub 2011. PMID: 21659609.
258. Evans SE, Leventakos K, Ben-Ami R, You D, Thakkar SG, Lewis RE, Kontoyiannis DP. Toll-deficient Drosophila are resistant to infection by Pneumocystis spp.: additional evidence of specificity to mammalian hosts. Virulence 1(6):523-5, 2010. e-Pub 2010. PMID: 21178507.
259. Nguyen MH, Husain S, Clancy CJ, Peacock JE, Hung CC, Kontoyiannis DP, Morris AJ, Heath CH, Wagener M, Yu VL. Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect 61(5):419-26, 2010. e-Pub 2010. PMID: 20732350.
260. Milito MA, Kontoyiannis DP, Lewis RE, Liu P, Mawlawi OR, Truong MT, Marom EM. Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis. Med Mycol 48(6):817-23, 2010. e-Pub 2010. PMID: 20109093.
261. Feldman EM, Kontoyiannis DP, Sharabi SE, Lee E, Kaufman Y, Heller L. Breast implant infections: is cefazolin enough?. Plast Reconstr Surg 126(3):779-85, 2010. e-Pub 2010. PMID: 20811212.
262. Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, McDermott LA, Tsai K, Marty FM, Kontoyiannis DP, Golan Y. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?. J Antimicrob Chemother 65(7):1460-5, 2010. e-Pub 2010. PMID: 20430790.
263. Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyiannis DP, Rolston KV, Walsh TJ, Champlin RE, Raad II. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore) 89(4):236-44, 2010. e-Pub 2010. PMID: 20616663.
264. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MG, Wingard JR, Patterson TF, Ito JI, Williams OD, Chiller T, Pappas PG. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 50(12):1559-67, 2010. e-Pub 2010. PMID: 20450350.
265. Panackal AA, Li H, Kontoyiannis DP, Mori M, Perego CA, Boeckh M, Marr KA. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 50(12):1588-97, 2010. e-Pub 2010. PMID: 20450414.
266. Chamilos G, Bignell EM, Schrettl M, Lewis RE, Leventakos K, May GS, Haas H, Kontoyiannis DP. Exploring the concordance of Aspergillus fumigatus pathogenicity in mice and Toll-deficient flies. Med Mycol 48(3):506-10, 2010. e-Pub 2010. PMID: 20370364.
267. Campo M, Lewis RE, Kontoyiannis DP. Invasive Fusariosis in Patients with Hematologic Malignancies at a Cancer Center: 1998-2009. J Infect 60(5):331-7, 2010. e-Pub 2010. PMID: 20138081.
268. Ben-Ami R, Varga V, Lewis RE, May GS, Nierman WC, Kontoyiannis DP. Characterization of a 5-azacytidine-induced developmental Aspergillus fumigatus variant. Virulence 1(3):164-73, 2010. e-Pub 2010. PMID: 21178435.
269. Ben-Ami R, Lewis RE, Leventakos K, Latgé JP, Kontoyiannis DP. A Cutaneous model of invasive aspergillosis. Antimicrob Agents Chemother 54(5):1848-54, 2010. e-Pub 2010. PMID: 20145078.
270. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50(8):1091-100, 2010. e-Pub 2010. PMID: 20218877.
271. Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant 45(4):647-55, 2010. e-Pub 2010. PMID: 19684637.
272. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50(8):1101-11, 2010. e-Pub 2010. PMID: 20218876.
273. Ben-Ami R, Lamaris GA, Lewis RE, Kontoyiannis DP. Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis. Med Mycol 48(2):1-9, 2010. e-Pub 2010. PMID: 19642052.
274. Tan CH, Kontoyiannis DP, Viswanathan C, Iyer RB. Tuberculosis: a benign impostor. AJR Am J Roentgenol 194(3):555-61, 2010. e-Pub 2010. PMID: 20173128.
275. Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 54(3):1298-304, 2010. e-Pub 2010. PMID: 20038620.
276. Vigil KJ, Johnson JR, Johnston BD, Kontoyiannis DP, Mulanovich VE, Raad II, Dupont HL, Adachi JA. Escherichia coli pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis 50(3):374-80, 2010. e-Pub 2010. PMID: 20038242.
277. Ben-Ami R, Lasala PR, Lewis RE, Kontoyiannis DP. Lack of galactomannan reactivity in dematiaceous molds recovered from cancer patients with phaeohyphomycosis. Diagn Microbiol Infect Dis 66(2):200-3, 2010. e-Pub 2010. PMID: 19836185.
278. Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 65(2):293-5, 2010. e-Pub 2010. PMID: 20016020.
279. Evans SE, Scott BL, Clement CG, Larson DT, Kontoyiannis DP, Lewis RE, Lasala PR, Pawlik J, Peterson JW, Chopra AK, Klimpel G, Bowden G, Höök M, Xu Y, Tuvim MJ, Dickey BF. Stimulated Innate Resistance of Lung Epithelium Protects Mice Broadly Against Bacteria and Fungi. Am J Respir Cell Mol Biol 42(1):40-50, 2010. e-Pub 2010. PMID: 19329554.
280. Ben-Ami R, Lewis RE, Tarrand J, Leventakos K, Kontoyiannis DP. Antifungal activity of colistin against Mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother 54(1):484-90, 2010. e-Pub 2010. PMID: 19858263.
281. Chamilos G, Ganguly D, Lande R, Gregorio J, Meller S, Goldman WE, Gilliet M, Kontoyiannis DP. Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of T(H)-17 responses. PLoS One 5(9):e12955, 2010. e-Pub 2010. PMID: 20886035.
282. Ben-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 114(26):5393-9, 2009. e-Pub 2009. PMID: 19843884.
283. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27(32):5425-30, 2009. e-Pub 2009. PMID: 19805674.
284. Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Balajee SA, Pappas PG, Moser SA. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the transplant-associated infection surveillance network. J Clin Microbiol 47(10):3271-5, 2009. e-Pub 2009. PMID: 19692558.
285. Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, Andes D, Kontoyiannis DP, Perrone G, Peterson S, Brandt ME, Pappas PG, Chiller T. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 47(10):3138-41, 2009. e-Pub 2009. PMID: 19675215.
286. Pongas GN, Ben-Ami R, Lewis RE, Walsh TJ, Kontoyiannis DP. Culture medium composition affects the lethality of Cunninghamella bertholletiae in a fly model of mucormycosis. Antimicrob Agents Chemother 53(10):4569, 2009. e-Pub 2009. PMID: 19635953.
287. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, Kontoyiannis DP. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115(20):4745-52, 2009. e-Pub 2009. PMID: 19634156.
288. Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer 115(17):3919-23, 2009. e-Pub 2009. PMID: 19551882.
289. Roussos P, Lewis RE, Kontoyiannis DP. Azoles and antidepressants: a mini-review of the tolerability of co-administration. Mycoses 52(5):433-9, 2009. e-Pub 2009. PMID: 19207836.
290. Ben-Ami R, Luna M, Lewis RE, Walsh TJ, Kontoyiannis DP. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect 59(2):134-8, 2009. e-Pub 2009. PMID: 19576639.
291. Chamilos G, Nobile CJ, Bruno VM, Lewis RE, Mitchell AP, Kontoyiannis DP. Candida albicans Cas5, a Regulator of Cell Wall Integrity, Is Required for Virulence in Murine and Toll Mutant Fly Models. J Infect Dis 200(1):152-7, 2009. e-Pub 2009. PMID: 19463063.
292. Sipsas NV, Lewis RE, Raad II, Kontoyiannis DP. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study. Int J Antimicrob Agents 34(1):95-8, 2009. e-Pub 2009. PMID: 19251404.
293. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 48(12):1743-51, 2009. e-Pub 2009. PMID: 19435437.
294. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 199(9):1399-406, 2009. e-Pub 2009. PMID: 19358672.
295. Ben-Ami R, Lewis RE, Raad II, Kontoyiannis DP. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 48(8):1033-41, 2009. e-Pub 2009. PMID: 19267655.
296. Yang Z, Kontoyiannis DP, Wen X, Xiong C, Zhang R, Albert ND, Li C. Gamma scintigraphy imaging of murine invasive pulmonary aspergillosis with a (111)In-labeled cyclic peptide. Nucl Med Biol 36(3):259-66, 2009. e-Pub 2009. PMID: 19324271.
297. Kontoyiannis DP, Ratanatharathorn V, Young JA, Raymond J, Laverdière M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, Marr KA. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 11(1):89-93, 2009. e-Pub 2009. PMID: 18983417.
298. Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 47(1):129-33, 2009. e-Pub 2009. PMID: 19005145.
299. Qiao J, Kontoyiannis DP, Calderone R, Li D, Ma Y, Wan Z, Li R, Liu W. Afyap1, encoding a bZip transcriptional factor of Aspergillus fumigatus, contributes to oxidative stress response but is not essential to the virulence of this pathogen in mice immunosuppressed by cyclophosphamide and triamcinolone. Med Mycol 46(8):1-10, 2008. e-Pub 2008. PMID: 18608886.
300. Torres HA, Aguilera E, Safdar A, Rohatgi N, Raad II, Sepulveda C, Luna M, Kontoyiannis DP, Chemaly RF. Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study. Clin Microbiol Infect 14(12):1160-6, 2008. e-Pub 2008. PMID: 19046167.
301. Raad II, Hachem RY, Hanna HA, Fang X, Jiang Y, Dvorak T, Sherertz RJ, Kontoyiannis DP. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm. Int J Antimicrob Agents 32(6):515-8, 2008. e-Pub 2008. PMID: 18783924.
302. Sipsas NV, Kontoyiannis DP. Occupation, lifestyle, diet, and invasive fungal infections. Infection 36(6):515-25, 2008. e-Pub 2008. PMID: 18998051.
303. Lewis RE, Albert ND, Kontoyiannis DP. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 52(11):4178-80, 2008. e-Pub 2008. PMID: 18725439.
304. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 52(11):4181-3, 2008. e-Pub 2008. PMID: 18794386.
305. Kasai M, Harrington SM, Francesconi A, Petraitis V, Petraitiene R, Beveridge MG, Knudsen T, Milanovich J, Cotton MP, Hughes J, Schaufele RL, Sein T, Bacher J, Murray PR, Kontoyiannis DP, Walsh TJ. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol 46(11):3690-702, 2008. e-Pub 2008. PMID: 18845827.
306. Ibrahim AS, Gebremariam T, Liu M, Chamilos G, Kontoyiannis D, Mink R, Kwon-Chung KJ, Fu Y, Skory CD, Edwards JE, Spellberg B. Bacterial endosymbiosis Is widely present among Zygomycetes but does not contribute to the pathogenesis of mucormycosis. J Infect Dis 198(7):1083-90, 2008. e-Pub 2008. PMID: 18694335.
307. Atkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol 46(6):541-6, 2008. e-Pub 2008. PMID: 19180749.
308. Lionakis MS, Samonis G, Kontoyiannis DP. Endocrine and metabolic manifestations of invasive fungal infections and systemic antifungal treatment. Mayo Clin Proc 83(9):1046-60, 2008. e-Pub 2008. PMID: 18775205.
309. Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 47(5):674-83, 2008. e-Pub 2008. PMID: 18637757.
310. Lamaris GA, Ben-Ami R, Lewis RE, Kontoyiannis DP. Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. J Antimicrob Chemother 62(3):539-42, 2008. e-Pub 2008. PMID: 18544603.
311. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47(4):503-9, 2008. e-Pub 2008. PMID: 18611163.
312. Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 112(6):1282-7, 2008. e-Pub 2008. PMID: 18224662.
313. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, of America IDS. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327-60, 2008. e-Pub 2008. PMID: 18177225.
314. Chamilos G, Lewis RE, Lamaris GA, Albert ND, Kontoyiannis DP. Genomewide screening for genes associated with gliotoxin resistance and sensitivity in Saccharomyces cerevisiae. Antimicrob Agents Chemother 52(4):1325-9, 2008. e-Pub 2008. PMID: 18212113.
315. Lamaris GA, Esmaeli B, Chamilos G, Desai A, Chemaly RF, Raad II, Safdar A, Lewis RE, Kontoyiannis DP. Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. Eur J Clin Microbiol Infect Dis 27(5):343-7, 2008. e-Pub 2008. PMID: 18183439.
316. Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 61(5):1140-4, 2008. e-Pub 2008. PMID: 18305201.
317. Jacobson KL, Miceli MH, Tarrand JJ, Kontoyiannis DP. Legionella pneumonia in cancer patients. Medicine (Baltimore) 87(3):152-9, 2008. e-Pub 2008. PMID: 18520324.
318. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112(11):2493-9, 2008. e-Pub 2008. PMID: 18412153.
319. Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother 52(2):722-4, 2008. e-Pub 2008. PMID: 18025115.
320. Quezada G, Koshkina NV, Zweidler-McKay P, Zhou Z, Kontoyiannis DP, Kleinerman ES. Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob Agents Chemother 52(2):716-8, 2008. e-Pub 2008. PMID: 17984233.
321. Chemaly RF, Torres HA, Hachem R, Kontoyiannis DP, Safdar A, Raad II. Human herpesvirus-6 DNAemia in immunosuppressed adult patients with leukemia at risk for mold infection. Haematologica 93(1):157-8, 2008. e-Pub 2008. PMID: 18166808.
322. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 46(11):1733-7, 2008. e-Pub 2008. PMID: 18419427.
323. Marom EM, Holmes AM, Bruzzi JF, Truong MT, O'Sullivan PJ, Kontoyiannis DP. Imaging of pulmonary fusariosis in patients with hematologic malignancies. AJR Am J Roentgenol 190(6):1605-9, 2008. e-Pub 2008. PMID: 18492913.
324. Chamilos G, Lewis RE, Hu J, Xiao L, Zal T, Gilliet M, Halder G, Kontoyiannis DP. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A 105(27):9367-72, 2008. e-Pub 2008. PMID: 18583479.
325. Lamaris GA, Lewis RE, Chamilos G, May GS, Safdar A, Walsh TJ, Raad II, Kontoyiannis DP. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 198(2):186-92, 2008. e-Pub 2008. PMID: 18500936.
326. Awais A, Tam CS, Kontoyiannis D, Ferrajoli A, Duvic M, Cortes J, Keating MJ. Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. Clin Infect Dis 46(7):e69-71, 2008. e-Pub 2008. PMID: 18444808.
327. Kontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, Del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Albert ND, Wagener MM, Singh N. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 52(2):735-8, 2008. e-Pub 2008. PMID: 18070977.
328. Spikes S, Xu R, Nguyen CK, Chamilos G, Kontoyiannis DP, Jacobson RH, Ejzykowicz DE, Chiang LY, Filler SG, May GS. Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis 197(3):479-86, 2008. e-Pub 2008. PMID: 18199036.
329. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83(2):181-94, 2008. e-Pub 2008. PMID: 18241628.
330. Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol 46(1):23-9, 2008. e-Pub 2008. PMID: 18297544.
331. Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, Kontoyiannis DP, Hachem RY. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22(3):496-503, 2008. e-Pub 2008. PMID: 18094720.
332. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 51(6):2257-9, 2007. e-Pub 2007. PMID: 17438060.
333. Wise MG, Healy M, Reece K, Smith R, Walton D, Dutch W, Renwick A, Huong J, Young S, Tarrand J, Kontoyiannis DP. Species identification and strain differentiation of clinical Candida isolates using the DiversiLab system of automated repetitive sequence-based PCR. J Med Microbiol 56(Pt 6):778-87, 2007. e-Pub 2007. PMID: 17510263.
334. Lass-Flörl C, Grif K, Kontoyiannis DP. Molecular typing of Aspergillus terreus isolates collected in Houston, Texas, and Innsbruck, Austria: evidence of great genetic diversity. J Clin Microbiol 45(8):2686-90, 2007. e-Pub 2007. PMID: 17581930.
335. Chamilos G, Luna M, Lewis RE, Chemaly R, Raad II, Kontoyiannis DP. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin Ther 29(9):1980-6, 2007. e-Pub 2007. PMID: 18035197.
336. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, Manning JT, Han X. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110(6):1303-6, 2007. e-Pub 2007. PMID: 17614303.
337. Mulanovich V, Lewis RE, Raad II, Kontoyiannis DP. Random plasma concentrations of voriconazole decline over time. J Infect 55(5):e129-30, 2007. e-Pub 2007. PMID: 17804077.
338. Qiao J, Kontoyiannis DP, Wan Z, Li R, Liu W. Antifungal activity of statins against Aspergillus species. Med Mycol 45(7):589-93, 2007. e-Pub 2007. PMID: 18033614.
339. Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 27(12):1644-50, 2007. e-Pub 2007. PMID: 18041885.
340. Lamaris GA, Chamilos G, Lewis RE, Kontoyiannis DP. Virulence studies of Scedosporium and Fusarium species in Drosophila melanogaster. J Infect Dis 196(12):1860-4, 2007. e-Pub 2007. PMID: 18190268.
341. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, Chamilos G, Palella F, Kennedy L, Mullane K, Tallman MS, Evens A, Scheetz MH, Blum W, Kontoyiannis DP. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 39(7):425-9, 2007. e-Pub 2007. PMID: 17310132.
342. Safdar A, Rodriguez G, Rolston KV, O'Brien S, Khouri IF, Shpall EJ, Keating MJ, Kantarjian HM, Champlin RE, Raad II, Kontoyiannis DP. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 39(3):157-64, 2007. e-Pub 2007. PMID: 17245424.
343. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. A comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 51(4):1253-8, 2007. e-Pub 2007. PMID: 17261624.
344. Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob Agents Chemother 51(3):1078-81, 2007. e-Pub 2007. PMID: 17194825.
345. Kontoyiannis DP, Chamilos G, Hassan SA, Lewis RE, Albert ND, Tarrand JJ. Increased culture recovery of Zygomycetes under physiologic temperature conditions. Am J Clin Pathol 127(2):208-12, 2007. e-Pub 2007. PMID: 17210526.
346. Chamilos G, Lionakis MS, Lewis RE, Kontoyiannis DP. Role of mini-host models in the study of medically important fungi. Lancet Infect Dis 7(1):42-55, 2007. e-Pub 2007. PMID: 17182343.
347. Chamilos G, Lewis RE, Kontoyiannis DP. Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: A hypothesis. Fungal Genet Biol 44(2):88-92, 2007. e-Pub 2007. PMID: 16990037.
348. Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis 26(1):13-20, 2007. e-Pub 2007. PMID: 17200840.
349. Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RE. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 106(12):2664-71, 2006. e-Pub 2006. PMID: 16691620.
350. Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis 193(7):1014-22, 2006. e-Pub 2006. PMID: 16518764.
351. Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, Rolston KV, Raad II, Kontoyiannis DP. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 25(6):382-8, 2006. e-Pub 2006. PMID: 16767486.
352. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis 43(12):1580-4, 2006. e-Pub 2006. PMID: 17109292.
353. Kumashi PR, Safdar A, Chamilos G, Chemaly RF, Raad II, Kontoyiannis DP. Fungal osteoarticular infections in patients treated at a comprehensive cancer centre: a 10-year retrospective review. Clin Microbiol Infect 12(7):621-6, 2006. e-Pub 2006. PMID: 16774557.
354. Torres HA, Kontoyiannis DP, Aguilera EA, Younes A, Luna MA, Tarrand JJ, Nogueras GM, Raad II, Chemaly RF. Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality. Clin Lymphoma Myeloma 6(5):393-8, 2006. e-Pub 2006. PMID: 16640816.
355. Yusuf SW, Ali SS, Swafford J, Durand JB, Bodey GP, Chemaly RF, Kontoyiannis DP, Tarrand J, Rolston KV, Yeh E, Raad II, Safdar A. Culture-positive and culture-negative endocarditis in patients with cancer: a retrospective observational study, 1994-2004. Medicine (Baltimore) 85(2):86-94, 2006. e-Pub 2006. PMID: 16609347.
356. Singh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del Busto R, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81(3):320-6, 2006. e-Pub 2006. PMID: 16477215.
357. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 42(11):1584-91, 2006. e-Pub 2006. PMID: 16652316.
358. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis 43(11):1449-55, 2006. e-Pub 2006. PMID: 17083020.
359. Rolston KV, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients. Int J Infect Dis 10(3):223-30, 2006. e-Pub 2006. PMID: 16439177.
360. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 42(10):1398-403, 2006. e-Pub 2006. PMID: 16619151.
361. Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 50(2):469-73, 2006. e-Pub 2006. PMID: 16436698.
362. Lionakis MS, Chamilos G, Lewis RE, Wiederhold NP, Raad II, Samonis G, Kontoyiannis DP. Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis. Antimicrob Agents Chemother 50(1):294-7, 2006. e-Pub 2006. PMID: 16377700.
363. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 50(1):96-103, 2006. e-Pub 2006. PMID: 16377673.
364. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 91(7):986-9, 2006. e-Pub 2006. PMID: 16757415.
365. Chamilos G, Lewis RE, Kontoyiannis DP. Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin. Antimicrob Agents Chemother 50(2):744-7, 2006. e-Pub 2006. PMID: 16436735.
366. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42(7):e61-5, 2006. e-Pub 2006. PMID: 16511748.
367. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 50(2):658-66, 2006. e-Pub 2006. PMID: 16436724.
368. Lewis RE, Wiederhold NP, Prince RA, Kontoyiannis DP. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. J Antimicrob Chemother 57(2):288-93, 2006. e-Pub 2006. PMID: 16387749.
369. Garey KW, Neuhauser MM, Bearden DT, Cannon JP, Lewis RE, Gentry LO, Kontoyiannis DP. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses 49(3):226-31, 2006. e-Pub 2006. PMID: 16681815.
370. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 5(12):775-85, 2005. e-Pub 2005. PMID: 16310149.
371. Lewis RE, Wiederhold NP, Lionakis MS, Prince RA, Kontoyiannis DP. Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center. J Clin Microbiol 43(12):6120-2, 2005. e-Pub 2005. PMID: 16333108.
372. Tarrand JJ, Han XY, Kontoyiannis DP, May GS. Aspergillus hyphae in infected tissue: evidence of physiologic adaptation and effect on culture recovery. J Clin Microbiol 43(1):382-6, 2005. e-Pub 2005. PMID: 15634998.
373. Stanzani M, Orciuolo E, Lewis R, Kontoyiannis DP, Martins SL, St John LS, Komanduri KV. Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood 105(6):2258-65, 2005. e-Pub 2005. PMID: 15546954.
374. Lionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Pharmacotherapy 25(9):1174-80, 2005. e-Pub 2005. PMID: 16164392.
375. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 49(12):5146-8, 2005. e-Pub 2005. PMID: 16304189.
376. Lewis RE, Wiederhold NP, Chi J, Han XY, Komanduri KV, Kontoyiannis DP, Prince RA. Detection of gliotoxin in experimental and human aspergillosis. Infect Immun 73(1):635-7, 2005. e-Pub 2005. PMID: 15618207.
377. Lionakis MS, Lahdenranta J, Sun J, Liu W, Lewis RE, Albert ND, Pasqualini R, Arap W, Kontoyiannis DP. Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis. Infect Immun 73(11):7747-58, 2005. e-Pub 2005. PMID: 16239579.
378. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41(5):634-53, 2005. e-Pub 2005. PMID: 16080086.
379. Torres HA, Kontoyiannis DP, Bodey GP, Adachi JA, Luna MA, Tarrand JJ, Nogueras GM, Raad II, Chemaly RF. Gastrointestinal cytomegalovirus disease in patients with cancer: a two decade experience in a tertiary care cancer center. Eur J Cancer 41(15):2268-79, 2005. e-Pub 2005. PMID: 16143517.
380. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 52(1):15-20, 2005. e-Pub 2005. PMID: 15878437.
381. Kontoyiannis DP, Boktour M, Hanna H, Torres HA, Hachem R, Raad II. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 103(11):2334-7, 2005. e-Pub 2005. PMID: 15844093.
382. Lewis RE, Kontoyiannis DP. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother 56(5):887-92, 2005. e-Pub 2005. PMID: 16188916.
383. Rolston KV, Kontoyiannis DP, Yadegarynia D, Raad II. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis 51(3):215-8, 2005. e-Pub 2005. PMID: 15766609.
384. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103(6):1103-13, 2005. e-Pub 2005. PMID: 15666328.
385. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41(1):60-6, 2005. e-Pub 2005. PMID: 15937764.
386. Lionakis, MS, Lewis RE, Chamilos G, Kontoyiannis DP. Problems in correlation of the in vitro susceptibility testing of Aspergillus to amphotericin B with outcome of initial amphotericin B therapy in cancer patients with invasive aspergillosis. Pharmacotherapy 9:1174-1180, 2005. e-Pub 2005.
387. Torres HA, Prieto VG, Raad II, Kontoyiannis DP. Proven pulmonary cryptococcosis due to capsule-deficient Cryptococcus neoformans does not differ clinically from proven pulmonary cryptococcosis due to capsule-intact C. neoformans. Mycoses 48(1):21-4, 2005. e-Pub 2005. PMID: 15679661.
388. Safdar A, Rodriguez G, Ohmagari N, Kontoyiannis DP, Rolston KV, Raad II, Champlin RE. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 103(4):731-9, 2005. e-Pub 2005. PMID: 15641032.
389. Lionakis MS, Lewis RE, May GS, Wiederhold NP, Albert ND, Halder G, Kontoyiannis DP. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis 191(7):1188-95, 2005. e-Pub 2005. PMID: 15747256.
390. Healy M, Reece K, Walton D, Huong J, Frye S, Raad II, Kontoyiannis DP. Use of the Diversi Lab System for species and strain differentiation of Fusarium species isolates. J Clin Microbiol 43(10):5278-80, 2005. e-Pub 2005. PMID: 16207996.
391. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191(8):1350-60, 2005. e-Pub 2005. PMID: 15776383.
392. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24(10):654-61, 2005. e-Pub 2005. PMID: 16261306.
393. Xue T, Nguyen CK, Romans A, Kontoyiannis DP, May GS. Isogenic auxotrophic mutant strains in the Aspergillus fumigatus genome reference strain AF293. Arch Microbiol 182(5):346-53, 2004. e-Pub 2004. PMID: 15365692.
394. Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP, Chatzinikolaou I, Perego C, Kantarjian HM, Raad II. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101(7):1594-600, 2004. e-Pub 2004. PMID: 15378491.
395. Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, Mavroudis D, Georgoulias V, Rolston KV, Kontoyiannis DP, Galanakis E, Samonis G. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. Infection 32(2):65-71, 2004. e-Pub 2004. PMID: 15057569.
396. Raad, I, Hanna H, Boktour M, Girgawy E, Danawi H, Mardani M, Kontoyiannis DP, Darouiche R, Hachem R, Bodey GP. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 38:1119-1127, 2004. e-Pub 2004.
397. De La Rosa GR, Jacobson KL, Rolston KV, Raad II, Kontoyiannis DP, Safdar A. Mycobacterium tuberculosis at a comprehensive cancer centre: active disease in patients with underlying malignancy during 1990-2000. Clin Microbiol Infect 10(8):749-52, 2004. e-Pub 2004. PMID: 15301678.
398. Torres HA, Kontoyiannis DP, Rolston KV. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study. Support Care Cancer 12(7):511-6, 2004. e-Pub 2004. PMID: 14986077.
399. Boktour MR, Kontoyiannis DP, Hanna HA, Hachem RY, Girgawy E, Bodey GP, Raad II. Multiple-species candidemia in patients with cancer. Cancer 101(8):1860-5, 2004. e-Pub 2004. PMID: 15386338.
400. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104(3):649-54, 2004. e-Pub 2004. PMID: 15069017.
401. Ohmagari N, Raad II, Hachem R, Kontoyiannis DP. Invasive aspergillosis in patients with solid tumors. Cancer 101(10):2300-2, 2004. e-Pub 2004. PMID: 15452832.
402. Liu W, May GS, Lionakis MS, Lewis RE, Kontoyiannis DP. Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus. Antimicrob Agents Chemother 48(7):2490-6, 2004. e-Pub 2004. PMID: 15215099.
403. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis DP, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100(3):581-9, 2004. e-Pub 2004. PMID: 14745876.
404. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190(8):1464-71, 2004. e-Pub 2004. PMID: 15378439.
405. Lionakis MS, Bodey GP, Tarrand JJ, Raad II, Kontoyiannis DP. The significance of blood cultures positive for emerging saprophytic moulds in cancer patients. Clin Microbiol Infect 10(10):922-5, 2004. e-Pub 2004. PMID: 15373888.
406. Lionakis MS, Kontoyiannis DP. The significance of isolation of saprophytic molds from the lower respiratory tract in patients with cancer. Cancer 100(1):165-72, 2004. e-Pub 2004. PMID: 14692037.
407. Mattiuzzi GN, Kantarjian H, O'Brien S, Kontoyiannis DP, Giles F, Zhou X, Lim J, Bekele BN, Faderl S, Cortes J, Pierce S, Leitz GJ, Raad I, Estey E. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100(3):568-73, 2004. e-Pub 2004. PMID: 14745874.
408. Steinbach WJ, Benjamin DK, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 39(2):192-8, 2004. e-Pub 2004. PMID: 15307028.
409. Kontoyiannis DP, Bodey GP, Hanna H, Hachem R, Boktour M, Girgaway E, Mardani M, Raad II. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma 45(1):139-41, 2004. e-Pub 2004. PMID: 15061210.
410. Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, Raad II. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis 36(8):564-9, 2004. e-Pub 2004. PMID: 15370667.
411. Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B, Freireich EJ, Raad II. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 101(12):2859-65, 2004. e-Pub 2004. PMID: 15529309.
412. Healy M, Reece K, Walton D, Huong J, Shah K, Kontoyiannis DP. Identification to the species level and differentiation between strains of Aspergillus clinical isolates by automated repetitive-sequence-based PCR. J Clin Microbiol 42(9):4016-24, 2004. e-Pub 2004. PMID: 15364984.
413. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98(4):773-8, 2003. e-Pub 2003. PMID: 12910522.
414. Torres HA, Rivero GA, Lewis RE, Hachem R, Raad II, Kontoyiannis DP. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 46(1):25-8, 2003. e-Pub 2003. PMID: 12742315.
415. Hicks KL, Chemaly RF, Kontoyiannis DP. Common community respiratory viruses in patients with cancer: more than just "common colds". Cancer 97(10):2576-87, 2003. e-Pub 2003. PMID: 12733157.
416. Han XY, Weinberg JS, Prabhu SS, Hassenbusch SJ, Fuller GN, Tarrand JJ, Kontoyiannis DP. Fusobacterial brain abscess: a review of five cases and an analysis of possible pathogenesis. J Neurosurg 99(4):693-700, 2003. e-Pub 2003. PMID: 14567605.
417. Torres HA, Bodey GP, Tarrand JJ, Kontoyiannis DP. Protothecosis in patients with cancer: case series and literature review. Clin Microbiol Infect 9(8):786-92, 2003. e-Pub 2003. PMID: 14616698.
418. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis DP, Koller C, Munsell M, Beran M, Kantarjian H. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97(2):450-6, 2003. e-Pub 2003. PMID: 12518369.
419. Raad, II, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, Boktour MR, Whimbey E, Kontoyiannis DP, Jacobson K, Kantarjian H Levett LM, Rolston KVI. Treatment of febrile neutropenic cancer patients requiring hospitalization: a prospective, randomized study comparing imipenem and cefepime. Cancer 98:1039-1047, 2003. e-Pub 2003.
420. Lionakis MS, Lewis RE, Samonis G, Kontoyiannis DP. Pentamidine is active in vitro against Fusarium species. Antimicrob Agents Chemother 47(10):3252-9, 2003. e-Pub 2003. PMID: 14506038.
421. Rivero GA, Torres HA, Rolston KV, Kontoyiannis DP. Listeria monocytogenes infection in patients with cancer. Diagn Microbiol Infect Dis 47(2):393-8, 2003. e-Pub 2003. PMID: 14522512.
422. Kontoyiannis DP, Lewis RE, Lionakis MS, Albert ND, May GS, Raad II. Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity. Diagn Microbiol Infect Dis 47(2):415-9, 2003. e-Pub 2003. PMID: 14522515.
423. Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer 98(1):86-93, 2003. e-Pub 2003. PMID: 12833460.
424. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 362(9398):1828-38, 2003. e-Pub 2003. PMID: 14654323.
425. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98(2):292-9, 2003. e-Pub 2003. PMID: 12872348.
426. Maraki S, Margioris AN, Orfanoudaki E, Tselentis Y, Koumantakis E, Kontoyiannis DP, Rovithi M, Samonis G. Effects of doxycycline, metronidazole and their combination on Candida species colonization of the human oropharynx, intestinal lumen and vagina. J Chemother 15(4):369-73, 2003. e-Pub 2003. PMID: 12962365.
427. Tarrand JJ, Lichterfeld M, Warraich I, Luna M, Han XY, May GS, Kontoyiannis DP. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol 119(6):854-8, 2003. e-Pub 2003. PMID: 12817433.
428. Pham AS, Tarrand JJ, May GS, Lee MS, Kontoyiannis DP, Han XY. Diagnosis of invasive mold infection by real-time quantitative PCR. Am J Clin Pathol 119(1):38-44, 2003. e-Pub 2003. PMID: 12520695.
429. Mattiuzzi, GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis DP, Giles FJ, Raad II, Verstovsek S, Ferrajoli A, Kantarjian H. Development of varicella-zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 9:976-980, 2003. e-Pub 2003.
430. Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 51(2):313-6, 2003. e-Pub 2003. PMID: 12562696.
431. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, Han XY, Rolston KV, Safdar A, Raad II, Kontoyiannis DP. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 82(5):309-21, 2003. e-Pub 2003. PMID: 14530780.
432. Liu W, Lionakis MS, Lewis RE, Wiederhold N, May GS, Kontoyiannis DP. Attenuation of itraconazole fungicidal activity following preexposure of Aspergillus fumigatus to fluconazole. Antimicrob Agents Chemother 47(11):3592-7, 2003. e-Pub 2003. PMID: 14576123.
433. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, Hachem RY, Kontoyiannis DP, Raad II. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112(5):380-5, 2002. e-Pub 2002. PMID: 11904112.
434. Kontoyiannis DP, Reddy BT, Torres HA, Luna M, Lewis RE, Tarrand J, Bodey GP, Raad II. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 34(3):400-3, 2002. e-Pub 2002. PMID: 11774088.
435. Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46(10):3208-14, 2002. e-Pub 2002. PMID: 12234846.
436. Nannini EC, Keating M, Binstock P, Samonis G, Kontoyiannis DP. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J Infect 44(3):201-3, 2002. e-Pub 2002. PMID: 12099753.
437. Bodey, GP, Boktour M, Mays S, Duvic M, Kontoyiannis DP, Hachem R, Raad II. Skin lesions associated with Fusarium infection. Journal of the American Academy of Dermatology 47:659-666, 2002. e-Pub 2002.
438. Keating, MJ, O'Brien S, Kontoyiannis DP, Plunkett W, Koller C, Beran M, Lerner S, Kantarjian H. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leukemia and Lymphoma 43:1755-62, 2002. e-Pub 2002.
439. Osherov N, May GS, Albert ND, Kontoyiannis DP. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother 46(8):2462-9, 2002. e-Pub 2002. PMID: 12121919.
440. Shaikh ZH, Torres HA, Walsh GL, Champlin RE, Kontoyiannis DP. Open lung biopsy in bone marrow transplant recipients has a poor diagnostic yield for a specific diagnosis. Transpl Infect Dis 4(2):80-4, 2002. e-Pub 2002. PMID: 12220244.
441. Torres HA, Reddy BT, Raad II, Tarrand J, Bodey GP, Hanna HA, Rolston KV, Kontoyiannis DP. Nocardiosis in cancer patients. Medicine (Baltimore) 81(5):388-97, 2002. e-Pub 2002. PMID: 12352633.
442. Lewis RE, Lo HJ, Raad II, Kontoyiannis DP. Lack of catheter infection by the efg1/efg1 cph1/cph1 double-null mutant, a Candida albicans strain that is defective in filamentous growth. Antimicrob Agents Chemother 46(4):1153-5, 2002. e-Pub 2002. PMID: 11897612.
443. Raad, I, Tarrand J, Hanna H, Albitar M, Janssen E, Boktour M, Bodey G, Mardani M, Hachem R, Kontoyiannis DP, Whimbey E, Rolston K. Epidemiology, molecular mycology and environmental sources of Fusarium infection in cancer patients. Infect Control Hosp Epidemiol 23:532-537, 2002. e-Pub 2002.
444. Torres HA, Rivero GA, Kontoyiannis DP. Endemic mycoses in a cancer hospital. Medicine (Baltimore) 81(3):201-12, 2002. e-Pub 2002. PMID: 11997717.
445. Samonis G, Maraki S, Anatoliotakis N, Anatoliotaki M, Apostolakou H, Margioris AN, Tselentis Y, Kontoyiannis DP. Effects of erythromycin, clarithromycin, roxithromycin and azithromycin on murine gut colonization by Candida albicans. Med Mycol 40(2):139-42, 2002. e-Pub 2002. PMID: 12058726.
446. Kontoyiannis DP, Reddy BT, Hanna H, Bodey GP, Tarrand J, Raad II. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol 23(9):542-5, 2002. e-Pub 2002. PMID: 12269454.
447. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 359(9312):1135-44, 2002. e-Pub 2002. PMID: 11943280.
448. Lewis RE, Kontoyiannis DP, Darouiche RO, Raad II, Prince RA. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob Agents Chemother 46(11):3499-505, 2002. e-Pub 2002. PMID: 12384356.
449. Reddy BT, Torres HA, Kontoyiannis DP. Breast implant infection caused by Trichosporon beigelii. Scand J Infect Dis 34(2):143-4, 2002. e-Pub 2002. PMID: 11928852.
450. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 44(5):125-35, 2001. e-Pub 2001. PMID: 11486448.
451. Samonis G, Maraki S, Hajiioannou I, Chatzinikolaou I, Rolston KV, Bodey GP, Kontoyiannis DP. Effect of ketoconazole, itraconazole and fluconazole on the gastrointestinal colonization of mice by Candida albicans. J Chemother 13(1):66-9, 2001. e-Pub 2001. PMID: 11233803.
452. Kontoyiannis DP, Tarrand J, Prince R, Samonis G, Rolston KV. Effect of fluconazole on agar invasion by Candida albicans. J Med Microbiol 50(1):78-82, 2001. e-Pub 2001. PMID: 11192509.
453. Kontoyiannis DP, Peitsch WK, Reddy BT, Whimbey EE, Han XY, Bodey GP, Rolston KV. Cryptococcosis in patients with cancer. Clin Infect Dis 32(11):E145-50, 2001. e-Pub 2001. PMID: 11340547.
454. Osherov N, Kontoyiannis DP, Romans A, May GS. Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14alpha-demethylase gene, pdmA. J Antimicrob Chemother 48(1):75-81, 2001. e-Pub 2001. PMID: 11418514.
455. Mattiuzzi, GN Kantarjian H, Faderl S, Lim J, Kontoyiannis DP, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100(3):581-589, 2001. e-Pub 2001.
456. LaRosa, A, Champlin RE, Gajewski J, Giralt S, Rolston KVI, Raad I, Jacobson K, Kontoyiannis DP, Elting L, Whimbey E. Adenovirus infections in adult blood and marrow transplant recipients. Clin Infect Dis 32:871-876, 2001. e-Pub 2001.
457. Mavromanolakis E, Maraki S, Cranidis A, Tselentis Y, Kontoyiannis DP, Samonis G. The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans. Scand J Infect Dis 33(6):477-8, 2001. e-Pub 2001. PMID: 11450873.
458. Kontoyiannis DP, Andersson BS, Lewis RE, Raad II. Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. Clin Infect Dis 32(5):E94-6, 2001. e-Pub 2001. PMID: 11229866.
459. Maraki S, Mouzas IA, Kontoyiannis DP, Chatzinikolaou I, Tselentis Y, Samonis G. Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by Candida species. Chemotherapy 47(3):215-8, 2001. e-Pub 2001. PMID: 11306791.
460. Ghosh, S, Champlin R, Ueno NAnderlini P, Rolston K, Raad I, Kontoyiannis DP, Jacobson K, Luna M, Tarrand J, Whimbey E. RSV infections in autologous blood and marrow transplant (BMT) recipients with breast cancer: combination therapy with aerosolized ribavirin and immunotherapy. Bone Marrow Transplant 28:271-275, 2001. e-Pub 2001.
461. Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J, Hachem R, Bodey GP, Raad II. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 33(10):1676-81, 2001. e-Pub 2001. PMID: 11568858.
462. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 31(1):188-9, 2000. e-Pub 2000. PMID: 10913421.
463. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 30(6):851-6, 2000. e-Pub 2000. PMID: 10852735.
464. Kontoyiannis DP, Rupp S. Cyclic AMP and fluconazole resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother 44(6):1743-4, 2000. e-Pub 2000. PMID: 10817746.
465. Kontoyiannis DP. Fluconazole inhibits pseudohyphal growth in Saccharomyces cerevisiae. Chemother 46(2):100-3, 2000. e-Pub 2000. PMID: 10671759.
466. Kontoyiannis DP. Modulation of fluconazole sensitivity by the interaction of mitochondria and erg3p in Saccharomyces cerevisiae. J Antimicrob Chemother 46(2):191-7, 2000. e-Pub 2000. PMID: 10933640.
467. Kontoyiannis DP, Lewis RE, Sagar N, May G, Prince RA, Rolston KV. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob Agents Chemother 44(10):2915-8, 2000. e-Pub 2000. PMID: 10991890.
468. Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc 75(10):1039-54, 2000. e-Pub 2000. PMID: 11040852.
469. Kontoyiannis DP. Efflux-mediated resistance to fluconazole could be modulated by sterol homeostasis in Saccharomyces cerevisiae. J Antimicrob Chemother 46(2):199-203, 2000. e-Pub 2000. PMID: 10933641.
470. Kontoyiannis DP, Jacobson KL, Whimbey EE, Rolston KV, Raad II. Central venous catheter-associated Nocardia bacteremia: an unusual manifestation of nocardiosis. Clin Infect Dis 31(2):617-8, 2000. e-Pub 2000. PMID: 10987735.
471. Kontoyiannis DP, Sagar N, Hirschi KD. Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother 43(11):2798-800, 1999. e-Pub 1999. PMID: 10543768.
472. Kontoyiannis DP. Genetic analysis of azole resistance by transposon mutagenesis in Saccharomyces cerevisiae. Antimicrob Agents Chemother 43(11):2731-5, 1999. e-Pub 1999. PMID: 10543755.
473. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129(7):559-66, 1998. e-Pub 1998. PMID: 9758577.
474. Kontoyiannis DP, Ruoff K, Hooper DC. Nocardia bacteremia. Report of 4 cases and review of the literature. Medicine (Baltimore) 77(4):255-67, 1998. e-Pub 1998. PMID: 9715730.
475. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, Williams T, Kontoyiannis DP, Karl CL, Bodey GP. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23(5):964-72, 1996. e-Pub 1996. PMID: 8922787.
476. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad II, Gilbreath J, Bodey GP. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 101(2):170-6, 1996. e-Pub 1996. PMID: 8757357.
477. Kontoyiannis DP, Calia KE, Basgoz N, Calderwood SB. Primary septicemia caused by Vibrio cholerae non-O1 acquired on Cape Cod, Massachusetts. Clin Infect Dis 21(5):1330-3, 1995. e-Pub 1995. PMID: 8589171.
478. Anaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE, Karl C, Prince RA, Bosso J, Bodey GP. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 172(2):599-602, 1995. e-Pub 1995. PMID: 7622915.
479. Anaissie, EJ, Samonis G, Kontoyiannis DP, Raad I, Rosenbaum B, Sabharwal U, Costerton JW, Bodey GP. Biofilm and Central venous catheter-related infections: Evidence of universal colonization and low risk of hematogenous seeding. Eur J Clin Microbiol 14:134-137, 1995. e-Pub 1995.
480. Kontoyiannis DP, Vartivarian S, Anaissie EJ, Samonis G, Rinaldi M, Bodey GP. Cunnighamella bertolletiae infections in patients with leukemia: Report of three cases and review. Clin Infect Dis 18:925-928, 1994. e-Pub 1994.
481. Anaissie EJ, Kontoyiannis DP, Vartivarian S, Kantarjian HM, O'Brien S, Giralt SA, Andersson BS, Karl C, Champlin RE, Bodey GP. Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. Clin Infect Dis 17(6):1022-31, 1993. e-Pub 1993. PMID: 8110925.
482. Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 117(6):466-9, 1992. e-Pub 1992. PMID: 1354425.
483. Kantarjian, HM, Talpaz M, Kontoyiannis DP, Gutterman J, Keating MJ, Estey EH, O’Brien S, Rios MB, Beran M, Deisseroth A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony stimulating factor. J Clin Oncol 3:398-405, 1992. e-Pub 1992.

Invited Articles

1. Vuong NN, Hammond D, Kontoyiannis DP. Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges. J Fungi (Basel) 9(4), 2023. e-Pub 2023. PMID: 37108918.
2. Alqarihi A, Kontoyiannis DP, Ibrahim AS. Mucormycosis in 2023: an update on pathogenesis and management. Front Cell Infect Microbiol 13:1254919, 2023. e-Pub 2023. PMID: 37808914.
3. Lamoth F, Lewis RE, Kontoyiannis DP. Investigational antifungal agents for invasive mycoses: a clinical perspective. Clin Infect Dis 75(3):534-544, 2022. e-Pub 2022. PMID: 34986246.
4. Wurster S, Albert ND, Kontoyiannis DP. Drosophila melanogaster as a Rapid and Reliable In Vivo Infection Model to Study the Emerging Yeast Pathogen Candida auris. Methods Mol Biol 2517:299-316, 2022. e-Pub 2022. PMID: 35674964.
5. Wurster S, Ruiz OE, Tatara AM, Kontoyiannis DP, Eisenhoffer GT. Protocol for fungal infection following the induction of epithelial cell loss in larval zebrafish. STAR Protoc 2(4):100963, 2021. e-Pub 2021. PMID: 34849488.
6. Ben-Ami R, Kontoyiannis DP. Resistance to Antifungal Drugs. Infect Dis Clin North Am 35(2):279-311, 2021. e-Pub 2021. PMID: 34016279.
7. Lamoth F, Lewis RE, Walsh TJ, Kontoyiannis DP. Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA). J Infect Dis. e-Pub 2021. PMID: 33770176.
8. Lockhart SR, Bialek R, Kibbler CC, Cuenca-Estrella M, Jensen HE, Kontoyiannis DP. Molecular Techniques for Genus and Species Determination of Fungi From Fresh and Paraffin-Embedded Formalin-Fixed Tissue in the Revised EORTC/MSGERC Definitions of Invasive Fungal Infection. Clin Infect Dis 72(Suppl 2):S109-S113, 2021. e-Pub 2021. PMID: 33709128.
9. Dadwal SS, Hohl TM, Fisher CE, Boeckh M, Papanicolaou G, Carpenter PA, Fisher BT, Slavin MA, Kontoyiannis DP. American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. Transplant Cell Ther 27(3):201-211, 2021. e-Pub 2021. PMID: 33781516.
10. Lamoth F, Lewis RE, Kontoyiannis DP. Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. J Fungi (Basel) 7(1), 2020. e-Pub 2020. PMID: 33396870.
11. Puerta-Alcalde P, Champlin R, Kontoyiannis DP. How I transplant a patient with a history of invasive fungal disease. Blood. e-Pub 2020. PMID: 32845974.
12. Koehler P, Denis B, Denning DW, Gangneux JP, Hoenigl M, Kontoyiannis DP, Krause R, Lagrou K, Lass-Flörl C, Maertens J, Marekovic I, Meis JF, Molina JM, Pleško S, Prattes J, Rath PM, Rautemaa-Richardson R, Richardson M, Segal E, Seidel D, Spriet I, Steinmann J, Verweij PE, Cornely OA, Medical Mycology ECO. European confederation of medical mycology expert consult-An ECMM excellence center initiative. Mycoses 63(6):566-572, 2020. e-Pub 2020. PMID: 32181546.
13. Pappas PG, Boulware DR, Kontoyiannis DP, Miceli MH, Ostrosky-Zeichner L, Spec A, Thompson GR, Chen S, Perfect JR, investigators M. Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. Med Mycol. e-Pub 2020. PMID: 32407483.
14. Lamoth F, Kontoyiannis DP. Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients. Antimicrob Agents Chemother 63(11), 2019. e-Pub 2019. PMID: 31481441.
15. Chikley A, Ben-Ami R, Kontoyiannis DP. Mucormycosis of the central nervous system. J Fungi (Basel) 5(3), 2019. e-Pub 2019. PMID: 31288475.
16. Walsh TJ, Hospenthal DR, Petraitis V, Kontoyiannis DP. Necrotizing Mucormycosis of Wounds Following Combat Injuries, Natural Disasters, Burns, and Other Trauma. J Fungi (Basel) 5(3), 2019. e-Pub 2019. PMID: 31277364.
17. Yong MK, Slavin MA, Kontoyiannis DP. Invasive Fungal Disease and Cytomegalovirus infection: is there an association?. Curr Opin Infect Dis 31(6):481-489, 2018. e-Pub 2018. PMID: 30299361.
18. Dadwal SS, Kontoyiannis DP. Recent advances in the molecular diagnosis of mucormycosis. Expert Rev Mol Diagn 18(10):845-854, 2018. e-Pub 2018. PMID: 30203997.
19. Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of Mucormycosis. J Fungi (Basel) 4(3), 2018. e-Pub 2018. PMID: 30065232.
20. Mulanovich V, Kontoyiannis DP. Acute myeloid leukemia and the infectious diseases consultant. Leuk Lymphoma:1-8, 2018. e-Pub 2018. PMID: 28914100.
21. Lionakis MS, Lewis RE, Kontoyiannis DP. Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. Clin Infect Dis, 2018. e-Pub 2018. PMID: 29860307.
22. Kumaresan PR, da Silva TA, Kontoyiannis DP. Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells. Front Immunol 8:1939, 2018. e-Pub 2018. PMID: 29358941.
23. Carmona-Gutierrez D, Bauer MA, Zimmermann A, Aguilera A, Austriaco N, Ayscough K, Balzan R, Bar-Nun S, Barrientos A, Belenky P, Blondel M, Braun RJ, Breitenbach M, Burhans WC, Büttner S, Cavalieri D, Chang M, Cooper KF, Côrte-Real M, Costa V, Cullin C, Dawes I, Dengjel J, Dickman MB, Eisenberg T, Fahrenkrog B, Fasel N, Fröhlich KU, Gargouri A, Giannattasio S, Goffrini P, Gourlay CW, Grant CM, Greenwood MT, Guaragnella N, Heger T, Heinisch J, Herker E, Herrmann JM, Hofer S, Jiménez-Ruiz A, Jungwirth H, Kainz K, Kontoyiannis DP, Ludovico P, Manon S, Martegani E, Mazzoni C, Megeney LA, Meisinger C, Nielsen J, Nyström T, Osiewacz HD, Outeiro TF, Park HO, Pendl T, Petranovic D, Picot S, Polcic P, Powers T, Ramsdale M, Rinnerthaler M, Rockenfeller P, Ruckenstuhl C, Schaffrath R, Segovia M, Severin FF, Sharon A, Sigrist SJ, Sommer-Ruck C, Sousa MJ, Thevelein JM, Thevissen K, Titorenko V, Toledano MB, Tuite M, Vögtle FN, Westermann B, Winderickx J, Wissing S, Wölfl S, Zhang ZJ, Zhao RY, Zhou B, Galluzzi L, Kroemer G, Madeo F. Guidelines and recommendations on yeast cell death nomenclature. Microb Cell 5(1):4-31, 2018. e-Pub 2018. PMID: 29354647.
24. Tatara AM, Kontoyiannis DP, Mikos AG. Drug delivery and tissue engineering to promote wound healing in the immunocompromised host: Current challenges and future directions. Adv Drug Deliv Rev. e-Pub 2017. PMID: 29221962.
25. Farmakiotis D, Kontoyiannis DP. Epidemiology of antifungal resistance in human pathogenic yeasts: Current viewpoint and practical recommendations for management. Int J Antimicrob Agents 50(3):318-324, 2017. e-Pub 2017. PMID: 28669831.
26. McCarthy MW, Kontoyiannis DP, Cornely OA, Perfect JR, Walsh TJ. Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. J Infect Dis 216(suppl_3):S474-S483, 2017. e-Pub 2017. PMID: 28911042.
27. Watson E, Tatara A, Kontoyiannis DP, Mikos A. Inherently Antimicrobial Biodegradable Polymers in Tissue Engineering. ACS Biomaterials Science & Engineering 3(7):1207-1220, 2017. e-Pub 2017.
28. Osherov N, Kontoyiannis DP. The anti-Aspergillus drug pipeline: Is the glass half full or empty?. Med Mycol 55(1):118-124, 2017. e-Pub 2017. PMID: 27562862.
29. Chitasombat MN, Kontoyiannis DP. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents. Curr Opin Infect Dis 29(4):340-5, 2016. e-Pub 2016. PMID: 27191199.
30. Tverdek FP, Kofteridis D, Kontoyiannis DP. Antifungal agents and liver toxicity: a complex interaction. Expert Rev Anti Infect Ther 14(8):765-76, 2016. e-Pub 2016. PMID: 27275514.
31. Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am 30(1):143-63, 2016. e-Pub 2016. PMID: 26897065.
32. Halpern AB, Lyman GH, Walsh TJ, Kontoyiannis DP, Walter RB. Evidence-based focused review of primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood 126(26):2790-7, 2015. e-Pub 2015. PMID: 26504183.
33. Chitasombat MN, Kontoyiannis DP. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Expert Opin Pharmacother 16(10):1543-58, 2015. e-Pub 2015. PMID: 26100603.
34. Davoudi S, Graviss LS, Kontoyiannis DP. Health care-associated outbreaks due to Mucorales and other uncommon fungi. Eur J Clin Invest 45(7):767-73, 2015. e-Pub 2015. PMID: 25989947.
35. Ananda-Rajah MR, Kontoyiannis D. Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Future Microbiol 10:693-708, 2015. e-Pub 2015. PMID: 26000646.
36. Farmakiotis D, Kontoyiannis DP. Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipients. Am J Transplant 15(5):1141-7, 2015. e-Pub 2015. PMID: 25655091.
37. Kontoyiannis DP, Lewis RE. Treatment principles for the management of mold infections. Cold Spring Harb Perspect Med 5(4), 2015. e-Pub 2015. PMID: 25377139.
38. Walsh TJ, Skiada A, Cornely OA, Roilides E, Ibrahim A, Zaoutis T, Groll A, Lortholary O, Kontoyiannis DP, Petrikkos G. Development of new strategies for early diagnosis of mucormycosis from bench to bedside. Mycoses 57 Suppl 3:2-7, 2014. e-Pub 2014. PMID: 25475924.
39. Kontoyiannis DP, Patterson TF. Diagnosis and treatment of invasive fungal infections in the cancer patient: Recent progress and ongoing questions. Clin Infect Dis 59 Suppl 5:S356-9, 2014. e-Pub 2014. PMID: 25352631.
40. McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold Infections of the Central Nervous System. N Engl J Med 371(2):150-160, 2014. e-Pub 2014. PMID: 25006721.
41. Ariza-Heredia EJ, Kontoyiannis DP. Our recommendations for avoiding exposure to fungi outside the hospital for patients with haematological cancers. Mycoses 57(6):336-41, 2014. e-Pub 2014. PMID: 24446760.
42. Kontoyiannis DP, Mathur M, Chen YB, Shellito PC, Tse JY. Case records of the Massachusetts General Hospital. Case 13-2014. A 41-year-old man with fever and abdominal pain after stem-cell transplantation. N Engl J Med 370(17):1637-46, 2014. e-Pub 2014. PMID: 24758620.
43. Ibrahim AS, Kontoyiannis DP. Update on mucormycosis pathogenesis. Curr Opin Infect Dis 26(6):508-15, 2013. e-Pub 2013. PMID: 24126718.
44. Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol 8:1163-75, 2013. e-Pub 2013. PMID: 24020743.
45. Kontoyiannis DP. Rational approach to pulmonary infiltrates in leukemia and transplantation. Best Pract Res Clin Haematol 26(3):301-6, 2013. e-Pub 2013. PMID: 24309535.
46. Granwehr BP, Kontoyiannis DP. The impact of infectious diseases consultation on oncology practice. Curr Opin Oncol 25(4):353-9, 2013. e-Pub 2013. PMID: 23736876.
47. Georgiadou SP, Kontoyiannis DP. The impact of azole resistance on aspergillosis guidelines. Ann N Y Acad Sci 1272:15-22, 2012. e-Pub 2012. PMID: 23231710.
48. Lewis RE, Viale P, Kontoyiannis DP. The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence 3(4):368-76, 2012. e-Pub 2012. PMID: 22722245.
49. Sipsas NV, Kontoyiannis DP. Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents 39(6):464-71, 2012. e-Pub 2012. PMID: 22337064.
50. Muhammed M, Feldmesser M, Shubitz LF, Lionakis MS, Sil A, Wang Y, Glavis-Bloom J, Lewis RE, Galgiani JN, Casadevall A, Kontoyiannis DP, Mylonakis E. Mouse models for the study of fungal pneumonia: a collection of detailed experimental protocols for the study of Coccidioides, Cryptococcus, Fusarium, Histoplasma and combined infection due to Aspergillus-Rhizopus. Virulence 3(3):329-38, 2012. e-Pub 2012. PMID: 22546902.
51. Kontoyiannis DP, Lewis RE, Lortholary O, Lotholary O, Spellberg B, Petrikkos G, Roillides E, Ibrahim A, Walsh TJ. Future directions in mucormycosis research. Clin Infect Dis 54 Suppl 1:S79-85, 2012. e-Pub 2012. PMID: 22247450.
52. Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against zygomycetes. Clin Infect Dis 54 Suppl 1:S61-6, 2012. e-Pub 2012. PMID: 22247447.
53. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 54 Suppl 1:S55-60, 2012. e-Pub 2012. PMID: 22247446.
54. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, Walsh TJ. How does antifungal pharmacology differ for mucormycosis versus aspergillosis?. Clin Infect Dis 54 Suppl 1:S67-72, 2012. e-Pub 2012. PMID: 22247448.
55. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 54 Suppl 1:S16-22, 2012. e-Pub 2012. PMID: 22247441.
56. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 54 Suppl 1:S23-34, 2012. e-Pub 2012. PMID: 22247442.
57. Walsh TJ, Bloom BE, Kontoyiannis DP. Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis. Clin Infect Dis 54 Suppl 1:S1-4, 2012. e-Pub 2012. PMID: 22247440.
58. Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G, Kontoyiannis DP, Walsh TJ. Combination therapy for mucormycosis: why, what, and how?. Clin Infect Dis 54 Suppl 1:S73-8, 2012. e-Pub 2012. PMID: 22247449.
59. Gamaletsou M, Sipsas NV, Kontoyiannis DP. Micafungin in hematology. Mycoses 55(Suppl 1):13-23, 2012. e-Pub 2012.
60. Hamilos G, Samonis G, Kontoyiannis DP. Recent Advances in the Use of Drosophila melanogaster as a Model to Study Immunopathogenesis of Medically Important Filamentous Fungi. Int J Microbiol 2012:583792, 2012. e-Pub 2012. PMID: 22518146.
61. Lionakis MS, Kontoyiannis DP. Drosophila melanogaster as a model organism for invasive aspergillosis. Methods Mol Biol 845:455-68, 2012. e-Pub 2012. PMID: 22328395.
62. Ben-Ami R, Kontoyiannis DP. A nonlethal murine cutaneous model of invasive aspergillosis. Methods Mol Biol 845:569-82, 2012. e-Pub 2012. PMID: 22328405.
63. Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med 32(6):693-702, 2011. e-Pub 2011. PMID: 22167397.
64. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 118(5):1216-24, 2011. e-Pub 2011. PMID: 21622653.
65. Marom EM, Kontoyiannis DP. Imaging studies for diagnosing invasive fungal pneumonia in immunocompromised patients. Curr Opin Infect Dis 24(4):309-14, 2011. e-Pub 2011. PMID: 21673574.
66. Mulanovich VE, Kontoyiannis DP. Fungal pneumonia in patients with hematologic malignancies: current approach and management. Curr Opin Infect Dis 24(4):323-32, 2011. e-Pub 2011. PMID: 21666457.
67. Chen SC, Lewis RE, Kontoyiannis DP. Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species. Virulence 2(4):280-95, 2011. e-Pub 2011. PMID: 21701255.
68. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 52(9):1144-55, 2011. e-Pub 2011. PMID: 21467021.
69. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-rhizopus, -mucor, and -lichtheimia species. Clin Microbiol Rev 24(2):411-45, 2011. e-Pub 2011. PMID: 21482731.
70. Person AK, Kontoyiannis DP, Alexander BD. Fungal infections in transplant and oncology patients. Hematol Oncol Clin North Am 25(1):193-213, 2011. e-Pub 2011. PMID: 21236398.
71. Chen SC, Kontoyiannis DP. New molecular and surrogate biomarker-based tests in the diagnosis of bacterial and fungal infection in febrile neutropenic patients. Curr Opin Infect Dis 23(6):567-77, 2010. e-Pub 2010. PMID: 20827189.
72. Lionakis MS, Kontoyiannis DP. The growing promise of Toll-deficient Drosophila melanogaster as a model for studying Aspergillus pathogenesis and treatment. Virulence 1(6):488-99, 2010. e-Pub 2010. PMID: 21178494.
73. Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol 150(4):406-17, 2010. e-Pub 2010. PMID: 20618330.
74. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them?. Clin Infect Dis 50(3):405-15, 2010. e-Pub 2010. PMID: 20047485.
75. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?. Clin Microbiol Infect 15 Suppl 5:93-7, 2009. e-Pub 2009. PMID: 19754766.
76. Nedel WL, Kontoyiannis DP, Pasqualotto AC. Aspergillosis in patients treated with monoclonal antibodies. Rev Iberoam Micol 26(3):175-83, 2009. e-Pub 2009. PMID: 19635439.
77. Ben-Ami R, Lewis RE, Kontoyiannis DP. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr Opin Infect Dis 22(4):376-84, 2009. e-Pub 2009. PMID: 19491674.
78. Kontoyiannis DP, Lewis RE, Marr K. The burden of bacterial and viral infections in hematopoietic stem cell transplant. Biol Blood Marrow Transplant 15(1 Suppl):128-33, 2009. e-Pub 2009. PMID: 19147091.
79. Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Med Mycol 47 Suppl 1:1-11, 2009. e-Pub 2009. PMID: 18654923.
80. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 47(2):226-35, 2008. e-Pub 2008. PMID: 18540822.
81. Mays SR, Kunishige JH, Truong E, Kontoyiannis DP, Hymes SR. Approach to the morbilliform eruption in the hematopoietic transplant patient. Semin Cutan Med Surg 26(3):155-62, 2007. e-Pub 2007. PMID: 18070682.
82. Chamilos G, Kontoyiannis DP. Defining the diagnosis of invasive aspergillosis. Med Mycol 44 Suppl:163-72, 2006. e-Pub 2006. PMID: 17050435.
83. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 20(3):581-607, vi, 2006. e-Pub 2006. PMID: 16984870.
84. Chamilos G, Kontoyiannis DP. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. Curr Opin Infect Dis 19(4):380-5, 2006. e-Pub 2006. PMID: 16804387.
85. May GS, Xue T, Kontoyiannis DP, Gustin MC. Mitogen activated protein kinases of Aspergillus fumigatus. Med Mycol 43 Suppl 1:S83-6, 2005. e-Pub 2005. PMID: 16110797.
86. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, Fridkin SK, Pappas PG, Warnock DW. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 43 Suppl 1:S49-58, 2005. e-Pub 2005. PMID: 16110792.
87. Lionakis MS, Kontoyiannis DP. Fruit flies as a minihost model for studying drug activity and virulence in Aspergillus. Med Mycol 43 Suppl 1:S111-4, 2005. e-Pub 2005. PMID: 16110801.
88. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 8(6):344-58, 2005. e-Pub 2005. PMID: 16488654.
89. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 126(2):165-75, 2004. e-Pub 2004. PMID: 15238137.
90. Lionakis MS, Kontoyiannis DP. Fusarium infections in critically ill patients. Semin Respir Crit Care Med 25(2):159-69, 2004. e-Pub 2004. PMID: 16088459.
91. Kontoyiannis DP. Mycofungin. A viewpoint. Drugs 64(9):983-984, 2004. e-Pub 2004.
92. Antoniadou A, Kontoyiannis DP. Status of combination therapy for refractory mycoses. Curr Opin Infect Dis 16(6):539-45, 2003. e-Pub 2003. PMID: 14624103.
93. Wiederhold NP, Lewis RE, Kontoyiannis DP. Invasive aspergillosis in patients with hematologic malignancies. Pharmacotherapy 23(12):1592-610, 2003. e-Pub 2003. PMID: 14695039.
94. Torres HA, Raad II, Kontoyiannis DP. Infections caused by Fusarium species. J Chemother 15 Suppl 2:28-35, 2003. e-Pub 2003. PMID: 14708964.
95. Kontoyiannis DP, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 53(4):243-58, 2003. e-Pub 2003. PMID: 12660121.
96. Kontoyiannis DP, Lewis RE. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 6(5):257-69, 2003. e-Pub 2003. PMID: 14643296.
97. De La Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transpl Infect Dis 4(1):3-9, 2002. e-Pub 2002. PMID: 12123420.
98. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 21(3):161-72, 2002. e-Pub 2002. PMID: 11957017.
99. Bodey GP, Kontoyiannis DP, Lewis R. Empiric antifungal therapy for persistently febrile neutropenic patients. Curr Opin Infect Dis 4:521-533, 2002. e-Pub 2002.
100. Samonis G, Kontoyiannis DP. Infectious complications of purine analog therapy. Curr Opin Infect Dis 14(4):409-13, 2001. e-Pub 2001. PMID: 11964857.
101. Kontoyiannis DP. A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America. Pharmacotherapy 21(8 Pt 2):175S-187S, 2001. e-Pub 2001. PMID: 11501990.
102. Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy 21(8 Pt 2):149S-164S, 2001. e-Pub 2001. PMID: 11501988.
103. Shaikh ZH, Ueno NT, Kontoyiannis DP. Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. Transpl Infect Dis 3(1):29-33, 2001. e-Pub 2001. PMID: 11429037.
104. Kontoyiannis DP. Case records of the Massachusetts General Hospital. Case 20-2001. New England Journal of Medicine 344:2009-2014, 2001. e-Pub 2001.
105. Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 14(3):721-39, 2000. e-Pub 2000. PMID: 10987117.
106. Kontoyiannis DP, Rubin RH. Infection in the organ transplant recipient. An overview. Infect Dis Clin North Am 9(4):811-22, 1995. e-Pub 1995. PMID: 8747767.
107. Dailey Garnes J, Kontoyiannis DP. Mucormycosis: an update in diagnosis and management. Current Opinion in Infectious Diseases.
108. Lamoth F, Kontoyiannis DP. PCR diagnostics for infections caused by non-Aspergillus molds: Ready for prime time?. Current Opinion in Molecular Diagnostics.
109. Matsuo T, Wurster S, Kontoyiannis DP. Point of care diagnostics in medical mycology. Current Opinion in Molecular Diagnostics.

Manuals, Teaching Aids, Other Teaching Publications

1. Kontoyiannis DP, Thompson GR, Nguyen M-H T. Interactive Web-Based MSG Education and Research Consortium Activity. COVID19-associated invasive fungal infections, 2021.
2. . ASM Editors in conversation/AAC Podcast: Candida auris at the intersection of COVID-19 pandemic, 2021.
3. Kontoyiannis DP. Fusariosis in a neutropenic AML patient. DrFungus.org, 2019.
4. Kontoyiannis DP. Chair, Interactive Web-Based MSG Education and Research Consortium Activity. The New Antifungals Toolkit, 2017.
5. Kontoyiannis DP. (honorary contributor, state to the art monograph): A clinical approach to assess immunosupression in the leukemia patient, 2012.
6. Tarrand JJ, Wagar EA, Love GL, Kontoyiannis DP. Environmental molds and systemic fungal infections. Clinical Laboratory International-online.com, 2011.
7. Mulanovich V, Kontoyiannis DP. (honorary contributor, state to the art monograph): The future of antibacterial prophylaxis for patients with hematologic malignancies, 2010.
8. Kontoyiannis DP. Insights into early empiric or prophylactic antifungal therapy in the transplant setting. Blood and Marrow Transplantation Review, 2007.
9. Kontoyiannis DP. Scedosporiosis in a neutropenic AML patient. Fungus.org, 2006.
10. Kontoyiannis DP. (honorary contributor, state to the art monograph): Evolution of Invasive Fungal Infections: Epidemiology and Treatment, 2005.
11. Kontoyiannis DP. Infectious Diseases Outlook: A StratFOCUSÔ Report, 1999.

Other Articles

1. Shirazi, F, Farmakiotis, D, Yan, Y, Albert, ND, Kim-Anh, D, Kontoyiannis, DP Erratum. PloS one 20(1):e0317530, 2025. PMID: 39787201.
2. Kontoyiannis DP Is Candida auris here to stay? An interview with Dimitrios Kontoyiannis. Future Microbiol 14:1083-1085, 2019. PMID: 31512518.
3. Spallone A, Kontoyiannis DP Case of the Month//Fusariosis. DrFungus.org.
4. Kontoyiannis DP, Lewis RE A fly model to study fungal disease. Microbe, ASM Press 5(7):291-4, 2009.
5. Campo M, Kontoyiannis DP A man with AML, fever and hip pain. The J of Inv Fungal Infect(3):15-17, 2009.
6. Liu W, May GS, Kontoyiannis DP, Li RY Cloning of the Aspergillus fumigatus squalene epoxidase gene. Beijing Da Xue Xue Bao 36(5):476-82, 2004. PMID: 15489926.
7. Kontoyiannis DP Invasive aspergillosis: a management overview 7:42-44, 2003.
8. Kontoyiannis DP SCH 56592: Hosted in Aspergillus web page, 2000.

Editorials

1. Lynch JP, Kontoyiannis DP. Special Issue "Diagnosis and Treatment of Invasive Pulmonary Fungal Infections". J Fungi (Basel) 9(7), 2023. PMID: 37504732.
2. Skaria J, John TM, Varkey S, Kontoyiannis DP. Are Unique Regional Factors the Missing Link in India's COVID-19-Associated Mucormycosis Crisis?. mBio 13(2):e0047322, 2022. PMID: 35357212.
3. Korompoki E, Gavriatopoulou M, Kontoyiannis DP. COVID-19 Vaccines in Patients With Cancer-A Welcome Addition, but There Is Need for Optimization. JAMA Oncol 7(8):1113-1114, 2021. PMID: 33983372.
4. Casadevall A, Kontoyiannis DP, Robert V. Environmental Candida auris and the Global Warming Emergence Hypothesis. mBio 12(2), 2021. PMID: 33727350.
5. Colombo AL, Agnelli C, Kontoyiannis DP. Knowledge gaps in candidaemia/invasive candidiasis in haematological cancer patients. J Antimicrob Chemother 76(3):543-546, 2021. PMID: 33150364.
6. Garcia-Vidal C, Lewis RE, Kontoyiannis DP. Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine. J Antimicrob Chemother. PMID: 32719877.
7. Malek AE, Granwehr BP, Kontoyiannis DP. Doxycycline as a potential partner of COVID-19 therapies. IDCases 21:e00864, 2020. PMID: 32566483.
8. Casadevall A, Kontoyiannis DP, Robert V. On the emergence of Candida auris: climate change, azoles, swamps and birds. MBio 10(4), 2019. PMID: 31337723.
9. Cornely OA, Kontoyiannis DP. How to prophylax against invasive fungal infections in adult ALL? An unmet need. Mycoses, 2018. PMID: 29693737.
10. Lamoth F, Kontoyiannis DP. The Candida auris Alert: Facts and Perspectives. J Infect Dis 217(4):516-520, 2018. PMID: 29390110.
11. Kontoyiannis DP. Antifungal Resistance: An Emerging Reality and A Global Challenge. J Infect Dis 216(suppl_3):S431-S435, 2017. PMID: 28911044.
12. Kontoyiannis DP. Infections following allogeneic stem cell transplantation: New concepts, improved insights, and renewed hope for better outcomes. Virulence:0. PMID: 27791470.
13. Granwehr B, Kontoyiannis DP. The evolving landscape of gastrointestinal infections in neutropenic patients. Oncology (Williston Park) 29(8):590, 592-3, 2015. PMID: 26349340.
14. Askew DS, Kontoyiannis DP, Clemons KV. Advances Against Aspergillosis: Biology, Host response, Diagnosis and Treatment. Mycopathologia 178(5-6):321-4, 2014. PMID: 25287755.
15. Jung DS, Kontoyiannis DP. Co-infection with Influenza: Do Not Forget Aspergillus in the Immunosuppressed Neutropenic Host. Tuberc Respir Dis (Seoul) 76(5):249, 2014. PMID: 24920954.
16. Kontoyiannis DP. Are respiratory complications more likely in patients with pulmonary aspergillosis treated with echinocandins in the setting of neutrophil influx?. Virulence 5(3):375-7, 2014. PMID: 24569451.
17. Kontoyiannis DP, Perlin DS, Roilides E, Walsh TJ. What can we learn and what do we need to know amidst the iatrogenic outbreak of exserohilum rostratum meningitis?. Clin Infect Dis 57(6):853-9, 2013. PMID: 23650291.
18. Kontoyiannis DP. Virulence Profile: Dimitrios P Kontoyiannis. Virulence 4(5):429-31, 2013. PMID: 23799666.
19. Thompson GR, Kontoyiannis DP, Patterson TF. Real-world experience in the midst of an Exserohilum meningitis outbreak. JAMA 309(23):2493-5, 2013. PMID: 23780464.
20. Kontoyiannis DP. Preventing fungal disease in chronically immunosuppressed outpatients: time for action?. Ann Intern Med 158(7):555-6, 2013. PMID: 23546567.
21. Pappas PG, Kontoyiannis DP, Perfect JR, Chiller TM. Real-Time Treatment Guidelines: Considerations during the Exserohilum rostratum Outbreak in the United States. Antimicrob Agents Chemother 57(4):1573-6, 2013. PMID: 23384532.
22. Ben-Ami R, Kontoyiannis DP. Resistance to echinocandins comes at a cost: the impact of FKS1 hotspot mutations on Candida albicans fitness and virulence. Virulence 3(1):95-7, 2012. PMID: 22286697.
23. Kontoyiannis DP. A clinical approach to assess treatment for presumed and documented invasive mold infections in patients with hematologic malignancies: focus on Spanish Society of Chemotherapy Guidelines. Rev Esp Quimioter 24(4):173-4, 2011. PMID: 22173185.
24. Kontoyiannis DP. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success. Bone Marrow Transplant 46(2):165-73, 2011. PMID: 21042306.
25. Chamilos G, Samonis G, Kontoyiannis DP. Drosophila melanogaster as a Model Host for the Study of Microbial Pathogenicity and the Discovery of Novel Antimicrobial Compounds. Curr Pharm Des 17(13):1246-53, 2011. PMID: 21470115.
26. Tsatsanis C, Margioris AN, Kontoyiannis DP. Association between H1N1 infection severity and obesity-adiponectin as a potential etiologic factor. J Infect Dis 202(3):459-60, 2010. PMID: 20557238.
27. Kontoyiannis DP. Manipulation of host angioneogenesis: A critical link for understanding the pathogenesis of invasive mold infections?. Virulence 1(3):192-6, 2010. PMID: 21178441.
28. Adachi J, Kontoyiannis DP. Gastrointestinal Mucormycosis: An Elusive, Unusual, and Severe. Gastroenterology & Hepatology 5:661-62, 2009.
29. Walsh TJ, Kontoyiannis DP. Editorial commentary: what is the role of combination therapy in management of zygomycosis?. Clin Infect Dis 47(3):372-4, 2008. PMID: 18558877.
30. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 11(7):515-7, 2005. PMID: 15966968.
31. Kontoyiannis DP. Cutaneous zygomycosis. Infections in Medicine 22(42), 2005.
32. Lewis RE, Lewis RE, Kontoyiannis DP, Kontoyiannis DP. The epidemiology of invasive candidiasis in BMT patients in the 2000s: Is fluconazole the only factor for the emergence of some-non-albicans Candida species?. Infections in Medicine 21:40, 2004.

Abstracts

1. Chamilos G, Luna M, Lewis RE, Bodey GP, Raad II, Kontoyiannis DP. Invasive aspergillosis (IA) in autopsy of patients with hematological malignancies (2000-2004). 2nd International Meeting in advances against aspergillosis, 2006. e-Pub 2006.
2. Trifilio S, Bennett CL, Yarnold PR, Mehta J, Palella F, Kennedy L, Parada J, Blum W, and Kontoyiannis DP. Risk factors associated with mortality among persons with breakthrough zygomycosis and prior voriconazole exposure. 7th 2006 BMT Tandem Meeting Honolulu, HA, 2006. e-Pub 2006.
3. Burik V, JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Treatment for zygomycosis: Posaconazole as a treatment option in 91 cases. 7th 2006 BMT Tandem Meeting. Honolulu, HA, 2006. e-Pub 2006.
4. Lewis RE, Liao G, Chamilos G, Kontoyiannis DP. Pseudomonas aeruginosa kills Aspergillus fumigatus hyphae in vitro - A possible pathogenic relationship and role for quorum signaling in hyphal growth. 2nd International Meeting in advances against aspergillosis. 2nd International Meeting in advances against aspergillosis, 2006. e-Pub 2006.
5. Sipsas NVI, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. 2nd International Meeting in advances against aspergillosis, 2006. e-Pub 2006.
6. Raad II, Boktour MR, Hanna HA, Kontoyiannis DP, Hachem RY. Posaconazole compared with amphotericin B lipid formulations in combination with caspofungin as salvage therapy for invasive aspergillosis in patients with hematologic malignancy. 2nd International Meeting in advances against aspergillosis, 2006. e-Pub 2006.
7. Hachem RY, Boktour MR, Hanna HA, Torres H, Afif C, Kontoyiannis DP, Raad II. Amphotericin B lipid complex vs. liposomal amphotericin B monotherapy of ivasive aspergillosis in patients with hematological malignancy. 2nd International Meeting in advances against aspergillosis, 2006. e-Pub 2006.
8. Trifilio, S, Balasubramanian B, Mehta J, tallman MS, Keennedy L, Bennett CL, Kontoyiannis DP. A multi-institution retrospective case report analysis of emergence of breakthrough zygomycosis in patients on prior voriconazole. 47th Annual Meeting of the American Society of Hematology (ASH), 2005. e-Pub 2005.
9. Lionakis, M, Lahdenranta J, Pasqualini R, Chamilos G, Lewis RE, Arap W, Kontoyiannis DP. Combinatorial selection of targeting peptides in a murine model of invasive pulmonary aspergillosis. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-732, 2005. e-Pub 2005.
10. Chamilos, G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes in vitro and in vivo and shows in vitro synergy with voriconazole. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-768, 2005. e-Pub 2005.
11. Safdar, A, Rodriguez G, Rolston K, Kantarjian H, Champlin R, Raad II, Kontoyiannis DP. Efficacy of high-dose caspofungin in 22 cancer patients with invasive fungal infections. 15th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Copenhagen, Denmark:Abstract #A-343, 2005. e-Pub 2005.
12. Hachem, R, Lee L, Hackett B, Chemaly R, Perego C, Kontoyiannis DP, Raad II. Nosocomial aspergillosis in patients with hematologic malignancy: is it waterborne or airborne? . 15th Society for Healthcare Epidemiology of America (SHEA), Los Angeles, CA:Abstract #A-05-A-477, 2005. e-Pub 2005.
13. Chamilos, G, Lewis RE, Kontoyiannis DP. The unique alternative mitochondria pathway of C. parapsilosis and reduced in vitro susceptibility to caspofungin . 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-842, 2005. e-Pub 2005.
14. Aisenberg, G, Tarrand J, Rolston K, Kontoyiannis DP, Raad I, Safdar A. Stenotrophomonas maltophilia: changing spectrum of bacterial pneumonia in cancer patients with low suspicion of S. maltophilia infection. 15th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Copenhagen, Denmark:Abstract #A-1374, 2005. e-Pub 2005.
15. Kontoyiannis, DP, Hare RS, Solomon HF, Corrado ML, VanBurik, JA. Posaconazole is highly effective as a second-line agent in zygomycosis: Summary of 91 cases. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-974, 2005. e-Pub 2005.
16. Aboufaycal, H, Adachi J, Hachem R, Weiss LT, Kontoyiannis DP, Safdar A, Chemaly R, Rolston K, Raad I. Risk factors and outcome of infection with multidrug-resistant Escherichia coli in patients with cancer. 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, CA:Abstract #716, 2005. e-Pub 2005.
17. Chamilos, G, Bodey GP, Luna M, Lewis RE, Rolston KV, Chemaly R, Safdar A, Raad II, Kontoyiannis DP. Trends in incidence of invasive fungal infections at a tertiary cancer center over 14-year period: An autopsy study. 15th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Copenhagen, Denmark:Abstract #A-336, 2005. e-Pub 2005.
18. Hachem, RY, Boktour M, Hanna HA, Torres H, Afif C, Kontoyiannis DP, Raad II. Amphotericin B lipid complex (ABLC) vs. liposomal amphotericin B monotherapy of invasive aspergillosis in patients with hematological malignancy. 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, CA:Abstract #743, 2005. e-Pub 2005.
19. Chemaly, RF, Torres HA, Rohtgi N, Kontyiannis DP, Sepulveda C, Hachem R, Raad II. Human herpesviruses-6 viremia is associated with donor granulocyte transfusions in heavily immunosuppressed patients with leukemia. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #V-592, 2005. e-Pub 2005.
20. Chamilos, G, Rolston KV, Kontoyiannis DP. Analysis and impact of infectious disease outpatient consultations in a comprehensive cancer center. 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, CA:Abstract #748, 2005. e-Pub 2005.
21. Yusuf, SW, Ali S, Tong A, Swafford J, Durand JB, Kontoyiannis DP, Rolston KV, Raad II, Safdar A. Clinical spectrum of endocarditis in patients with cancer: a case-control evaluation of culture-positive and culture-negative disease, 1994-2004. 15th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Copenhagen, Denmark:Abstract #A-1382, 2005. e-Pub 2005.
22. Hanna, H, Kontoyiannis DP, Buddineni J, Boktour M, Antoniadou A, Hachem R, Raad I. The changing epidemiology of candidemia in hematologic malignancy: Candida glabrata and Candida krusei are the leading causes of fungemia. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract # 2005, 2005. e-Pub 2005.
23. Lewis, RE, Chamilos G, Komanduri KV, Prince RA, Kontoyiannis DP. Liposomal amphotericin B is superior to amphotericin B deoxycholate in reducing inflammatory lung injury and fungal burden in corticosteroid-treated mice with invasive pulmonary aspergillosis. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-1028, 2005. e-Pub 2005.
24. Chamilos, G, Lewis RE, Prince RA, Kontoyiannis DP. Zygomycetes hyphae are less susceptible to killing by polymorphonuclear neutrophils than Aspergillus hyphae through Toll-like receptor independent mechanisms. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-1232, 2005. e-Pub 2005.
25. Lewis, RE, Singh N, Limaye A, Husain A, Safdar N, Munoz P, Pursell K, Kontoyiannis DP. Detection of synergy by XTT-enhanced checkerboard dilution testing of Aspergillus: Correlation with outcome in patients with invasive aspergillosis treated with combination voriconazole and caspofungin therapy. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-1053, 2005. e-Pub 2005.
26. Hachem, RY, Hanna HA, Dvorak T, Kontoyiannis DP, Raad II. Antifungal activity of amphotericin B lipid complex with EDTA against Candida embedded in biofilm. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #2005, 2005. e-Pub 2005.
27. Park, BJ, Morrison VA, Kontoyiannis DP, Ito J, Walsh TJ, Pappas PG, Fridkin SK, Marr K. Description of very-late invasive mould infections among hematopoietic stem cell transplant recipients reported in Transnet. 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco:Abstract #745, 2005. e-Pub 2005.
28. Kumashi, P, Safdar A, Chemaly RF, Chamilos G, Raad I, Kontoyiannis DP. Fungal osteoarticular infections in cancer patients: a 10-year retrospective study. 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, CA:Abstract #742, 2005. e-Pub 2005.
29. Lewis RE, Kontoyiannis DP. Micafungin in combination with voriconazole in Aspergillus species: A pharmacodynamic approach for detection of synergy in vitro. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-1083, 2005. e-Pub 2005.
30. Lionakis, M, Chamilos G, Lewis RE, Samonis G, Raad II, Kontoyiannis DP. Pentamidine has activity in a neutropenic murine model of acute invasive pulmonary fusariosis. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-1386, 2005. e-Pub 2005.
31. Tsiodras S, Kontoyiannis DP. Invasive fungal infections complicating TNF blockade therapy: A review Of 248 cases. 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, CA:Abstract #267, 2005. e-Pub 2005.
32. Chamilos, G, Lewis RE, Lionakis MS, Halder G, Kontoyiannis DP. Experimental zygomycosis in Drosophila melanogaster. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-1198, 2005. e-Pub 2005.
33. Kontoyiannis, DP, Chamilos G, Lewis RE, Tarrand JJ. Increased culture recovery of zygomycetes under physiologic temperature conditions number. 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, CA:Abstract #279, 2005. e-Pub 2005.
34. Chamilos, G, Luna M, Lewis RE, Safdar A, Bodey GP, Raad I, Kontoyiannis DP. Invasive fungal infections in patients with hematological malignancies (1989-2003): An autopsy study. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-996, 2005. e-Pub 2005.
35. Singh, N, Limaye A, Safdar N, Forrest G, Pursell K, Munoz P, Rosso F, Montoya J, Aguado J, Patton P, Houston S, De Busto R, Lewis R, Kontoyiannis DP, Husain S. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-587, 2005. e-Pub 2005.
36. Lewis, RE, Chamilos G, Kontoyiannis DP, Prince RA. Pseudomonas aeruginosa attenuates human polymorphonuclear neutrophil killing of Aspergillus fumigatus hyphae. 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #A-1082, 2005. e-Pub 2005.
37. Lionakis, MS, Lewis RE, Kontoyiannis DP. In Vitro Susceptibility Testing Of Aspergillus to amphotericin B: Correlation with outcome of initial amphotericin B therapy in cancer patients with invasive aspergillosis. Abstracts of the 13th International Symposium on Infections in the Immunocompromised Host. Granada, Spain, 2004. e-Pub 2004.
38. Pappas, P, Alexander B, Marr K, Kontoyiannis DP. Invasive fungal infections in hematopoietic stem cell and organ transplant recipients. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:#671, 2004. e-Pub 2004.
39. Kontoyiannis, DP, Lionakis MS, Lewis RE, Walsh TJ, Raad II. Zygomycosis in the era of voriconazole in a cancer center: A matched case-control observational study of 27 recent cancer patients. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, 2004. e-Pub 2004.
40. Torres, HA, Storey R, Chemaly RF, Aguilera E, Luamd M, Rolston KVI, Raad I, Kontoyiannis DP. Pneumocystis jiroveci pneumonia in a cancer center: Influence of HIV status to presentation and outcome. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #687, 2004. e-Pub 2004.
41. Baddley, JW, Benjamin P, Marr KA, Andes DR, Kontoyiannis DP, Hadley S, Schuster M, Alexander BD, Walsh TJ, Oster RA, Pappas PG. Factors influencing mortality in transplant recipients with invasive aspergillosis. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #673, 2004. e-Pub 2004.
42. Jacobson, K, Miceli MH, Tarrand J, Kontyiannis DP. Legionella pneumonia in a tertiary care cancer center. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #663, 2004. e-Pub 2004.
43. Ohmagari, N, Kontoyiannis DP, Chemaly RF, Hachem R, Raad II. Invasive aspergillosis among cancer patients with solid tumor: a 10-year experience at a tertiary cancer hospital. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #675, 2004. e-Pub 2004.
44. Lionakis, MS, Halder G, Lewis RE, Wiederhold NP, May GS, Kontoyiannis DP. Experimental aspergillosis in Drosophila: Influence of mode of infection on Aspergillus virulence. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-223, 2004. e-Pub 2004.
45. Morgan, J, Alexander B, Wannemuehler K, Fan K, Daram P, Marr K, Kontoyiannis D, Kauffman C, Ito J, Hadley S, Fridkin S, Pappas P, Walsh T. TRANSNET Investigators. Quantification of risk for invasive fungal infections among transplant recipients reporting to TRANSNET. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC,:Abstract #M-1058, 2004. e-Pub 2004.
46. Lionakis, MS, Halder G, Lewis R, Wiederhold NP, Kontoyiannis DP. Efficacy of voriconazole in experimental aspergillosis in Drosophila. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-1139, 2004. e-Pub 2004.
47. Chamilos, MS, Lionakis MS, Kontoyiannis DP. Drosophila melanogaster as an alternative in vivo model to study candidiasis. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-240, 2004. e-Pub 2004.
48. Raad, II, Boktour MR, Hanna HA, Kontoyiannis DP, Hachem RY. Caspofungin amphotericin B lipid formulations or the combination as salvage therapy for invasive aspergillosis in patients with hematologic malignancy. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #678, 2004. e-Pub 2004.
49. Park, BJ, Kontoyiannis DP, Pappas PG, Wannemuehler K, Fridkin S, Walsh TJ. Comparison of zygomycosis and fusariosis to invasive aspergillosis among transplant recipients reporting to TRANSNET. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-666, 2004. e-Pub 2004.
50. Raad, II, Boktour MR, Hanna HA, Kontoyiannis DP, Hachem RY. Posaconazole compared to amphotericin B lipid formulations alone or in combination with itraconazole as salvage therapy for invasive aspergillosis in patients with hematologic malignancy. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #679, 2004. e-Pub 2004.
51. Raad, I, Boktour JA, Hanna HA, Hachem RY, Kontoyiannis DP. Posaconazole compared to amphotericin B lipid formulations in combination with caspofungin as salvage therapy for invasive aspergillosis in patients with hematologic malignancy. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-1035, 2004. e-Pub 2004.
52. Wiederhold, NP, Kontoyiannis DP, Lewis RE. Eagle-like effect of caspofungin against Candida and Aspergillus spp; Association with homeostatic mechanisms of cell-wall integrity. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-1682, 2004. e-Pub 2004.
53. Hussein, S, Peacock J, Hung CC, Kontoyiannis DP, Morris AJ, Heath C, Nguyen MH, Yu ML. Differences in the presentation of cryptococcosis among different hosts: A multicenter prospective observational study. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #685, 2004. e-Pub 2004.
54. Healy, M, Reece K, Walton D, Lising M, Bittner T, Frye S, Schrock R, Raad II, Kontoyiannis DP. Identification and strain discrimination of clinical Candida bloodstream isolates using the diversiLab system and DNA sequencing . 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #D-464, 2004. e-Pub 2004.
55. Healy, D, Walton D, Reece K, Listing M, Bittner T, Frye S, Kontoyiannis DP. Species identification of clinical zygomycetes isolates by automated rep-PCR and DNA sequencing. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #D-466, 2004. e-Pub 2004.
56. Tarrand, J, Lionakis M, Han X, Kontoyiannis DP. Aspergillus galactomannan detection: New sensitive latex micro-agglutination procedure. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #618, 2004. e-Pub 2004.
57. Healy, M, Walton D, Reece K, Bittner T, Manry J, Raad II, Kontoyiannis DP. Identification and molecular typing of clinical Fusarium isolates by two DNA sequencing methods and automated rep-PCR. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #D-465, 2004. e-Pub 2004.
58. Kontoyiannis, DP, Lionakis M, Halder G. Toll pathway in Drosophila melanogaster: A possible role to study the impact of immune senescence in poor responses against Aspergillus fumigatus. 14th FOCUS on fungal Infection meeting:Abstract #31, 2004. e-Pub 2004.
59. Hadley S, Kontoyiannis DP. Voriconazole in vitro activity against clinical Aspergillus species by three methods. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-1680, 2004. e-Pub 2004.
60. Kamana, M, Rolston K, Kontoyiannis DP. Actinomycosis in cancer patients. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #683, 2004. e-Pub 2004.
61. Hachem, R, Boktour M, Hanna H, Tarrand J, Kontoyiannis DP, Chemaly RF, Willams TP, Daugherty T, Raad I. Serum galactomannan: Which assay (or LATEX) is useful in diagnosing invasive aspergillosis? . 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #617, 2004. e-Pub 2004.
62. Torres, H, Younes A, Aguilera AA, Kontoyiannis DP, Luna MA, Tarrand JJ, Nogueras G, Raad I, Chemaly RF. Cytomegalovirus infection in patients with lymphoma. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, MA:Abstract #638, 2004. e-Pub 2004.
63. Kontoyiannis, DP, Liu W, May GS. Extra copies of Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: A genetic approach to study gene dose-dependent resistance to antifungals in Aspergillus fumigatus. . 14th FOCUS on fungal Infection meeting:Abstract #55, 2004. e-Pub 2004.
64. Lewis, RE, Wiederhold NP, Lionakis MS, Chi J, Prince A, Kontoyiannis DP. Frequency and distribution of gliotoxin producing Aspergillus isolates recovered from patients at a tertiary care cancer center. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract M-245, 2004. e-Pub 2004.
65. Kontoyiannis, DP, Boktour M, Hanna H, Hachem R, Raad II. Does itraconazole added to amphotericin B or its lipid formulation improve outcome of primary treatment of invasive aspergillosis ?. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-1032, 2004. e-Pub 2004.
66. Wiederhold, NP, Kontoyiannis DP, Lewis RE. Relationship between interferon gamma/ Interleukin-10 and mycological efficacy of amphotericin B in invasive pulmonary aspergillosis. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC:Abstract #M-230, 2004. e-Pub 2004.
67. Hogan, H, Chemaly RF, Coyle EA, Kamana M, Kontoyiannis DP, Safdar A, Bodey GP, Raad II. Early combination antiviral therapy for cytomegalovirus infection in patients with hematological malignancies. 41st Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, CA:Abstract #364, 2003. e-Pub 2003.
68. Lionakis, MS, Lahdenranta J, Liu W, Lewis RE, Pasqualini R, WArap, Kontoyiannis DP. Biopanning as an approach to study the pathogenesis of invasive aspergillosis. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# M-472, 2003. e-Pub 2003.
69. Stanzani, M, Lewis R, Martins S, Kontoyiannis DP, Komanduri K. Aspergillus fumigatus subverts the human T cell immune response via gliotoxin-mediated effects in antigen presentation. 45th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA:Abstract#3615, 2003. e-Pub 2003.
70. Garey, KW, Neuhauser MM, Bearden DT, Cannon JP, Lewis RE, Gentry LO, Kontoyiannis, DP. Evaluation of antifungal usage in SICU patients: A multi-institutional study. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# K-452h, 2003. e-Pub 2003.
71. Wiederhold, NP, Chi J, Kontoyiannis DP, Prince RA, Lewis RE. In vitro reduction of the Aspergillus fumigatus metabolite gliotoxin by amphotericin B, caspofungin, and voriconazole. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# M-1243, 2003. e-Pub 2003.
72. Ullman, AJ, Cornely OA, Burchardt A, Huber C, Hachem R, et al KD. Safety and efficacy of posaconazole in a pharmacokinetic study in patients with febrile neutropenia or refractory invasive fungal infections. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract M- 1257, 2003. e-Pub 2003.
73. Girgawy, E, Raad II, Safdar A, Bodey GP, Kontoyiannis DP. The significance of a positive respiratory culture for Aspergilluss versicolor in cancer patients. 41st Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, CA:Abstract #389, 2003. e-Pub 2003.
74. Safdar, A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Raad II. Donor granulocyte transfusions in cancer patients with hematogenous candidiasis – Impact on fungemia outcome. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# M-969, 2003. e-Pub 2003.
75. Wiederhold, NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. In vivo pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# M-476, 2003. e-Pub 2003.
76. Rolston, KV, Kontoyiannis DP, Raad II, Leblanc BJ, Streeter HL, Ho DH. Susceptibility surveillance among gram-negative bacilli at comprehensive cancer center. 45th Annual Meeting of the American Society of Hematology (ASH), San Diego:Abstract#2362, 2003. e-Pub 2003.
77. Lewis, RE, Chi J, Widerhold NP, Kontoyiannis DP, XHan, RAPrince. Detection of gliotoxin, an immunologically active metabolite secreted by Aspergillus fumigatus, in animals and humans with invasive aspergillosis. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# M-1015, 2003. e-Pub 2003.
78. Healy M, Kontoyiannis DP. Molecular fingerprinting of Candida and Aspergillus spp by automated rep-PCR. 45th Annual Meeting of the American Society of Hematology (ASH), San Diego:Abstract#2477, 2003. e-Pub 2003.
79. Lionakis, M, Halder B, Lewis RE, May GS, Albert ND, Kontoyiannis DP. A non-vertebrate in vivo model to study invasive aspergillosis and its treatment with oral antifungals: early experience with Drosophila. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# M-477, 2003. e-Pub 2003.
80. Kontoyiannis, DP, Reece K, Healy M. Fusarium discrimination using automated rep-PCR DNA fingerprinting. 15th Annual Meeting of the International Society for Human and Animal Mycology, (ISHAM), San Antonio, TX:Abstract# 290, 2003. e-Pub 2003.
81. Mattiuzzi, G, Kantarjian H, Alvarado G, Kontoyiannis DP, Pierce S, Cortes J, Giles F, Raad II, Verstovesek S, Estey E. Intravenous itraconazole vs. caspofungin prophylaxis in patients with acute myelogenous leukemia on induction chemotherapy. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# M-984, 2003. e-Pub 2003.
82. Wiederhold, NP, Kontoyiannis DP, Lewis RE. In vitro pharmacodynamics of rapid vs. continuous infusion amphotericin B deoxycholate in the presence of human serum albumin. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract#M-1259, 2003. e-Pub 2003.
83. Torres, HA, Raad II, Reddy BT, Kontoyiannis DP. Pulmonary cryptococcosis due to capsule-deficient Cryptococcus neoformans. 41st Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, CA:Abstract #352, 2003. e-Pub 2003.
84. Rolston, KVI, Kontoyiannis DP, Raad II. In vitro activity of quinolones against viridans streptococci isolated from cancer patients. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# E-148, 2003. e-Pub 2003.
85. Steinbach, WJ, JrDK B, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Jafri H, Walsh TJ. Invasive aspergillosis caused by Aspergillus terreus: Review of preclinical data and a multicenter retrospective analysis of 87 recent cases. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# M-1753, 2003. e-Pub 2003.
86. Lionakis, MS, Lewis RE, Torres HA, Rolston KVI, Raad II, Kontoyiannis DP. In vitro susceptibility of Aspergillus clinical isolates to AMB, ITZ and VRC by E-test and the effect of prior antifungal exposure. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract#M-1248, 2003. e-Pub 2003.
87. Ezzet, F, Wexler D, Courtney R, Martino M, Cellary A, Huber C, Hachem R, Kontoyiannis D, Topelt K, Corcoran G, Cornely OA, Raad I, Ullmann AJ. Comparative bioavailability of oral posaconazole in different dosage regimens: A population pharmacokinetic analysis. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract# A-1565, 2003. e-Pub 2003.
88. Hanna, HA, Chatzinikolaou I, Alakech, Hachem R, Lewis R, Kontoyiannis DP, Tarrand J, Raad I. Differential positive quanitative blood cultures and the diagnosis of catheter-related bloodstream infections. 41st Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, CA:Abstract #334, 2003. e-Pub 2003.
89. Lionakis, MS, Lewis RE, Liu W, Bodey GP, Albert ND, Rolston KV, Raad II, Kontoyiannis DP. Comparison of the in vitro activities of modern antifungals against Aspergillus isolates from cancer patients. 41st Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, CA:Abstract #142, 2003. e-Pub 2003.
90. Lionakis, MS, Tarand JJ, Bodey GP, Raad II, Kontoyiannis DP. The significance of blood cultures positive for Scedosporium species and other rare molds in cancer patients. 41st Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, CA:Abstract #396, 2003. e-Pub 2003.
91. Kontoyiannis DP, Lionakis MS. The significance of isolation of rare molds from the respiratory tract in patients with cancer? . 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract#M-2055, 2003. e-Pub 2003.
92. Boktour, MR, Kontoyiannis DP, Hend HA, Hachem RY, Girgawy E, Bodey GP, Raad II. Multiple species candidemia in cancer patients: Risk factors and response to antifungal therapy. 41st Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, CA:Abstract #391, 2003. e-Pub 2003.
93. Coyle, EA, Lewis RE, Chi J, Rolston KV, Tarrand J, Kontoyiannis DP, Prince RA. Varying doses of levofloxacin and the corresponding relationship of antimicrobial activity and resistance selection against Pseudomonas aeruginosa. 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA:Abstract #1207, 2002. e-Pub 2002.
94. Hachem, R, Kontoyiannis D, Boktour M, Afif C, Cooksley C, Chatzinikolaou I, Raad I. Invasive Aspergillosis with Aspergillus fumigatus and Aspergillus terreus: A comparative analysis of risk factors and outcome in cancer patients. 40th Annual Meeting of the Infectious Diseases Society of America (IDSA), Chicago, IL:Abstract #338, 2002. e-Pub 2002.
95. Torres, H, Kontoyiannis DP, Rolston K. High dose fluconazole therapy for cancer patients with candidemia. 40th Annual Meeting of the Infectious Diseases Society of America (IDSA), Chicago, IL:Abstract#350, 2002. e-Pub 2002.
96. Liu, W, Lewis RE, May GS, Kontoyiannis DP. Preexposure of A. fumigatus to fluconazole induces tolerance to itraconazole in vitro. 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA:Abstract #M-852, 2002. e-Pub 2002.
97. Chagua, MR, Hachem R, Raad I, Kontoyiannis DP. Trichosporonosis in a tertiary care cancer center: Risk factors, spectrum and determinants of outcome. 40th Annual Meeting of the Infectious Diseases Society of America (IDSA), Chicago, IL:Abstract #100859, 2002. e-Pub 2002.
98. Tarrand, JJ, Kontoyiannis DP, Han XY, May GS. Culture incubation conditions affect the growth of Aspergillus spp. in an in vitro model system of tissue phase fungal growth. 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA:Abstract #M-909, 2002. e-Pub 2002.
99. Kontoyiannis, DP, Lewis RE, May GS, Albert ND, Raad I. Sequential exposure of A. fumigatus to itraconazole and caspofungin: Evidence of enhanced in vitro activity of this combination. 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA:Abstract #M-851, 2002. e-Pub 2002.
100. Kontoyiannis, DP, May GS, Lewis RE, Albert DN, Prade RA. Deletion of hogA gene, an Osmotic stress regulator, results in hypersensitivity to caspofungin in the model mold A. nidulans. 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA:Abstract #M-217, 2002. e-Pub 2002.
101. Ratanatharathorn, V, Flynn P, van Burik J, McSweeney P, Niederwieser D, Kontoyiannis DP. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. 44th Annual Meeting of the American Society of Hematology (ASH), Philadelphia, PA:Abstract#2472, 2002. e-Pub 2002.
102. Antoniadou, A, Torres H, Lewis RE, Raad II, Thornby J, Tarrand JJ, Rolston K, Han X, Bodey G, Kontoyiannis DP. In vitro susceptibility of bloodstream candidiasis in cancer patients: Correlation with outcome of antifungal therapy. 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA:Abstract #M-1499, 2002. e-Pub 2002.
103. Kontoyiannis, DP, Hanna H, Hachem R, Boktour M, Girgawy E, Mardani M, Bodey G, Raad I. Risk factors of poor outcome of fusariosis in a tertiary care cancer center. 40th Annual Meeting of the Infectious Diseases Society of America (IDSA), Chicago, IL:Abstract #100522, 2002. e-Pub 2002.
104. Kontoyiannis, DP, Hachem R, Lewis RE, Rivero G, Kantarjian H, Raad I. Efficacy and toxicity of the caspofungin/liposomal amphotericin B combination in documented or possible invasive aspergillosis in patients with hematologic malignancies. 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA:Abstract #M-1820, 2002. e-Pub 2002.
105. Lewis, RE, Torres HA, May GS, Raad II, Thornby J, Rolston KV, Upadhyaya D, Bodey GP, Kontoyiannis DP. In vitro susceptibility and tolerance of Aspergillus species in a tertiary care cancer center. Correlation with invasive aspergillosis and its outcome. 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA:Abstract #M-1491, 2002. e-Pub 2002.
106. Hanna, H, Boktour M, Bodey G, Girgawy E, Kontoyiannis D, Hachem R, Raad I. Candida parapsilosis fungemia responds better to antifungal therapy than fungemia due to Candida albicans in immunocompromised cancer patients. 40th Annual Meeting of the Infectious Diseases Society of America (IDSA), Chicago, IL:Abstract #349, 2002. e-Pub 2002.
107. Pham, AS, Tarand JJ, May GS, Lee MS, Raad LL, Kontoyiannis DP, Han XY. Diagnosis of invasive mold infection by a quanitative real-time PCR. 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA:Abstract #M-903, 2002. e-Pub 2002.
108. Torres HA, Kontoyiannis DP. Protothecosis in cancer patients. 39th Annual Meeting of the Infectious Diseases Society of America (IDSA):39th Annual Meeting of the Infectious Diseases Soc, 2001. e-Pub 2001.
109. Kontoyiannis DP. Overexpression of Sbe2p, a golgi protein involved in cell wall formation confers resistance to caspofungin in Saccharomyces cerevisiae. 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract #1843, 2001. e-Pub 2001.
110. Kontoyiannis, DP, Buell D, Frisbee-Hume S, Reddy BT, Rolston KVI. Initial Experience with FK463 for the treatment of candidemia in cancer patients. 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract #1629, 2001. e-Pub 2001.
111. Viudes, A, Peman J, Gobernado M, Kontoyiannis DP, X-H H, Tarrand JJ, Patterson TF, Lopez-Ribot JL. Identification of continuous immunoglobulin G-reactive epitopes on immunodominant antigens from Aspergillus spp. 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract #467, 2001. e-Pub 2001.
112. Lewis, RE, H-J L, Raad II, Kontoyiannis DP. Lack of catheter colonization by the cph1/cph1 efg1/efg1 double null mutant, a C. albicans strain that is defective in filamentous growth. 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract #108, 2001. e-Pub 2001.
113. Lewis, RE, Prince RA, Kontoyiannis DP. Pretreatment with itraconazole attenuates the efficacy of increasing amphotericin B dosages in a murine model of invasive pulmonary aspergillosis. 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract #1837, 2001. e-Pub 2001.
114. Raad II, Kontoyiannis DP. Comparison between Imipenem/Cilastatin and Cefepime as initial therapy for febrile neutropenic cancer patients requiring hospitalization. 39th Annual Meeting of the Infectious Diseases Society of America (IDSA):Abstract #67, 2001. e-Pub 2001.
115. Kontoyiannis DP, et al. Comparison of breakthrough candidemia and de novo candidemia in cancer patients. 39th Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, CA:Abstract #622, 2001. e-Pub 2001.
116. Torres, H, Rolston KVI, Raad II, Kontoyiannis DP. Infections in Patients with Aplastic Anemia: The experience of a tertiary care cancer center . 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract #1244, 2001. e-Pub 2001.
117. Bodey, GP, Boktour M, May S, Duvic M, Girgawy E, Kontoyiannis DP, Hachem R, RaadII. Cutaneous Manifestation of Fusarium Infections. 39th Annual Meeting of the Infectious Diseases Society of America (IDSA):Abstract #637, 2001. e-Pub 2001.
118. Kontoyiannis, DP, Osherov N, Lewis R, Albert ND, May G. L685, 818, an Non-immunosuppressive calcineurin inhibitor enhances the activity of caspofungin. 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract #123, 2001. e-Pub 2001.
119. Lewis, RE, Kontoyiannis DP, Darouiche, RO, Raad II, Prince RA. Antifungal activity of amphotericin B, itraconazole, and voriconazole In an in vitro model of Candida catheter-related bloodstream infection (CRBSI). 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract #J-108, 2001. e-Pub 2001.
120. Kontoyiannis, DP, Reddy BT, Bodey GP, Luna M, Lewis RE, Tarrand J, Rolston K, Whimbey E, Jacobson K, Nguyen M, Raad II. Pulmonary candidiasis in cancer patients: An autopsy study. 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL:Abstract #677, 2001. e-Pub 2001.
121. Lewis, RE, Neuhauser M, Tarrand J, Kontoyiannis DP. Species distribution and antifungal susceptibility of Candida species at an oncology-specialty hospital. Annual Meeting American College of Clinical Pharmacy, Tampa, FL:Abstract #129, 2001. e-Pub 2001.
122. LaRosa, AM, Englund JA, Couch R, Raad II, Rolston KVI, Jacobson KJ, Kontoyiannis DP, Whimbey EE. Influenza A in hospitalized adults with leukemia and hematopoietic stem cell transplant recipients: risk factors for progression to pneumonia. 39th Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, CA:Abstract #418, 2001. e-Pub 2001.
123. Keating, MJ, Reddy BTBodey GP, Kontoyiannis DP. Infectious complications in fludarabine-refractory CLL patients. 43rd Annual Meeting of the American Society of Hematology, Orlando, FL:Abstract #2651, 2001. e-Pub 2001.
124. Osherov, N, Kontoyiannis DP, May G. Extra Copies of the Aspergillus nidulans P450 14a-demethylase result in resistance to itraconazole. 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Ontario, Canada:Abstract #1710, 2000. e-Pub 2000.
125. Ghosh, S, Champlin R, Ueno N, Rolston K, Raad I, Jacobson K, Kontoyiannis DP, Whimbey E. RSV infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and immunotherapy. 38th Annual Meeting of the Infectious Diseases Society of America (IDSA), New Orleans, LA:Abstract #612, 2000. e-Pub 2000.
126. Jacobson, KL, Miceli MM, Kontoyiannis DP, Tarrand JJ, Whimbey EE. Legionella pneumonia in the 1990s in a tertiary care cancer center. 38th Annual Meeting of the Infectious Diseases Society of America (IDSA), New Orleans, LA:Abstract #139, 2000. e-Pub 2000.
127. LaRosa, A, Champlin R, Gajewski J, Giralt S, Rolston K, Raad I, Jacobson K, Kontoyiannis DP, Whimbey E. Therapy of invasive Adenovirus infections in adult blood and marrow transplant recipients. Is intravenous ribavirin efficacious? . 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Ontario, Canada:Abstract #73, 2000. e-Pub 2000.
128. Hachem, R, Afif C, Cooksley C, Boktour M, Chatzinikolaou I, Khan A, Kontoyiannis DP, Rolston KV, Raad II. Invasive aspergillosis in patients with leukemia and bone marrow transplant patients: poor outcome despite aggressive therapy. 42nd Annual Meeting of the American Society of Hematology (ASH), San Francisco, CA:Abstract #3815, 2000. e-Pub 2000.
129. Shaikh, ZA, Ueno N, Kontoyiannis DP. Fatal Salmonella G enteritis mimicking intestinal graft-versus-host disease in an allogeneic peripheral blood stem cell transplant (PBSCT) recipient. 38th Annual Meeting of the Infectious Diseases Society of America (IDSA), New Orleans, LA:Abstract #220, 2000. e-Pub 2000.
130. Shaikh, ZA, Champlin R, Kontoyiannis DP. The diagnostic yield of open lung biopsy in bone marrow transplant recipients. 38th Annual Meeting of the Infectious Diseases Society of America (IDSA), New Orleans, LA:Abstract #547, 2000. e-Pub 2000.
131. Jacobson, KL, Whimbey EE, Kontoyiannis DP. Fungal osteomyelitis in a normal host due to Curvularia species, successfully treated with itraconazole alone. 38th Annual Meeting of the Infectious Diseases Society of America (IDSA), New Orleans, LA:Abstract #226, 2000. e-Pub 2000.
132. Raad II, Huaringa A, Sumoza D, Hanna HA, Rolston KVI, Kontoyiannis DP, Hachem RY, Albitar M. Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction- based detection of Aspergillus in bronchoalveolar lavage (BAL). 38th Annual Meeting of the Infectious Diseases Society of America (IDSA), New Orleans, LA:Abstract #40, 2000. e-Pub 2000.
133. Rosa DL, G, Jacobson K, Whimbey E, Kontoyiannis DP. Tuberculosis in the 90s in a tertiary care cancer center. 38th Annual Meeting of the Infectious Diseases Society of America (IDSA), New Orleans, LA:Abstract #552, 2000. e-Pub 2000.
134. Kontoyiannis, DP, Peitsch W, Reddy B, X-Y H, Raad I, Bodey G, Rolston K. Cryptococcosis in the 90s in a tertiary care cancer center. 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Ontario, Canada:Abstract #1694, 2000. e-Pub 2000.
135. Tarrand J, Lichterfeld M, Warraich IA, Luna MA, Han X, Kontoyiannis DP. Culture yield from immunosupressed cancer patients with invasive aspergillosis. 38th Annual Meeting of the Infectious Diseases Society of America (IDSA), New Orleans, LA:Abstract #276, 2000. e-Pub 2000.
136. Ghosh S, Koller C, Kantarjian H, Keating M, Raad I, Rolston K, Kontoyiannis DP, Jacobson K, Whimbey E. Therapy of RSV pneumonia in myelosuppressed adults with leukemia: combination aerosolized ribavirin and immunotherapy. 38th Annual Meeting of the Infectious Diseases Society of America (IDSA), New Orleans, LA:Abstract #613, 2000. e-Pub 2000.
137. Kontoyiannis DP, May G. Delta-aminolevulinic acid (a-ALA) modulates the resistance to fluconazole in the hem1 mutant. 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Ontario, Canada:Abstract #244, 2000. e-Pub 2000.
138. Blumenschein, G, Herbst RS, Hong WK, Pisters K, Lee JS, Khuri FR, Kontoyiannis DP. Pneumocystis carinii pneumonia in non-small cell lung cancer patients treated with combination of gemcitabine and vinorelbine therapy. 35th Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA:Abstract #1919, 1999. e-Pub 1999.
139. Kontoyiannis DP. Fluconazole inhibits agar invasion in Candida albicans . 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA:Abstract #697, 1999. e-Pub 1999.
140. Wessel, VC, Rolston KVI, Kontoyiannis DP. Mucormycosis in the 90s in a tertiary care cancer center. 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco:Abstract #977, 1999. e-Pub 1999.
141. Chatzinikolaou, I, Dholakia NA, Kontoyiannis DP, Tarrand JJ, Rolston KVI. Rhodococcus spp. infection in cancer patients. 37th Annual Meeting of the Infectious Diseases Society of America (IDSA), Philadelphia, PA:Abstract #128, 1999. e-Pub 1999.
142. Kontoyiannis, DP, Sumoza D, Raad II. The significance of aspergillemia in patients with cancer: a 10 year study. 37th Annual Meeting of the Infectious Diseases Society of America (IDSA), Philadelphia, PA:Abstract #277, 1999. e-Pub 1999.
143. Afif, CM, Kontoyiannis DP, Sneige N, Rolston KVI. Pneumocystis carinii pneumonia in a cancer center: risk factors, clinical features and outcome. 37th Annual Meeting of the Infectious Diseases Society of America (IDSA), Philadelphia, PA:Abstract #274, 1999. e-Pub 1999.
144. Kontoyiannis DP, Rupp S. Activated Ras and azole resistance in S. cerevisiae. . 37th Annual Meeting of the Infectious Diseases Society of America (IDSA), Philadelphia, PA:Abstract #283, 1999. e-Pub 1999.
145. Kontoyiannis, DP, Sagar N, Hirschi K. Overexpression of Erg11p by the regulatable GAL1 promoter confers azole resistance in Saccharomyces cerevisiae. 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA:Abstract #2074, 1999. e-Pub 1999.
146. Kontoyiannis, DP, Styles CA, Fink GR. Pdr5p could regulate ergosterol homeostasis in Saccharomyces cerevisiae. 36th Annual Meeting of the Infectious Diseases Society of America (IDSA), Denver, CO:Abstract #903, 1998. e-Pub 1998.
147. Kontoyiannis, DP, Styles CA, Fink GR. Fluconazole sensitivity is modulated by the interaction of mitochondria and Erg3p in Saccharomyces cerevisiae. 36th Annual Meeting of the Infectious Diseases Society of America (IDSA), Denver, CO:Abstract #897, 1998. e-Pub 1998.
148. Kontoyiannis DP, Styles CA, Fink GR. Dissection of fluconazole resistance by transposon mutagenesis in Saccharomyces cerevisiae. 36th Annual Meeting of the Infectious Diseases Society of America (IDSA), Denver, CO:Abstract #904, 1998. e-Pub 1998.
149. Anaissie, EJ, Kontoyiannis DP, O’Brien S, Kantarjian H, Lerner S, Keating M. A new spectrum of infections in patients with chronic lymphocytic leukemia treated with fludarabine: Multivariate analysis of risk factors. 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Ontario:Abstract #J-88, 1997. e-Pub 1997.
150. Nguyen, Q, Samiy N, Kontoyiannis DP, Amico DJ, Baker AS. Fungal endophalmitis: A ten-year retrospective study, 1985-1995. American Academy of Opthalmology Annual Meeting, 1996. e-Pub 1996.
151. Boutati, E, Kontoyiannis DP, Anaissie EJ, Bodey GP. Analysis of 1818 consecutive febrile episodes in acute leukemia patients: The MD Anderson Cancer Center experience. European Journal of Internal Medicine 6(Suppl 1):133, 1995. e-Pub 1995.
152. Anaissie, EJ, Kontoyiannis DP, Huls C, Prince R, Bosso JA, Bodey GP. Efficacy, safety and pharmacokinetics of high dose fluconazole in cancer patients with fungal infections. 32nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Anaheim, CA:#626, 1992. e-Pub 1992.
153. Anaissie, EJ, Pinczowski H, Elting L, Kontoyiannis DP Kontoyiannis DP, Vartivarian S, Bodey GP. Response of fluconazole-treated cancer patients with candidemia compared with that of patients treated with amphotericin-B: A prospective matched pair study. 32nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Anaheim, CA:Abstract #630, 1992. e-Pub 1992.

Book Chapters

1. Sharma, D, Chao, AW, Kontoyiannis, DP. Invasive Fungal Sinusitis in Immunocompromised Hosts, 221-233, 2024.
2. Kontoyiannis DP, Lewis RE. Agents of Mucormucosis. In: Principle and Practices of Infectious Diseases. 7th Edition. Elsivier Press, 2010, 2015, 2020, 2023.
3. Shelburne, S, Lewis, RE, Kontoyiannis, DP. Key Considerations for Managing Infections in the Compromised Host, 1567-1582, 2022.
4. Chamilos G, DP K. Aspergillus and opportunistic fungal infections of the lung. In: Pulmonary Diseases and Disorders. 6th Edition. McGraw-Hill:, 2022.
5. Granwehr BP, Kontoyiannis DP. Fungal infections in cancer patients. In: The MD Anderson Manual of Medical Oncology, 4th Edition, 2022.
6. Granwher B, Kontoyiannis DP. Fungal infections in cancer. In: Encyclopedia of Mycology, 2021.
7. Granwehr BP, Sipsas NV, Kontoyiannis DP. Fungal infections in ICU cancer patients. In: Oncologic Critical Care. Springer Nature, 2019.
8. Thuro B, Thakar S, Sagiv O, Kontoyiannis DP, Esmaeli B. Orbital Infections in the Cancer Patient. In: Orbital Cellulitis and Periorbital Infections: Evaluation and Management. Springer Press, 2018.
9. Shelburne S, Lewis RE, Kontoyiannis DP. Clinical approach to infections in the Compromised Host. In: Hematology: Basic Principles and Practice. 7th Edition, 2018.
10. Chao A, Kontoyiannis DP. In: Invasive Fungal Sinusitis In Immunosuppressed Hosts. In Infections of the Ears, Nose, Throat and Sinuses. Springer, 177-188, 2017.
11. Shelburne S, Lewis RE, Kontoyiannis DP. Clinical approach to infections in the Compromised Host. In: Hematology: Basic Principles and Practice. 8th Edition, 2017.
12. Lewis RE, Kontoyiannis DP. Buftenafine. In: Use of Antibiotics. 7th Edition. ASM Press, 2016.
13. Lewis RE, Kontoyiannis DP. Echinocandins. In: Use of Antibiotics. 8th. ASM Press, 2016.
14. Georgiadou S, Kontoyiannis DP. In: Fungal Infections in Primary and Acquired Immunodeficiencies In: Carvalho's Book Immunogenetics of Fungal Diseases. 1st. Springer International Publishing, 2016.
15. Lewis RE, Kontoyiannis DP. Treatment Principles in non-Aspergillus molds. In: Human Fungal Pathogens. Cold Spring Harbor Press, 2015.
16. Kontoyiannis DP. Mycormycosis. In: Cecil Textbook of Medicine. 25th Edition. W. B. Saunders Co, 2015.
17. Chamilos, Kontoyiannis DP. In: Fishman's Pulmonary Diseases and Disorders. 5th. McGraw-Hill Professional, 2015.
18. Shelburne S, Lewis RE, Kontoyiannis DP. Clinical approach to infections in the Compromised Host. In: Hematology: Basic Principles and Practice. 6th Edition. Saunders, Inc, 2013.
19. Kontoyiannis DP. Mycetoma. In: Cecil Textbook of Medicine. W. B. Saunders Co, 2012.
20. Kontoyiannis DP. Mycormycosis. In: Cecil Textbook of Medicine. 24rd Edition. W. B. Sanders Co, 2012.
21. Granwher BP, Chemaly RF, Kontoyiannis DP. Fungal and viral infections in cancer patients. In: The MD Anderson Manual of Medical Oncology. Mc Graw Hill Medical, 2011.
22. Torres HA, Kontoyiannis DP. Hyalohyphomycoses (Hyaline molds). In: Essentials of Clinical Mycology. 2nd Edition. Springer, 2011.
23. Ben-Ami R, Kontoyiannis DP. Cutaneous model of aspergillosis. In: Host-Fungal Interactions. Humana Press, 2010.
24. Lewis RE, Kontoyiannis DP. Echinocandins. In: Use of Antibiotics. 6th Edition. ASM Press, 2010.
25. Kontoyiannis DP. Pathogenesis of invasive pulmonary aspergillosisis. In: Aspergillosis: from diagnosis to prevention. Springer, 2010.
26. Kontoyiannis DP, Lewis RE. A clinical approach to Candida resistance. In: Candida and Candidiasis. ASM Press, 2010.
27. Lionakis M, Kontoyiannis DP. Fly model to study fungal disease. In: Host-Fungal Interactions. Humana Press, 2010.
28. Kontoyiannis DP, Lewis RE, Walsh TJ. Fungal infections in immunocompromised hosts with cancer. In: Medical Care of Cancer Patients. BC Decker Inc, 2009.
29. Kontoyiannis DP. Primary and salvage treatment of aspergillosis. In: Aspergillus fumigatus and Aspergillosis. ASM Press, 2009.
30. Kontoyiannis DP. Trichosporon species and Blastoschizomyces capitatus. In: Antimicrobial Therapy and Vaccines. 3rd Edition. Williams and Wilkins Press, 2008.
31. Chamilos G, Kontoyiannis DP. Emerging role of mini-host models to study aspergillosis. In: The Aspergilli: Genomics, Medical Aspects, Biotechnology and Research Methods. CRC Press, 2008.
32. Chamilos G, Kontoyiannis DP. Aspergillus and opportunistic fungal infections of the lung. In: Pulmonary Diseases and Disorders. 5th Edition. McGraw-Hill, 2008.
33. Kontoyiannis DP. Insert models of infection. In: The Aspergilli: Genomics, Medicine, Biotechnology and Research Methods. CRC Press, 2008.
34. Kontoyiannis DP. Mycormycosis. In: Cecil Textbook of Medicine. 23rd Edition. W. B. Saunders Co, 2008.
35. Bodey GP, Kontoyiannis DP, Keating MJ. Infections in patients with chronic lymphocytic leukemia. In: Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. The Humana Press Inc, 2004.
36. Kontoyannis DP. Mycetoma. In: Cecil Textbook of Medicine. 22nd Edition. W. B. Sanders Co, 2004.
37. Bodey, GP, Chemaly R, Kontoyiannis DP. Fungal and Viral infections in cancer patients. In: The MD Anderson Manual of Medical Oncology. Mc Graw-Hill, 2004.
38. Kontoyiannis DP. Nocardia. In: Infectious Diseases. Lippincott Williams and Wilkins, 2004.
39. Torres H, Kontoyiannis DP. Hyalohyphomycoses. In: Oxford Textbook of Clinical Mycology. Oxford University Press, 252-270, 2003.
40. Kontoyiannis DP, Anaissie EJ, Bodey GP. Infection in chronic lymphocytic leukemia: A reappraisal. In: Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments. Marcel Dekker, 399-417, 1993.
41. Anaissie, EJ, Nelson P, Beremand M, Kontoyiannis DP, Rinaldi M. Fusarium caused hyalohyphomycosis: An overview. In: Current Topics in Medical Mycology. Springer-Verlag, 231-249, 1992.
42. Ostrosky-Zeichner L, Kontoyiannis DP. Mycormycosis. In: Cecil Textbook of Medicine. 27th Edition. W. B. Saunders Co.
43. Torres HA, Kontoyiannis DP, Rolston K. Infections in Patients with Cancer. In: Cancer Medicine. 10th Edition.
44. Pappas P, Kontoyiannis DP. Mycetoma and dematiaceous fungal Infections. In: Cecil Textbook of Medicine. 27nd Edition. W. B. Sanders Co.

Books (edited and written)

1. Co-Editor. Antifungal Host Responses: Translational Implications and Therapeutic Opportunities. Elsevier.

Letters to the Editor

1. Kawedia, J, Rausch, C, Liu, X, Qiao, W, DiNardo, C, Daver, N, Borthakur, G, Pemmaraju, N, Reville, PK, Kontoyiannis, DP, Short, NJ, Konopleva, M, Jabbour, EJ, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals. American journal of hematology 100: 740-743, 2025.
2. Matsuo T, Wurster S, Kontoyiannis DP. Good Outcomes in Salvage Therapy of Fusariosis in Patients With Leukemia: Is It the Host or the Drug?. Clin Infect Dis 79: 571-572, 2024.
3. Kontoyiannis DP. Statin use and aspergillosis risk -More that meets the eye?. Clin Infect Dis 76: 368, 2023.
4. Sassine J, Kontoyiannis DP. A 77-Year-Old Man with Multiple Myeloma and a Lytic Bone Lesion. Am J Med doi: 10.1016/j.amjmed.2021.01.032: 860-862, 2021.
5. Johnson MD, Lewis RE, Dodds Ashley ES, Perfect JR, Kontoyiannis DP. Reply to Day et al. J Infect Dis.
6. John TM, Kontoyiannis DP. Do not forget daptomycin as a cause of eosinophilic pneumonia. Chest 159: 1687-1688, 2021.
7. Malek AE, Kontoyiannis DP. Superficial Thrombophlebitis From Intravenous Pentamidine in Hematopoietic Cell Transplantation Recipient. Mayo Clin Proc 96: 257-258, 2021.
8. Yang X, Shi X, Chen W, Zhou Y, Lionakis MS, Kontoyiannis DP, Liu W. First report of kerion (tinea capitis) caused by combined Trichophyton mentagrophytes and Microsporum canis. Med Mycol Case Rep 29: 5-7, 2020.
9. Lewis RE, Kontoyiannis DP. Infectious disease consultation for candidaemia. Lancet Infect Dis 20: 164, 2020.
10. Malek AE, Taremi M, Spallone A, Alvarez-Cardona JJ, Kontoyiannis DP. Necrotizing soft tissue invasive aspergillosis in a cancer patient treated with immunosupressants due to checkpoint inhibitor-induced hepatitis. J Infect 80: 232-254, 2020.
11. Lewis RE, Kontoyiannis DP. Chimeric antigen receptor T cell immunotherapy and need for prophylaxis for invasive mold infections. Clin Infect Dis.
12. Magira EE, Chemaly RF, Jiang Y, Tarrand J, Kontoyiannis DP. Corrigendum: Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients With Hematologic Malignancies: A Case-Control Study. Open Forum Infect Dis 6: ofz458, 2019.
13. Dipippo AJ, Kontoyiannis DP. Azole-Associated Pseudohyperaldosteronism: A Class Effect or Azole-Specific?. Clin Infect Dis.
14. Mason MJ, McDaneld PM, Musick WL, Kontoyiannis DP. Serum Levels of Crushed Posaconazole Delayed Release Tablets. Antimicrob Agents Chemother 63, 2019.
15. De la Hoz A, Foolad F, Gallegos C, Kornblau S, Kontoyiannis DP. Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin's disease. Bone Marrow Transplant 54: 749-751, 2019.
16. Rausch CR, Kontoyiannis DP. Prolonged voriconazole treatment in a patient with chronic lymphocytic leukemia resulting in a litany of chronic overlapping toxicities. J Oncol Pharm Pract 25: 1078155218762624, 2019.
17. Zoran T, Sartori B, Sappl L, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, Kontoyiannis DP, Alastruey-Izquierdo A, Lagrou K, Lo Cascio G, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, Tortorano AM, Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadis J, Prammer W, Tullio V, Vehreschild JJ, Trovato L, Lewis RE, Segal E, Rath PM, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikan-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Uzun O, Roudbary M, de la Fuente S, Houbraken J, Risslegger B, Sabino R, Lass-Flörl C, Lackner M. Corrigendum: Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Front Microbiol 9: 3245, 2019.
18. Chamilos G, Lionakis MS, Kontoyiannis DP. Reply to Bazaz and Denning. Clin Infect Dis, 2018.
19. Daver N, Kontoyiannis DP. Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis. Lancet Oncol 18: 1571-1573, 2017.
20. Foolad F, Kontoyiannis DP. Persistent CNS toxicity in a patient receiving posaconazole tablets after discontinuation of voriconazole due to supratherapeutic serum levels. J Antimicrob Chemother, 2017.
21. Jain P, Nagarajan P, Prayag P, Benton CB, Kadia T, Groisberg R, Kontoyiannis DP, Mulanovich VE, Pemmaraju N. Mixed angioinvasive Exserohilum and Scedosporium infection in a patient with AML. Am J Hematol 92: 119-120, 2017.
22. Kontoyiannis DP. What to Do for the Asymptomatic Pulmonary Coccidioidal Nodule or Cavity in Immunosuppressed Patients? A Focus in the Recent Coccidioidomycosis Guidelines. Clin Infect Dis 64: 232-233, 2017.
23. Kontoyiannis DP. A Potential Explanation of a Positive Serum β-Glucan Assay in Mucormycosis. Open Forum Infect Dis 3: ofw209, 2016.
24. Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda W. PET-positive lymphadenopathy in CLL - Not always Richter transformation. Am J Hematol.
25. Aitken SL, Kontoyiannis DP, DePombo AM, Bhatti MM, Tverdek FP, Gettys SC, Nicolau DP, Nunez CA. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient. Pediatr Infect Dis J 35: 1040-1042, 2016.
26. Sunil M, Tarand JJ, Kontoyiannis DP. A Patient with Acute Promyelocytic Leukemia and Persistent Skin Lesions Following Thorn Injury. J Bacterial Mycol 3, 2016.
27. Oliver N, Luong T, Tchakarov A, Abdelrahim M, Mulanovich VE, Kontoyiannis DP, Jones R, Kebriaei P, Samuels J, Glass W, Abudayyeh A. Disseminated cryptococcal infection in allogeneic stem cell transplant patients: a rare cause of acute kidney injury. Bone Marrow Transplant.
28. Kyvernitakis A, Azzi J, Kontoyiannis DP. Mixed Mycobacterium Avium-Intracellulare and Serratia Marcescens Cellulitis of the Breast in an HIV-Negative Patient with Breast Cancer: A Case Report. Cureus 8: e634, 2016.
29. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. Reply to Bauer and Goff. Clin Infect Dis 61: 487-8, 2015.
30. Pemmaraju N, Shetty AV, Prieto VG, Jain N, Kontoyiannis DP, Borthakur G. Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum, and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia. Eur J Haematol 93: 543-4, 2014.
31. Zhao Y, Kontoyiannis DP, Roilides E, Walsh TJ, Perlin DS. Reply to "Detection of Multiple Fungal Species in Blood Samples by Real-Time PCR: an Interpretative Challenge". J Clin Microbiol 52: 3517, 2014.
32. Zhao Y, Kontoyiannis DP, Roilides E, Walsh TJ, Perlin DS. Reply to "Not Over Yet: Fungal Infections following Methyl Prednisolone Injections Smoulder On". J Clin Microbiol 52: 3508, 2014.
33. Kontoyiannis DP, Lewis RE. Reply to "Risk for Invasive Fungal Infections during Acute Myeloid Leukemia Induction Therapy: a True Association with Echinocandins?". Antimicrob Agents Chemother 58: 4990-4991, 2014.
34. Kontoyiannis DP. The power of a legend. Ann Intern Med 155: 400, 2011.
35. Kontoyiannis DP. Are serum cytokines sensitive and specific enough to prognosticate in aspergillosis?. J Infect Dis 203: 1503; author reply 1504, 2011.
36. Kontoyiannis DP. Deferasirox lacks in vitro activity against Fusarium and Scedosporium species and black molds. Virulence 2: 257-8, 2011.
37. Cahuayme-Zuniga L, Kontoyiannis DP. Is it safe to proceed with stem cell transplant in cancer patients treated for cryptococcal infection? A focus on recent IDSA cryptococcal guidelines. Clin Infect Dis 50: 1687-9, 2010.
38. Kontoyiannis DP. Echinocandin-based initial therapy in fungemic patients with cancer: a focus on recent guidelines of the Infectious Diseases Society of America. Clin Infect Dis 49: 638-9; author reply 639-40, 2009.
39. Kontoyiannis DP, Lewis RE. Posaconazole prophylaxis in hematologic cancer. N Engl J Med 356: 2214-5, 2007.
40. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 44: 1089-90, 2007.
41. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Grazziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silviera F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis 43: 1031-9, 2006.
42. Chamilos G, Kontoyiannis DP. Refractory Cellulitis in a Woman With Chronic Lymphedema. Infect Dis Clin Pract: 244-5, 2006.
43. Chamilos G, Kontoyiannis DP. Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukaemia on voriconazole prophylaxis. J Infect 51: e225-8, 2005.
44. Lionakis MS, Kontoyiannis DP. Sinus zygomycosis in a patient receiving voriconazole prophylaxis. Br J Haematol 129: 2, 2005.
45. Kontoyiannis DP, Lewis RE. Caspofungin versus liposomal amphotericin B for empirical therapy. N Engl J Med 352: 410-4; author reply 410-4, 2005.
46. Kontoyiannis DP, Lewis RE. Problems in evaluation of baseline and breakthrough fungal infections in modern febrile neutropenia trials. New Eng J Med 352: 410-14, 2005.
47. Montes M, White AC, Kontoyiannis DP. Symptoms of intestinal schistosomiasis presenting during treatment of large B cell lymphoma. Am J Trop Med Hyg 71: 552-3, 2004.
48. Lewis RE, Kontoyiannis DP. Challenges in designing animal studies to detect antagonism of polyene activity. Antimicrob Agents Chemother 48: 3211; author reply 3211-2, 2004.
49. Kontoyiannis DP. What is the significance of an isolated positive cryptococcal antigen in the cerebrospinal fluid of cancer patients?. Mycoses 46: 161-63, 2003.
50. Kontoyiannis DP, Chagua MR, Ramirez I, Prieto V. Locally invasive auricular aspergillosis after ear-piercing in a neutropenic patient with leukemia. Am J Hematol 73: 296-297, 2003.
51. Kontoyiannis DP, Murray PJ. Fluconazole toxicity is independent of oxidative stress and apoptotic effector mechanisms in Saccharomyces cerevisiae. Mycoses 46: 183-6, 2003.
52. Kontoyiannis DP, Pasqualini R, Arap W. Could aminopeptidase N inhibitors be effective against severe acute respiratory syndrome?. Lancet 361: 1558, 2003.
53. Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 45: 406-7, 2002.
54. Kontoyiannis DP. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 34: 1281-3; author reply 1283, 2002.
55. Kontoyiannis DP, May GS. Identification of azole-responsive genes by microarray technology: why are we missing the efflux transporter genes?. Antimicrob Agents Chemother 45: 3674-6, 2001.
56. Kontoyiannis DP, May GS. Delta-aminolaevulinic acid modulates the resistance to fluconazole in a hem1 mutant of Saccharomyces cerevisiae. J Antimicrob Chemother 46: 1044-6, 2000.
57. Kontoyiannis DP, Basgoz N. Klebsiella ozaniae empyema complicating longstanding oleothorax. Scand J Infect Dis 10: 579, 2000.
58. Kontoyiannis DP, Olivero JJ. Intestinal obstruction in a dialysis patient with a broken leg. Hosp Pract (Off Ed) 29: 133-4, 1994.

Patents

1. Polydiol Fumarates and Polydiol Fumarate Co-Succinate. Patent Number: 16/146, 258.
2. License Agreement OOTIITZ. Manufacture of Clinical-grade T Cells Using Sleeping Beauty (SB) System and Artificial Antigen Presenting Cell (aAPC) Platform. Patent Number: MDA13-113.